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ABSTRACT 
Ashley Garrett Rivenbark:  Epigenetic Mechanisms of Gene Regulation in  
Human Breast Cancer 
(Under the direction of William B. Coleman, Ph.D.) 
 
 Breast cancer represents a significant health problem and improvements in our ability to 
prevent, diagnose, and treat the disease requires a greater understanding of the molecular 
basis of breast carcinogenesis.  Epigenetic mechanisms play a major role in breast 
carcinogenesis, with DNA methylation accounting for most epigenetic gene silencing, 
affecting a number of different gene targets.  However, mechanisms of DNA methylation-
dependent silencing are poorly understood.  To identify epigenetically-regulated genes in 
breast cancer, MCF-7 breast cancer cells were exposed to demethylating treatment and gene 
expression patterns were examined by microarray analysis.  Genes with increased expression 
after demethylation treatment that returned to control levels after treatment withdrawal were 
directly assessed for DNA methylation by bisulfite sequencing.  A group of 20 putative 
methylation-sensitive genes were identified that could be classified into three groups based 
upon their promoter CpG features.  The majority of these methylation-sensitive genes lacked 
a conventional DNA methylation target (CpG island), resulting in an expanded model for 
epigenetic regulation of gene expression that recognizes the importance of all promoter 
CpGs.  The breast tumor suppressor gene CST6 (Cystatin M) is epigenetically silenced in 
MCF-7 breast cancer cells.  CST6 is subject to methylation-dependent regulation in multiple 
breast cancer cell lines, primary breast tumors, and lymph node metastases, and gene 
expression status correlates with promoter hypermethylation.  These results suggest that 
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methylation dependent gene silencing of CST6 represents an important mechanism for loss of 
CST6 during breast carcinogenesis.  The mechanisms that control CpG island methylation are 
poorly understood.  CST6 was utilized as an index gene for the identification of cis elements 
that direct promoter CpG methylation.  The methylation-sensitive CST6 promoter was 
assembled into luciferase reporter constructs and transfected into model breast cancer cell 
lines that methylate or do not methylate the CST6 promoter.  Truncation of the CST6 
promoter disassociated a putative instructional cis regulatory sequence located in the 5’ 
upstream promoter region of CST6 that functions to direct CpG methylation.  The 
observations and results described in this dissertation significantly advance our 
understanding of methylation-sensitive genes and mechanisms governing DNA methylation 
in breast carcinogenesis. 
 
 
 
 
 iv
ACKNOWLEDGMENTS 
 
First and foremost I would like to thank my advisor Bill Coleman, for his guidance, 
wisdom, support, and encouragement.  He has enriched my experience in graduate school by 
allowing me to help him with many endeavors, including writing grants, reviews, and 
manuscript commentaries.  My achievements and success in graduate school are mostly due 
to his mentorship and support.  I will forever be grateful to him.   
Thank you to all the people in my lab who have made coming to work exciting, always 
interesting, and mostly enjoyable.  I want to give special thanks to Devon, who has been my 
‘little sister’ in the lab.  Teaching and learning from her has been a joy.  I would like to 
express my gratitude to my dissertation committee members, Channing J. Der, William K. 
Funkhouser, Wendell D. Jones, and William K. Kaufmann.  I appreciate all of their time, 
effort, support, and encouragement.  I want to especially thank Wendell for all of his 
microarray analysis and statistical help.   
I want to give special thanks to my parents, who have taught me to live my life according 
to God’s will, and have encouraged and supported me throughout all endeavors.  Thank you 
for your prayers.  I love you both so much.  Thank you to my brother, Justin, for supporting 
me in graduate school, always keeping things in perspective, and making me laugh in all 
situations.  I want to thank Patsy, Dannie, and Ginnie for their enthusiasm and support 
throughout the years I have known them.  Thanks to my friends who have been my support 
system and prayer warriors throughout graduate school (and most of my life), Stephanie, 
Megan, and especially Laura.  Thank you Laura for being so understanding, encouraging, 
 v
enthusiastic, and someone I can count on for anything.  I am so blessed to have you as a 
friend!   
Most importantly, thank you to my husband and best friend, Jason, for your 
unconditional love, support, wisdom, advice, and uncanny ability to understand lab 
situations.  I truly appreciate all you have done for me.  I love you.                   
 
 
 
 
 
 vi
TABLE OF CONTENTS 
 
LIST OF TABLES...............................................................................................................xii 
 
LIST OF FIGURES ............................................................................................................xiii 
 
LIST OF ABBREVIATIONS.............................................................................................. xv 
 
I.  INTRODUCTION............................................................................................................. 1 
 
A.  Breast Cancer ................................................................................................................ 1 
 
Breast Cancer Epidemiology ........................................................................................ 1 
 
Natural History of Breast Cancer.................................................................................. 2 
 
B.  Molecular Pathogenesis of Breast Cancer..................................................................... 5 
 
Breast Cancer Susceptibility Genes .............................................................................. 6 
 
Environmental and Epigenetic Factors of Breast Cancer 
Susceptibility................................................................................................................. 7 
 
C.  Mechanisms of Epigenetic Regulation in Carcinogenesis ............................................ 7 
 
DNA Methylation in Cancer......................................................................................... 8 
 
DNA Methylation in Human Breast Cancer................................................................. 8 
 
Targets of DNA Methylation ...................................................................................... 12 
 
Mechanisms of Regulation of DNA Methylation....................................................... 15 
 
D.  Cystatins and Cancer:  Methylation-sensitive Genes that       
Contribute to Breast Tumorigenesis and Progression ................................................ 19 
 
Cysteine Protease Inhibitors - Cystatins ..................................................................... 19 
 
Cystatin Super-Family ................................................................................................ 19 
 
CST6 (Cystatin M):  A Prototype Methylation-sensitive Gene .................................. 20
 vii
E.  Summary and Significance.......................................................................................... 22 
 
II.  EXPERIMENTAL PROCEDURES .............................................................................. 24 
 
A.  Breast Cancer Cell Line Culture ................................................................................. 24 
 
B.  Treatment of Human Breast Cancer Cells with Demethylating 
Agents......................................................................................................................... 25 
 
MCF-7 Breast Cancer Cells Treated with 5-aza-2’-
deoxycytidine and Trichostatin A............................................................................... 25 
 
Hs578T, MDA-MB-435S, MDA-MB-436, MDA-MB-453, 
MCF-7, and ZR-75-1 Breast Cancer Cells Treated with 5-aza-
2’-deoxycytidine ......................................................................................................... 26 
 
C.  Human Breast and Lymph Node Tissues.................................................................... 26 
 
D.  RNA Isolation from Human Breast Cancer Cell Lines............................................... 27 
 
E.  Affymetrix Microarray Analysis of Gene Expression................................................. 27 
 
F.  Semiquantitative RT-PCR Analysis of Gene Expression............................................ 32 
 
G.  Quantitative Real-Time PCR ...................................................................................... 32 
 
H.  Promoter and 5’-Upstream Sequence Analysis of Putative 
Methylation-sensitive Genes ...................................................................................... 34 
 
I.  Construction of Reporter Gene Constructs................................................................... 35 
 
CST6 Gene Promoter Constructs ................................................................................ 35 
 
In Vitro CST6 Promoter Construct Methylation......................................................... 39 
 
J.  Luciferase Reporter Assay ........................................................................................... 39 
 
Transient Transfection of MCF-7 Breast Cancer Cells .............................................. 39 
 
Stable Transfection of Human Breast Cancer Cell Lines ........................................... 39 
 
K.  Genomic DNA Isolation ............................................................................................. 40 
 
Human Breast Cancer Cell Lines................................................................................ 40 
 
 viii
Human Primary Breast Tumors, Lymph Nodes, and Normal 
Breast Tissue............................................................................................................... 41 
 
L.  Bisulfite Modification of Genomic DNA, Cloning, and 
Sequencing ................................................................................................................. 41 
 
Human Breast Cancer Cell Lines................................................................................ 41 
 
Human Primary Breast Tumors, Lymph Nodes, and Normal 
Breast Tissue............................................................................................................... 44 
 
CST6 Reporter Gene Constructs ................................................................................. 44 
 
M.  Immunohistochemical Analysis of Human Primary Breast 
Tumors, Lymph Node Metastases, and Normal Breast Tissue .................................. 45 
 
N.  Statistical Analysis...................................................................................................... 46 
 
III.  RESULTS ..................................................................................................................... 47 
 
A.  DNA Methylation-Dependent Epigenetic Regulation of Gene 
Expression in MCF-7 Breast Cancer Cells................................................................. 47 
 
Identification of Putative Epigenetically-regulated Genes in 
MCF-7 Breast Cancer Cells Through Microarray Analysis of 
Gene Expression ......................................................................................................... 47 
 
Validation of Treatment-related Changes in Gene Expression 
by RT-PCR.................................................................................................................. 50 
 
Promoter Sequence Features of Putative Epigenetically-
regulated Genes........................................................................................................... 58 
 
Bisulfite Sequencing Demonstrates that Putative 
Epigenetically-regulated Genes are Subject to Methylation-
dependent Regulation.................................................................................................. 61 
 
B.  DNA Methylation-Dependent Silencing of CST6 in Human 
Breast Cancer Cell Lines ............................................................................................ 67 
 
CST6 is Differentially Expressed Among Breast Cancer Cell 
Lines............................................................................................................................ 67 
 
5-aza Treatment Induces CST6 Expression in Breast Cancer 
Cell Lines .................................................................................................................... 70 
 
 ix
Methylation-dependent Silencing of CST6 in Select Breast 
Cancer Cell Lines........................................................................................................ 76 
 
C.  Methylation-dependent Silencing of CST6 in Primary Human 
Breast Tumors and Metastatic Lesions....................................................................... 87 
 
Immunohistochemical Analysis of Cystatin M in Primary 
Breast Tumors and Lymph Node Metastases ............................................................. 87 
 
Methylation-Dependent Silencing of CST6 in Primary Breast 
Tumors and Lymph Node Metastases......................................................................... 97 
 
CST6 Gene Methylation Correlates with Loss of Cystatin M 
Expression in a Subset of Primary Breast Tumors and Lymph 
Node Metastases ....................................................................................................... 101 
 
F.  CST6 CpG Methylation Requires an Upstream DNA Sequence 
Element that Directs Promoter CpG Island Methylation.......................................... 104 
 
Cloning the Promoter Region of CST6 and Analysis of 
Luciferase Activity.................................................................................................... 104 
 
CST6 Promoter Construct Methylation Analysis in 
Differentially Expressing Breast Cancer Cell Lines................................................. 110 
 
IV.  DISCUSSION............................................................................................................. 116 
 
A.  Identification of Putative Epigenetically-regulated Genes in 
MCF-7 Breast Cancer Cells...................................................................................... 116 
 
B.  Classification of Epigenetically-regulated Genes Based Upon 
Promoter CpG Features ............................................................................................ 117 
 
Genes with Typical CpG Features ............................................................................ 120 
 
Genes with Intermediate CpG Features .................................................................... 121 
 
Genes with Atypical CpG Features........................................................................... 123 
 
C.  An Expanded Model for Methylation-dependent Epigenetic 
Regulation of Gene Expression ................................................................................ 123 
 
Mechanisms of DNA Methylation-dependent Silencing.......................................... 124 
 
D.  CST6 is Silenced by DNA Methylation in Breast Cancer Cells ............................... 128 
 
 x
CST6:  A Candidate Breast Tumor Suppressor Gene ............................................... 128 
 
CST6 is Silenced by Methylation in Multiple Cancers............................................. 129 
 
Epigenetic Mechanisms of CST6 Gene Silencing by DNA 
Methylation............................................................................................................... 130 
 
Methylation Events Leading to CST6 Silencing in Breast 
Cancer ....................................................................................................................... 132 
 
E.  Methylation-dependent Silencing of CST6 in Human Breast 
Cancer....................................................................................................................... 133 
 
Role of Tumor Suppressor CST6 in Human Breast Cancer...................................... 133 
 
Proposed Mechanism for Epigenetic Silencing of CST6 in 
Human Breast Cancer ............................................................................................... 134 
 
F.  CST6 CpG Methylation Requires an Upstream DNA Sequence 
Element that Directs Promoter Methylation Events ................................................. 135 
 
Regulation of DNA Methylation by Directive DNA 
Sequences.................................................................................................................. 135 
 
Methylation Directing Cis-acting Elements in DNA 
Sequences.................................................................................................................. 136 
 
Disassociation of Methylation Directing Cis-acting Elements 
From the Upstream Promoter Sequence of CST6 ..................................................... 137 
 
G.  Conclusions and Impact ............................................................................................ 138 
 
V.  REFERENCES............................................................................................................. 140 
 
 
 xi
LIST OF TABLES 
Table 1.  Oligodeoxynucleotide primers for RT-PCR analysis of gene 
expression………………………………………………………………………... 33 
 
Table 2.  Oligodeoxynucleotide primers for bisulfite sequencing  
  analysis of selected genes……………………………………………………….. 43 
 
Table 3.  Putative epigenetically-regulated genes identified in MCF-7 
  breast cancer cells after exposure to demethylating treatment………………….. 51 
 
Table 4.  Putative epigenetically-regulated genes identified in 
  MCF-7 cells after demethylating treatment with either 5-aza  
  or 5-aza + TSA………………………………………………………………….. 53 
 
Table 5.  Segmental methylation analysis of the CST6 
  promoter/exon 1 in CST6-positive and -negative  
  breast cancer cell lines..…………………………………………………………. 79 
 
Table 6.  Characteristics of human primary breast tumors and 
  normal breast tissues…….………………………………………………………. 88 
 
Table 7.  Characteristics of human lymph node metastases……………………………….. 92
 xii
LIST OF FIGURES 
Figure 1.  The natural history of breast cancer………………………………………… 3 
 
Figure 2.  Alteration of gene expression by promoter CpG  
 methylation …………………………………………………………………. 9 
 
Figure 3.  CpG island containing genes………………………………………………... 13 
 
Figure 4.  A model for cis element-mediated direction of DNA  
 methylation …………………………………………………………………. 17 
 
Figure 5.  Demethylating treatment of MCF-7 breast cancer     
cells………………………………………………………………………….. 29 
 
Figure 6.  Design of CST6 promoter luciferase reporter gene 
constructs……………………………………………………………………. 36 
 
Figure 7.  Identification of putative epigenetically-regulated genes  
 in MCF-7 breast cancer cells after exposure to  
 demethylating treatment…………………………………………………….. 48 
 
Figure 8.  Expression of putative epigenetically-regulated genes  
 in response to demethylating treatment in MCF-7  
 breast cancer cells…………………………………………………….……... 56 
 
Figure 9.  Correlative analysis of promoter methylation and gene  
 expression for CST6 in MCF-7 cells………………………………………... 62 
 
Figure 10.  Correlative analysis of promoter methylation and gene  
 expression for C8orf4 in MCF-7 cells………………………………………. 65 
 
Figure 11.  Correlative analysis of promoter methylation and gene  
 expression for IFI27 in MCF-7 cells………………………………………... 68 
 
Figure 12.  CST6 expression in human breast cancer cell lines and  
 normal mammary epithelial cells…………………………………………… 71 
 
Figure 13. Quantitative real-time PCR analysis of CST6 in breast  
 cancer cell lines……………………………………………………………... 74 
 
Figure 14.  Methylation analysis of the CST6 proximal promoter  
 and exon 1 in breast cancer cell lines and normal  
 mammary epithelial cells that differentially express 
CST6………………………………………………………………………… 77 
 
 xiii
Figure 15.  Methylation analysis of the CST6 proximal promoter  
 and exon 1 in CST6-negative breast cancer cell lines  
 that have been exposed to demethylating treatment………………….……... 81 
 
Figure 16.  Methylation analysis for individual CpG dinucleotides  
 in CST6-positive and CST6-negative breast cancer cell 
lines…………………………………………………………………………. 85 
 
Figure 17.  Immunohistochemical analysis of cystatin M  
 expression in human primary breast tumors…………………………….…... 89 
 
Figure 18.  Immunohistochemical analysis of cystatin M  
 expression in lymph node metastases……………………………………….. 93 
 
Figure 19.  Immunohistochemical analysis of cystatin M  
 expression in matched primary breast tumors and  
 lymph node metastases……………………………………………………… 95 
 
Figure 20.  Methylation analysis of the CST6 proximal promoter  
 and exon 1 in representative primary breast tumors  
 and lymph node metastases……….………………………………………… 98 
 
Figure 21.  Correlation analysis of cystatin M expression and  
 CST6 methylation status in primary breast tumors  
 and lymph node metastases…………………………………………………. 102 
 
Figure 22.  Analysis of luciferase activity of CST6 promoter  
 reporter constructs treated with SssI methylase ……………………………. 105 
 
Figure 23.  Analysis of luciferase activity of CST6 promoter  
 reporter constructs…………………………………………………………... 108 
 
Figure 24.  Methylation analysis of the CST6-500 promoter  
 reporter construct……………………………………………………………. 112 
 
Figure 25.  Methylation analysis of the CST6-1000 promoter 
 reporter construct……….…………………………………………………… 114 
 
Figure 26.  Alteration of gene expression and CpG methylation 
 status during demethylation treatment………………………………………. 118 
 
Figure 27.  A new model for methylation-dependent epigenetic 
 regulation of gene expression……………………………………………….. 125 
 xiv
LIST OF ABBREVIATIONS 
5-aza 5-aza-2’-deoxycytidine  
AH Atypical hyperplasia 
bp Basepair 
cm Centimeter  
cDNA Complementary deoxyribonucleic acid 
CST6 Cystatin M 
CK18 Cytokeratin 18 
dNTP Deoxynucleosidetriphosphate 
DNA Deoxyribonucleic acid 
DCIS Ductal carcinoma in situ 
EDTA Ethylenedinitrilotetraacetic acid 
EST Expressed sequence tag 
IHC Immunohistochemistry 
IDC Invasive ductal carcinoma 
kDa Kilodalton  
mRNA Messenger ribonucleic acid 
μg Microgram 
ml Milliliter 
mm Millimeter 
mM Millimolar 
ng Nanogram 
nM Nanomolar 
 xv
Neo Neomycin 
PCR Polymerase chain reaction 
PDNN Positional dependent nearest neighbor 
RNA Ribonucleic acid 
NaCl Sodium chloride 
S.E.M. Standard error of the mean 
TMA Tissue microarray 
TSA Trichostatin A 
TMI Total methylation index 
U Units 
 xvi
I.  INTRODUCTION 
 
A.  Breast Cancer 
  
Breast Cancer Epidemiology 
 Cancer of the breast is the most common malignant neoplasm among women in the 
United States and the state of North Carolina.  An estimated 178,000 new cases of breast 
cancer among women will be diagnosed in the United States in 2007, accounting for 26% of 
all new cancer cases among women (1).  During the same period, 4870 new cases of invasive 
breast cancer will be diagnosed in North Carolina (1).  Based on incidence rates from 2001 to 
2003, approximately 13% of women will be diagnosed with breast cancer in their lifetime 
(2).  In the 1980s, the number of new cases of breast cancer increased among women 
approximately 4% per year, due in part to the heightened surveillance of women in the 
general population using mammography, resulting in earlier breast cancer diagnosis (3).  The 
incidence of breast cancer rates among women plateaued between 2001 and 2003, possibly 
due to saturation of early mammography screening and reduced use of hormone replacement 
therapy (1).  Between 2000 and 2003, the median age of women diagnosed with breast 
cancer was 61 years of age, and approximately 58% of women diagnosed were between the 
ages of 20 and 64 (2).  The majority (61%) of breast cancer cases are diagnosed when the 
tumor is confined to the primary site (breast) (2).  In part due to early detection, the 5-year 
survival for breast cancer patients diagnosed between 1996 and 2002 was approximately 90% 
(2).  However, it has been documented that breast cancer can recur after long periods of time, 
well after five years from the initial diagnosis (3).              
 In 2007, an estimated 40,000 women will die in the United States from breast cancer (1).  
Among females ages 20 to 59, breast cancer is the leading cause of cancer-related deaths (1).  
In North Carolina, 1240 breast cancer-related deaths will occur in 2007, accounting for 7% of 
cancer-related deaths in the state (1).  Between 1990 and 2003, death rates from cancer 
decreased 8.5% among women, and the reduction of breast and colorectal cancer deaths 
combined accounted for over 60% of the decrease among women (1).  The reduction in 
breast cancer-related deaths directly reflects improvements in early detection and therapeutic 
treatments.   
    
Natural History of Breast Cancer 
The natural history of breast cancer is characterized by a progression of preneoplastic 
lesions, benign neoplastic disease, and culminating in malignant disease.  Figure 1 shows a 
highly simplified schematic representation of the natural history of breast cancer 
development and progression (4).  Breast hyperplasia is a recognized preneoplastic lesion, 
and the risk for developing invasive breast cancer increases with the presence of atypia or 
dysplastic components.  Hyperplastic lesions without atypia are less problematic, and are 
associated with only slightly increased risk for breast cancer development (4).  Atypical 
hyperplasia (AH) shows some characteristics of in situ carcinoma, and can present as either 
ductal or lobular in type (4) (Figure 1).  Ductal carcinoma in situ (DCIS) is a well-known and 
characterized precursor to invasive breast cancer (Figure 1).  The majority of invasive breast 
carcinomas have a DCIS component, suggesting that DCIS is an important precursor to
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Figure 1.  The natural history of breast cancer.  Representative H&E stained images 
corresponding to the individual stages of breast cancer development and progression are 
shown.  The cellular changes that characterize breast tumorigenesis include preneoplastic 
lesions and benign lesions that confer an increased risk for development of invasive breast 
cancer.  Invasive breast cancers will proliferate and grow destroying the surrounding breast 
architecture, leading to local invasion of normal tissue and eventually dissemination to 
distant sites, giving rise to metastatic tumors.        
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advanced disease (4).  However, some investigators have proposed a direct transition from 
normal breast epithelium to malignant epithelium (5).  Most invasive breast cancers 
(approximately 90%) are of the ductal or lobular histopathological type (6), and invasive 
ductal carcinoma (IDC) is the most frequently occurring breast cancer among women (4).  It 
is now accepted that there are two major pathways of multi-step breast cancer progression, (i) 
well-differentiated DCIS progressing to grade I IDC, and (ii) poorly-differentiated DCIS 
progressing to grade III IDC (7).  High grade (poorly-differentiated) DCIS is associated with 
necrosis, apoptosis, and cellular proliferation (6).  Changes in the molecular pattern of DCIS 
lesions may lead to the ability to collapse the myoepithelium, escape the ductal structure, and 
invade the surrounding stroma forming an invasive carcinoma (6,8) (Figure 1).  These IDC 
lesions will proliferate and grow, destroying surrounding stroma, and breast architecture.  
Continued disease progression can lead to tumor dissemination via lymphatic or 
hematogenous routes giving rise to metastatic lesions in distant organs (9) (Figure 1).  
Metastatic breast cancers have a tendency to metastasize to bone, lung, skin, and lymph 
nodes (10). 
 
B.  Molecular Pathogenesis of Breast Cancer 
 
Breast cancer is a heterogeneous disease that results from the accumulation of a complex 
series of genetic and epigenetic events driving divergent pathways that ultimately convey 
varying phenotypic properties to individual neoplastic lesions.  Numerous molecular markers 
have been examined for their predictive value in breast cancer prognostication, but 
histopathologic grade emerges as the most important indicator of long-term patient outcome 
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(6,7).  However, histopathologic grade generally correlates with the expression of genes 
associated with increased cell proliferation (Ki-67, p53), growth (HER-2), and invasiveness 
(matrix metalloproteinases) (11,12).  In contrast, low-grade breast tumors express genes 
associated with low cellular proliferation (p27) and differentiation (ER and PR) (6,13).    At 
present, the molecular mechanisms that control tumor progression, stromal invasion, and 
distant metastasis are poorly understood.  Nevertheless, the role of specific genes that 
contribute to breast tumor invasion and metastasis are beginning to be investigated and 
characterized. 
 
Breast Cancer Susceptibility Genes 
 Family history constitutes a strong and independent predictor of the development of 
breast cancer.  Women who have a family tree of relatives that have developed breast cancer 
exhibit a greater probability of developing breast cancer when compared to the general 
population.  Therefore, a substantial amount of research has focused on identifying breast 
cancer susceptibility genes.  However, only 5-10% of total breast cancer incidence is 
associated with genetic predisposition (4,14).  Genes that confer breast cancer susceptibility 
include, BRCA1, BRCA2, and p53 (15).  The inheritance of a mutation in BRCA1 and BRCA2 
genes confers a lifetime risk of breast cancer of 50-85% (16).  The major functions of these 
protein products are DNA repair and homologous recombination.  Mutations in BRCA1 and 
BRCA2 are found interspersed throughout the coding region, and the most common germline 
mutations found are frameshift mutations that result in the truncation of the protein product 
(4).  Breast cancers that exhibit mutations in BRCA1 and BRCA2 are characterized by a large 
number of chromosome alterations (16).  However, mutations in BRCA1 and BRCA2 only 
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account for a small percentage of familial susceptibility.  In non-BRCA1/BRCA2 breast 
cancer families, termed BRCAx, very little is known related to the genetic basis of inherited 
susceptibility (16).  Histopathological studies have shown that these tumors are of lower 
grade and lower mitotic activity compared to breast tumors related to BRCA1 and BRCA2 
mutation (17).  Patients with Li-Fraumeni cancer-predisposition syndrome have germline 
mutations in the p53 gene (18,19).  Breast cancer is one of the neoplasms that affect these 
patients, and is characterized by early-onset, bilaterality, and association with other familial 
cancers (4).     
 
Environmental and Epigenetic Factors of Breast Cancer Susceptibility 
 Although there is overwhelming evidence that breast cancer is essentially a genetically 
based disease, environmental and epigenetic factors play an important role in breast cancer 
development.  However, environmental and epigenetic influences are not well understood.  
The major risk factors for breast cancer development include:  advancing age (over 50 years 
of age), early age at menarche, first childbirth after the age of 35, late age at menopause, 
nulliparity, obesity, dietary factors (such as high-fat diets), and exposure to high-dose 
radiation to the chest before age 35 (20-23). Recent evidence suggests that epigenetic 
mechanisms play a major role in breast carcinogenesis (24).  Epigenetic alterations differ 
from genetic alterations in that they arise more frequently, are reversible, and occur at 
defined regions of specific genes (25).        
   
C.  Mechanisms of Epigenetic Regulation in Carcinogenesis 
 
 7
DNA Methylation in Cancer   
 Neoplastic transformation is associated with alterations in DNA methylation, including 
both global hypomethylation and gene-specific hypermethylation (26-28).  Hypomethylation 
of cancer cell genomes is associated with loss of methylation in CpG-depleted regions where 
most CpG dinucleotides would be expected to be methylated (29-31).  The loss of 
methylation in these regions of the genome may be associated with aberrant or inappropriate 
expression of some genes that could contribute to neoplastic transformation, tumorigenesis, 
or cancer progression (32).  In addition, genome-wide demethylation can contribute to 
chromosomal instability by destabilizing pericentromeric regions of certain chromosomes 
(33-35).  Gains in DNA methylation in cancer cells typically reflect hypermethylation of 
CpG islands in gene promoter regions, which can lead to gene silencing (26).  Methylation-
dependent gene silencing is a normal mechanism for regulation of gene expression (36).  
However, in cancer cells methylation-dependent epigenetic gene silencing represents a 
mutation-independent mechanism for inactivation of tumor suppressor genes (37) (Figure 2).  
A significant number of cancer-related genes have been identified that are subject to 
methylation-dependent silencing (38), and many of these genes contribute to the hallmarks of 
cancer (39).  These observations combine to strongly suggest that epigenetic events, and 
particularly those involving DNA methylation, represent fundamental aspects of cancer, and 
play key roles in neoplastic transformation and progression. 
 
DNA Methylation in Human Breast Cancer 
 It is now well recognized that epigenetic mechanisms play a major role in neoplastic 
transformation of breast epithelium and tumor progression (24,25).  DNA methylation is a
 8
Figure 2.  Alteration of gene expression by promoter CpG methylation.  A gene 
promoter CpG island located proximal to the transcription start site (indicated by the bent 
arrow) is depicted schematically (vertical lines indicate the relative position of individual 
CpG dinucleotides), including binding sites for transcription factor proteins (blue, green, and 
purple circles).  (A) Lack of CpG island methylation allows transcription factors to bind to 
the gene promoter to facilitate gene transcription.  (B) Promoter CpG island methylation 
(represented by green lollipops), inhibits transcription factor binding, resulting in inhibition 
of gene expression (methylation-dependent silencing).  (C) Methylated DNA binding 
proteins (pink circles) bind to methylated CpG dinucleotides inhibiting transcription factor 
binding and resulting in inhibition of gene expression (methylation-dependent silencing). 
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well known epigenetic mechanism, and a number of different genes have been shown to be 
inactivated in breast cancer through methylation-dependent gene silencing (25).  Some of 
these genes are silenced through a direct effect of DNA methylation, while others are 
affected through indirect mechanisms.  Genes that have been determined to be directly 
silenced by DNA methylation in breast cancer include cell cycle control genes (p16INK4a), 
steroid receptor genes (ERα, PR, RARβ2), tumor suppressor genes (BRCA1), genes associated 
with cancer metastasis (E-cadherin, TIMP-3), and others (24,40-43).  The p16INK4a cyclin-
dependent kinase inhibitor is inactivated through methylation in several human cancers.  In 
breast cancer, p16INK4a is methylated in 20-30% of tumors and cell lines, with a concomitant 
loss of expression (44,45).  Loss of p16INK4a expression in this subset of breast cancers may 
contribute to unregulated cell proliferation and tumorigenesis.  A significant percentage of 
breast cancers lack expression of the estrogen receptor (and other steroid receptors), but loss 
of ER gene expression is not associated with gene deletion or somatic mutation (46).  Rather, 
methylation-dependent silencing of the ER gene is responsible for the loss of expression in 
these tumors (47,48).  Somatic mutations of the BRCA1 gene have not been documented in 
non-hereditary breast cancers (49).  Therefore, an alternative mechanism for BRCA1 
inactivation involving DNA methylation was proposed (50-52).  Subsequently, several 
studies have documented methylation-dependent epigenetic silencing of BRCA1 in sporadic 
breast cancers (53-57).  Loss of E-cadherin gene expression in breast cancer is associated 
with an aggressive tumor phenotype and decreased patient survival (58).  Methylation-
dependent loss of E-cadherin gene expression has been shown in 30% of primary breast 
cancers, and up to 60% of metastatic tumors (59).  Loss of TIMP-3 expression in breast 
tumors potentially results in increased proteolytic activity from matrix metalloproteinase 
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enzymes (60).  The TIMP-3 promoter is methylated in ~30% of primary breast cancers and 
breast cancer cell lines (61).  Both of these methylation-related losses of gene expression are 
likely to contribute to tumor progression and spread.   
 
Targets of DNA Methylation 
 DNA methylation occurs almost exclusively on cytosines within CpG dinucleotides, 
which are relatively rare in the genome, occurring at about 20% of the predicted frequency 
(25).  However, regions of CpG density, termed CpG islands (62,63), occur in the promoter 
sequences of numerous genes, proximal to their transcription start site (64) (Figure 3).  Some 
investigators have suggested that as many as 50% of all human genes may contain a 
promoter CpG island.  These CpG islands are conventionally defined as >200 bp with >50% 
G+C and >0.6 CpG observed/CpG expected (65).  Numerous studies have shown that there is 
a strong inverse correlation between promoter methylation status and gene expression levels 
(66,67).  However, this inverse relationship has only been shown for methylation affecting 
promoter regions of genes, and not methylation that occurs in transcribed sequences (68).  
Studies that demonstrate extensive promoter CpG island methylation in genes that are 
transcriptionally silent, including imprinted genes like H19 (69), suggest that CpG island 
hypermethylation represents a normal mechanism for gene regulation.  A significant number 
of CpG island containing genes have been shown to be silenced by methylation in breast 
cancer.  The 14-3-3σ gene is silenced in the majority of human breast cancers (94%) as a 
consequence of CpG island methylation (70).  Likewise, the BRCA1 gene contains a 
promoter CpG island that is frequently methylated in breast cancers that lack BRCA1 
expression (51,53,54).  In addition, evidence for the importance of discrete methylation
 12
Figure 3.  CpG island containing genes.  The distribution of CpG dinucleotides proximal to 
the transcription start site in the promoter and exon 1 of estrogen receptor 1 (ESR1), 
myeloblastosis viral oncogene (MYB), and cystatin M (CST6) are depicted schematically 
(vertical lines indicate the relative position of individual CpG dinucleotides).  CpG islands 
are indicated by green lines and are found in all genes.  The CpG island is found in exon 1 
(indicated by a pink arrow) of ESR1.  In MYB and CST6, the CpG island is located in the 
proximal promoter and exon 1, spanning the transcription start site.      
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events within a larger methylation target (CpG island) has appeared in the literature. The AP-
2α tumor suppressor gene is subject to methylation-dependent silencing through methylation 
of a discrete region that is contained within a larger CpG island (71).  Numerous 
investigations have focused on methylation events that occur in CpG islands to characterize 
epigenetic changes in cancer (72-74).  However, most of these studies acknowledge that a 
significant percentage (48% to 64%) of putative epigenetically-regulated genes lack these 
regions of CpG density (72-74), and that genes lacking CpG islands as a methylation target 
are frequently induced in response to demethylating drugs (75-77).  Thus, it is probable that 
novel CpG targets for methylation are present in putative epigenetically-regulated genes that 
do not contain CpG islands.  There is some evidence indicating that methylation events in 
promoters lacking CpG islands can result in down-regulation of gene expression (62).  In 
fact, a number of studies have shown that methylation of novel CpG targets can result in 
epigenetic silencing of gene expression.  Well-characterized examples of methylation-
sensitive genes lacking CpG islands include E-cadherin, (25,78) RAR-β2, (79) APC, (80) and 
LAMB3 (81-84).  Combined, these findings from the literature suggest that targets for CpG 
methylation will include typical CpG islands, as well as novel methylation targets, such as 
specific CpG dinucleotides in critical gene regulatory regions. 
 
Mechanisms of Regulation of DNA Methylation 
 Both normal and cancer cells exhibit specific patterns of CpG methylation that reflect 
nonrandom hypermethylation of particular regions of DNA resulting in silencing of certain 
genes.  The mechanisms that control this nonrandom distribution of CpG methylation are 
poorly understood.  However, several lines of evidence support the notion that cis-acting 
sequence elements exist that regulate de novo methylation, including directive (methylation-
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promoting) instructions (85,86) and protective (methylation-preventing) instructions (87) 
(Figure 4).  It is conceivable that these directive and protective elements coexist in the 
promoter regions of epigenetically-regulated genes and that a balance between these forces 
dictate the methylation status of the promoter in specific cell types or under specific 
physiological conditions.  A number of studies have addressed the question of whether cis 
elements direct DNA methylation of specific target genes (Figure 4).  One of the most 
extensively studied genes is the mouse APRT gene.  When an unmethylated copy of the 
APRT gene was transfected into APRT-deficient mouse embryonal carcinoma cells, the 
promoter region of the transfected gene acquired a methylation pattern that was identical to 
the endogenous methylation pattern of APRT confirming the presence of a cis element in the 
5’-sequence of this gene (88,89).  Deletion analysis of the mouse APRT gene localized the 
cis element to a 838 bp region in the promoter sequence (90,91).  In a recent study, Feltus et 
al. performed a detailed sequence analysis of methylation-prone and methylation-resistant 
CpG islands to investigate the possibility that susceptibility to methylation might be 
conferred by cis-acting features of differing CpG islands (92).  When general characteristics 
of CpG islands were evaluated (size, G+C content, CpG frequency), no significant 
differences were detected between methylation-prone and methylation-resistant CpG islands 
(92).  However, using pattern recognition and supervised learning techniques to analyze 
sequences flanking CpG islands, a number of sequence elements were identified that predict 
methylation of promoter sequences with high discrimination potential (92).  It is not known if 
these sequences function to direct or promote methylation.  
 16
Figure 4.  A model for cis element-mediated direction of DNA methylation.  A gene 
promoter is depicted schematically, including a CpG island (pink box) located proximal to 
the transcription start site (indicated by the bent arrow) and a putative instructional sequence 
element (yellow box).  (A) Cis element binding proteins (indicated by green and orange 
circles) can recognize an instructional element within the upstream promoter region of a 
gene.  (B) Cis element binding proteins bind to the instructional sequence element and recruit 
DNA methyltransferase 3b (DNMT3b, blue circle) to the gene promoter region.  (C) Once 
recruited to the gene promoter, DNMT3b methylates (yellow circles) the target CpG island.   
 17
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D.  Cystatins and Cancer:  Methylation-sensitive Genes that Contribute to Breast 
Tumorigenesis and Progression 
 
Cysteine Protease Inhibitors - Cystatins 
Cystatins function as cysteine protease inhibitors and were discovered in the 1960s with a 
report on a factor capable of inhibiting the clotting activity of a thiol-dependent protease in 
mammalian cells (93).  Since that time, other groups identified cystatin proteins that control 
and regulate physiological processes that range from cell survival and proliferation, to 
differentiation, cell signaling, and immunomodulation (94,95).  By the early 1980s, it was 
recognized that cystatins are present in lysosomes of most if not all cell types (96,97).  
Aberrant regulation of these important homeostatic factors contributes to a range of 
pathologies.  Cystatins regulate the physiological activities of specific cysteine proteases 
(cathepsin family members) (98).  There is increasing evidence that an imbalance between 
cysteine proteases and their inhibitors (cystatins) leads to excess protease activity due to high 
cathepsin levels, which contributes to tumor cell invasion (99).  Consequently, imbalances in 
cystatins have been noted in a number of cancers (95).  
 
Cystatin Super-Family  
 Cysteine protease inhibitors belong to a cystatin super-family encompassing a large 
group of homologous proteins that inhibit papain family cysteine proteases (94,95,100).  
Twelve functional cystatins divide into three types based on protein structure, location in the 
body, and physiological role.  Type 1 cystatins (cystatins A and B) are polypeptides of 98 
amino acid residues and are found intracellulary, but occasionally appearing in body fluids at 
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detectable levels (95,100).  The majority of cysteine protease inhibitors encompass type 2 
cystatins including cystatin C, D, M, F, G, S, SN, and SA.  Type 2 cystatins consist of 120 
amino acid residues, two disulphide bridges, and an extracellular signaling peptide (101), and 
are found in most body fluids (95,100).  Kininogens comprising type 3 cystatins are large 
multifunctional proteins with three type 2-like cystatin domains, of which only two are 
capable of inhibiting cysteine proteases (95).  Kininogens are found in blood plasma (95).  
The tertiary structures of cystatin proteins are conserved and fold into a five-stranded beta-
sheet, which wraps around a five-turn alpha-helix, termed a ‘cystatin fold’ (94,102).  
Cystatins function to protect cells from lysosomal peptidases released during normal cell 
death, phagocyte degranulation, and/or during cancer cell proliferation (95).  Therefore, 
cystatins are essential in safeguarding against abnormal lysosomal cysteine protease activity 
that is essential for tumor invasion and metastasis. 
 
CST6 (Cystatin M):  A Prototype Methylation-sensitive Gene              
      Cystatin M was originally identified in breast cancer cell lines isolated from a metastatic 
lesion and matched primary breast tumor by differential RNA display RT-PCR (103).  In 
another investigation of EST-libraries of amniotic and fetal skin epithelial cells, cystatin M 
was independently cloned from cDNA (104).  The biochemical properties, chromosomal 
localization (chromosome 11), and biological distribution of cystatin M is significantly 
different compared to the other cystatins (105).  Cystatin M is expressed in a variety of 
normal human tissues including brain, lung, heart, liver, pancreas, spleen, thymus, small 
intestine, prostate, ovary, peripheral blood cells, and placenta (103,104).  Cystatin M consists 
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of 121 amino acids and unlike other type 2 cystatins, is found in two different protein forms:  
(i) glycosylated (17 kDa), and (ii) non-glycosylated (14.4 kDa) (104).   
 Cystatin M is involved in regulating the activity of cathepsin B and cathepsin L, and an 
imbalance between these proteases and cystatin M is important in driving tumor progression 
(106-108).  Cystatin M expression is diminished or lost in various forms of cancer including, 
(i) basal and squamous cell carcinomas of the skin (109), (ii) squamous cell carcinomas of 
the head and neck and lung regions (110), (iii) non-small cell lung cancer (111), (iv) 
metastatic oral cancer cell lines (105), (v) malignant glioma (112), (vi) melanoma cell lines 
(113), (vii) prostate cancer cell lines (113), and (viii) breast cancer (8,103,113-117).  Cystatin 
M has been suggested to function as a breast tumor suppressor gene (116).  The majority of 
human breast cancer cell lines derived from metastatic breast tumors lack cystatin M 
expression, whereas normal and premalignant cells express abundant levels of cystatin M 
(103,116).  Exogenous expression of cystatin M in MDA-MB-435S breast cancer cells 
results in the suppression of cell proliferation, migration, matrix invasion, and tumor-
endothelial cell adhesion in vitro (113).  No deletions or structural rearrangements of cystatin 
M have been characterized, suggesting that loss of gene expression may be the result of 
transcriptional silencing (94,118). 
Cystatin M contains a large CpG island (424 bp) including 54 CpG dinucleotides that 
spans the proximal promoter and exon 1, encompassing the start site for transcription.  The 
promoter region of cystatin M contains a 8% CpG dinucleotide content 1400 bp upstream of 
the transcription start site, with the most CpG density (12%) occurring in the proximal 500 
bp of the promoter.  Several studies have shown that cystatin M is epigenetically regulated by 
DNA methylation-dependent silencing in breast cancer cell lines and primary invasive ductal 
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carcinomas (8,115).  Furthermore, cystatin M was identified as a methylation-sensitive gene 
in glioma cell lines and primary brain tumors (112).  Overall, these observations suggest 
strongly that methylation-dependent epigenetic silencing of cystatin M represents an 
important mechanism for loss of cystatin M in multiple tumor systems. 
 
E.  Summary and Significance 
  
 The studies contained in this dissertation are relevant to breast cancer research in many 
important ways.  While the contribution of epigenetic mechanisms to breast cancer induction 
and progression is well recognized, epigenetically-regulated genes in breast cancer have not 
been comprehensively catalogued or characterized.  This dissertation characterizes a group of 
putative methylation-sensitive genes identified in MCF-7 breast carcinoma cells, validates 
that these genes are subject to methylation-dependent regulation, and identifies critical 
promoter methylation targets.  The genes characterized include genes of unknown function, 
as well as genes of known (or proposed) function, among which are putative breast cancer 
tumor suppressor genes and genes that are associated with growth suppressive pathways.  In 
addition, this dissertation evaluates the methylation of CST6 in primary breast cancers and 
lymph node metastases, and shows that CST6 is subject to DNA methylation-dependent 
epigenetic regulation in vivo.  Thus, these studies establish a role for methylation-dependent 
epigenetic regulation in the loss of function of genes important for the molecular 
pathogenesis of breast cancer.  In addition, this dissertation identifies several distinct classes 
of epigenetically-regulated genes and these classes can be distinguished based upon the CpG 
content and CpG organization of their promoters.  Consequently, the establishment of a new 
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definition for epigenetically-regulated genes that recognizes the importance of all CpG 
targets has been proposed.  This dissertation also addresses the unresolved question of what 
mechanisms govern methylation of CpG targets and identifies the existence of cis regulatory 
sequences located in the 5’ upstream promoter region of CST6 that functions to direct CpG 
methylation.  Consequently, these results advance our understanding of mechanisms 
governing DNA methylation in breast carcinogenesis.  
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II.  EXPERIMENTAL PROCEDURES 
 
A.  Breast Cancer Cell Line Culture 
  
 Human breast cancer cell lines were obtained from the Tissue Culture Core Facility of the 
UNC Lineberger Comprehensive Cancer Center at the University of North Carolina at 
Chapel Hill:  BT-20 (ATCC#HTB-19), BT549 (HTB-122), Hs578T (HTB-126), MCF-7 
(HTB-22), MDA-MB-231 (HTB-26), MDA-MB-415 (HTB-128), MDA-MB-435S (HTB-
129), MDA-MB-436 (HTB-130), MDA-MB-453 (HTB-131), MDA-MB-468 (HTB-132), 
SK-BR-3 (HTB-30), and ZR-75-1 (CRL-1500).  Normal breast epithelial cell lines, MCF12A 
(CRL-10782) and MCF10-2A (CRL-10781), were obtained from the ATCC (Manassas, VA).  
BT-20, MCF-7, and MDA-MB-231 cells were propagated in minimal essential medium 
(MEM) with Earle’s salts, containing 2 mM L-glutamine, 0.1 mM non-essential amino acids, 
1 mM sodium pyruvate, 10 μg/ml insulin (GIBCO/Invitrogen Life Technologies, Carlsbad, 
CA), and 10% fetal bovine serum (Hyclone, Logan, UT).  Hs578T, MDA-MB-435S, MDA-
MB-436, MDA-MB-453 cells were propagated in Dulbecco’s modified Eagle’s medium 
containing 4 mM L-glutamine, 10 μg/ml insulin (GIBCO/Invitrogen Life Technologies), and 
10% fetal bovine serum (Hyclone).  BT549 and ZR-75-1 cells were propagated in RPMI 
1640 containing 2 mM L-glutamine, 1 mM sodium pyruvate, 10 μg/ml insulin 
(GIBCO/Invitrogen Life Technologies), and 10% fetal bovine serum (Hyclone).  MDA-MB-
415 and MDA-MB-468 cells were propagated in Leibovitz’s L-15 medium containing 2 mM 
L-glutamine, 10 μg/ml insulin (GIBCO/Invitrogen Life Technologies), 10 mg/ml glutathione 
(Sigma Chemical Company, St Louis, MO, USA), 10% fetal bovine serum (Hyclone).  SK-
BR-3 cells were propagated in McCoy’s 5A medium containing 1.5 mM L-glutamine, and 
10% fetal bovine serum (Hyclone).  MCF12A and MCF10-2A cells were propagated in a 1:1 
mixture of Dulbecco’s modified Eagle’s medium and Ham’s F12 medium containing 20 
ng/ml human epithelial growth factor (Sigma Chemical Company, St. Louis, MO), 100 ng/ml 
cholera toxin (Sigma Chemical Company), 10 μg/ml insulin (GIBCO/Invitrogen Life 
Technologies), 500 ng/ml hydrocortisone (Sigma Chemical Company), and 5% horse serum 
(GIBCO/Invitrogen Life Technologies).    
 
B.  Treatment of Human Breast Cancer Cells with Demethylating Agents 
 
MCF-7 Breast Cancer Cells Treated with 5-aza-2’-deoxycytidine and Trichostatin A 
 Three MCF-7 cell treatment groups were established from a single founding MCF-7 cell 
population: (i) control medium, (ii) medium containing 250 nM 5-aza-2’-deoxycytidine (5-
aza), and (iii) medium containing 250 nM 5-aza and 50 nM trichostatin A (TSA).  5-aza and 
TSA were obtained from Sigma Chemical Company.  Cells were plated at 5,000 cells/cm2 in 
150 mm polystyrene dishes (Corning Inc., Corning, NY).  MCF-7 cells in the treatment 
groups were exposed to 5-aza or 5-aza + TSA for 3 weeks, with weekly subcultivation, 
followed by a 5 week recovery period in control growth medium, with weekly 
subcultivations during the last 3 weeks.  Control MCF-7 cells were subcultivated once per 
week during the 8 week cell culture period.  Cell cultures were fed fresh growth medium 
three times weekly. 
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Hs578T, MDA-MB-435S, MDA-MB-436, MDA-MB-453, MCF-7, and ZR-75-1 Breast 
Cancer Cells Treated with 5-aza-2’-deoxycytidine 
  Cell lines that lack expression of CST6 (including Hs578T, MDA-MB-435S, MDA-
MB-436, MDA-MB-453, MCF-7, and ZR-75-1) were treated with the demethylating agent 5-
aza (Sigma Chemical Company), as described above.  Briefly, two treatment groups were 
established from a single founding cell population: (i) control medium, and (ii) medium 
containing 250 nM 5-aza.  Cells in the treatment group were exposed to 5-aza for 3 weeks, 
with weekly subcultivation, followed by a 5 week recovery period in control growth medium 
with weekly subcultivations during the last 3 weeks.  Control cells were subcultivated once 
per week during the 8 week cell culture period.  Cell cultures were fed fresh growth medium 
three times weekly.   
 
C.  Human Breast and Lymph Node Tissues     
 
This study included 87 paraffin-embedded human tissues corresponding to primary breast 
tumors (n=54), lymph nodes metastases (n=22), and normal breast tissues (n=11).  Twenty-
one archival human tissues (primary breast tumors, lymph node metastases, and normal 
breast) were obtained from the University of North Carolina Lineberger Comprehensive 
Cancer Center and 6 archival primary breast tumors were acquired from the Louisiana State 
University Health Sciences Center, generously provided by Dr. Daniel Keppler (Shreveport, 
LA).  A breast tumor microarray (Imgenex Corporation, Sorrento Valley, CA) consisting of 
60 tissue cores was also utilized.  In total, this study included 46 primary breast specimens 
diagnosed invasive ductal carcinoma (IDC), 2 breast ductal carcinoma in situ specimens, 1 
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solid papillary carcinoma, 1 medullary carcinoma, 1 signet ring cell carcinoma, 3 infiltrating 
lobular carcinomas, 22 lymph node metastases from IDC (n=20), atypical medullary 
carcinoma (n=1), and infiltrating lobular carcinoma (n=1), and 11 normal breast tissue 
samples.  Five archival primary breast tumors were matched paired with lymph node 
metastases (3 independent lymph nodes corresponded to 1 primary tumor and 4 independent 
lymph nodes corresponded to one primary tumor).  Handling of tissue specimens and 
protection of patient privacy followed strict policies of the institutional review board of the 
University of North Carolina School of Medicine.   
 
D.  RNA Isolation from Human Breast Cancer Cell Lines 
 
Total RNA was isolated from cultured cells using a modification of the method of 
Chomczynski and Sacchi (119) utilizing TRIzol Reagent (Invitrogen Corporation, Carlsbad, 
CA), according to the manufacturer’s protocol.  Control breast cancer cells were harvested 
weekly for RNA preparation over an 8 week culture period, whereas cells treated with 5-aza 
or 5-aza + TSA were harvested for RNA preparation at 3 weeks and 8 weeks. Isolated total 
RNA was stored at -20°C as an ethanol precipitate prior to microarray analysis or RT-PCR.  
Cells were counted at the end of each week using a Model Z1 Coulter Cell and Particle 
Counter (Beckman Coulter Inc., Fullerton, CA).   
 
E.  Affymetrix Microarray Analysis of Gene Expression 
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 Large-scale gene expression analyses were performed by Expression Analysis 
(www.expressionanalysis.com), using the Affymetrix Human Genome GeneChip U133A 
oligonucleotide array (Affymetrix, Santa Clara, CA), which contains 500,000 
oligonucleotides corresponding to 22,000 probe sets directed against 18,400 mRNA 
transcripts and 14,400 well-characterized genes.  RNA samples corresponding to control 
MCF-7 cells (at week 3 and week 8), MCF-7 cells that were treated with 250 nM 5-aza 
(week 3 and week 8), and MCF-7 cells treated with 5-aza + TSA (week 3 and week 8) were 
utilized in this analysis.  RNA samples from week 3 were derived from cells harvested after 3 
weeks of exposure to 5-aza or 5-aza + TSA, whereas RNA samples from week 8 were 
derived from cells that were exposed to treatment for 3 weeks (to 5-aza or 5-aza + TSA) and 
then allowed to recover in control growth medium for 5 weeks (Figure 5).  Target was 
prepared and hybridized according to the Affymetrix Technical Manual.  Total RNA (10 μg) 
was converted into cDNA using Superscript II Reverse Transcriptase (Invitrogen 
Corporation) and a modified oligo(dT)24 primer that contains T7 promoter sequences 
(GenSet, Evry, France).  After first strand synthesis, residual RNA was degraded by the 
addition of RNaseH and a double-stranded cDNA molecule was generated using DNA 
Polymerase I and DNA Ligase (Invitrogen Corporation).  The cDNA was purified and 
concentrated using a standard phenol:chloroform extraction, followed by ethanol 
precipitation.  Labeled cRNA products were generated from the purified cDNAs by 
incubation with T7 RNA Polymerase and biotinylated ribonucleotides, using an In Vitro 
Transcription kit (Enzo Diagnostics, Farmingdale, NY).  cRNA products were purified on an 
RNeasy column (Qiagen Inc., Valencia, CA) and quantified spectrophotometrically.  Purified 
cRNA target (20 μg) was incubated at 94°C for 35 minutes in fragmentation buffer [200 mM
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Figure 5.  Demethylating treatment of MCF-7 breast cancer cells.  MCF-7 cells were 
exposed to 5-aza or 5-aza + TSA for three weeks, with weekly subcultivation and passage, 
followed by a five week recovery period in control growth medium, with weekly 
subcultivations and passages during the last three weeks.  MCF-7 cells were harvested for 
RNA and DNA preparation at 1, 2, 3, 6, 7, and 8 weeks.  RNA and DNA preparation at the 
end of the treatment period (3 weeks) and at the end of the recovery period (8 weeks) were 
used for microarray analysis.   
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Tris-acetate (pH 8.1), 500 mM potassium acetate, and 50 mM magnesium acetate], and then 
diluted into hybridization buffer [100 mM 2-(N-morpholino) ethanesulfonic acid, 20 mM 
EDTA, and 0.1% Tween 20] containing biotin-labeled OligoB2 and Eukaryotic 
Hybridization Controls (Affymetrix).  The hybridization cocktail was denatured at 99°C for 5 
minutes, incubated at 45°C for 5 minutes, and then injected onto a Human Genome U133A 
GeneChip cartridge.  The U133A GeneChip array was incubated at 42°C for at least 16 hours 
in a rotating oven at 60 rpm.  Subsequently, the hybridized GeneChips were washed under 
nonstringent conditions at 25°C in a buffer consisting of 0.9 M NaCl, 70 mM sodium 
phosphate (pH 7.4), 6 mM EDTA, and 0.01% Tween 20, and stringent conditions at 50°C in 
a buffer consisting of 100 mM 2-(N-morpholino) ethanesulfonic acid, 100 mM NaCl, and 
0.01% Tween 20.  The microarrays were then stained with Streptavidin Phycoerythrin and 
the fluorescent signal was amplified using a biotinylated antibody solution.  Fluorescent 
images were detected in an Agilent GeneArray Scanner (Agilent Technologies Inc.).  After 
probe-level data was extracted from the MicroArray Suite-derived CEL files, the probes were 
normalized using quantile probe normalization (120).  Signal was computed using the 
Positional Dependent Nearest Neighbor (PDNN) method (121), and scaled by Expression 
Analysis proprietary methods to mitigate bias in fold-change underestimation.  Microarray 
hybridizations were performed in duplicate (for each treatment group and time point) and the 
final values for (log) signal for all graphs were averages of the duplicates (equivalent to 
geometric averages of signal).  The one exception is the control average, which was an 
average of the control at two different time points (week 3 and week 8). 
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 F.  Semiquantitative RT-PCR Analysis of Gene Expression 
  
 Total RNA (2 μg) from control or cells treated with 5-aza or 5-aza + TSA was reverse-
transcribed into cDNA using Superscript II Reverse Transcriptase (Invitrogen Corporation) 
and oligo(dT) as the primer, 60 minutes at 42°C, according to standard methodology.  Gene-
specific oligodeoxynucleotide primers were generated by the UNC Oligodeoxynucleotide 
Synthesis Core Facility (Chapel Hill, NC) for selected mRNAs based upon their known 
cDNA sequence (Genbank, www.ncbi.nih.gov).  The sequences of gene-specific primers are 
given in Table 1.  Verification of equal template concentration between samples was 
accomplished using primers that amplify a portion of β-actin mRNA (5’-
AGAGATGGCCACGGCTGCTT-3’ and 5’-ATTTGCGGTGGACGATGGAG-3’).  PCR 
reactions were performed in a 50 μl total volume of buffer containing 50 mM KCl, 10 mM 
Tris-HCl (pH 8.3), 1.5 mM MgCl2, 0.001% gelatin, 200 μM of each dNTP (EasyStart Micro 
50 PCR-mix-in-a-tube, Molecular BioProducts, San Diego, CA), 0.4 μM of each primer, and 
2.5 U AmpliTaq enzyme (Perkin Elmer/Cetus, Foster City, CA).  Amplifications were 
carried out in a Perkin Elmer 9700 Thermocycler using a step-cycle program consisting of 
25-30 cycles of 94°C for denaturing (1 minute), 58°C for annealing (1 minute), and 72°C for 
extension (2 minutes).   
 
G.  Quantitative Real-Time PCR 
 32
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 Total RNA samples (20 μg) from Hs578T, MCF-7, MDA-MB-436, MDA-MB-453, and 
ZR-75-1 control and treated cells were DNAase treated (Promega, Madison, WI), purified 
using the Qiagen Rneasy mini-kit (Qiagen), and reversed transcribed using the High Capacity 
cDNA Archive Kit (Applied Biosystems, Foster City, CA) according to the manufacturer’s 
protocol.  Real-time primers and probes for CST6 and β-actin were purchased from Applied 
Biosystems.  Reactions were carried out using TaqMan Universal PCR Master Mix (Applied 
Biosystems) and the following PCR conditions: 95°C for 10 minutes, 40 cycles of 95°C for 
15 seconds and 60°C for 1 minute.  Gene expression levels were normalized using β-actin for 
each cell line and differences in CST6 gene expression were determined using the 
comparative Ct method described in the ABI Prism 7700 User Bulletin #2 (Applied 
Biosystems).   
 
H.  Promoter and 5’-Upstream Sequence Analysis of Putative Methylation-sensitive 
Genes 
  
 Genomic sequences corresponding to the promoter and 5’-upstream regions of select 
genes were identified using the Human Genome Browser Gateway 
(http://genome.ucsc.edu/cgi-bin/hgGateway) contained in the UCSC Genome Bioinformatics 
website (http://genome.ucsc.edu/).  GenBank accession numbers were utilized to identify 
RefSeq records corresponding to each gene, and then the promoter and 5’-upstream 
sequences were identified using the Genomic Sequence Near Gene tool.  For each gene of 
interest, 3000 bp of sequence 5’-upstream of exon 1 (containing the putative transcriptional 
promoter and associated elements) were identified.  CpG islands were identified within 
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promoter and exon 1 sequences using the CpGPLOT program from the European 
Bioinformatics Institute website (http://www.ebi.ac.uk/emboss/CpGplot/).  Typical CpG 
islands were defined as >200 bp of sequence with >50% C+G content and >0.6 CpG 
observed/CpG expected (22).  Weak CpG islands exhibit the same features (with >50% G+C 
content and >0.6 CpG observed/CpG expected), but over a shorter sequence segment (>50 bp 
but <200 bp).  Alu repetitive elements were identified using the RepeatMasker Web Server 
(http://repeatmasker.genome.washington.edu) from the Institute for Systems Biology at the 
University of Washington (Seattle, WA) and transcription factor binding sites were identified 
using ProSpector (http://prospector.nci.nih.gov). 
 
I.  Construction of Reporter Gene Constructs  
 
CST6 Gene Promoter Constructs  
 Segments of the CST6 promoter were amplified by PCR and inserted upstream of the 
firefly luciferase gene in the pGL4.17[luc2/Neo] vector (Promega, Madison, WI, USA) to 
generate CST6 reporter constructs.  The pGL4.17[luc2/Neo] plasmid contains a multiple 
cloning region, ampicillin resistance gene, luc2 reporter gene, and a SV40 early 
enhancer/promoter driving a neo resistance gene.  A series of reporter constructs were 
generated with different portions of the CST6 promoter with a common 3’ end, terminating at 
+33 bp relative to the designated transcription start site (Genebank accession number 
NM_001323.1).  Three constructs were generated, encompassing -1534 to +33 (designated 
CST6-1500), -1187 to +33 (designated CST6-1000), and -438 to +33 (designated CST6-500) 
(Figure 6).   The CST6-500 construct represents the minimal essential promoter and
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Figure 6.  Design of CST6 promoter luciferase reporter gene constructs.  A schematic 
representation of three CST6 promoter reporter gene constructs is shown.  Each of these 
reporter constructs consists of the firefly luciferase gene (pink box) driven by different 
portions of the CST6 promoter:  CST6-1500 (-1534 to +33 nucleotides), CST6-1000 (-1187 to 
+33 nucleotides), and CST6-500 (-438 to +33 nucleotides).  The distribution of the CpG 
dinucleotides in the CST6 promoter proximal to the luciferase gene is depicted schematically 
(vertical lines indicate the relative position of individual CpG dinucleotides).   
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37
encompasses the proximal promoter CpG island as predicted by CpGPLOT 
(www.ebi.uk/emboss/CpGplot/).  Likewise, the CST6-1000 construct encompasses the 
proximal promoter CpG island and spans approximately 1000 bp upstream of the 
transcription start site, and the CST6-1500 construct encompasses the CpG island and spans 
approximately 1500 bp upstream of the transcription start site.  The CST6 gene promoter was 
amplified using the following forward primers designed with BglII restriction sites (shown 
underlined):  CST6-1500, 5’-ATGCTAGAGATCTAGTTGTCAGTCCCCCTAGGTC-3’, 
CST6-1000, 5’-ATGCTAGAGATCTAGGGCAGAGCTGACATGACTGA-3’, CST6-500, 
5’-ATGCTAGAGATCTAGTCCAGCACCAGACCTCTTCT-3’.  A common reverse primer 
was used for all constructs and included a HindIII restriction site (shown underlined):  5’-
AGTCAAGCTTAGCCTCAGAGCCGTGAGTGC-3’.  Amplicons were inserted into 
pGEM-T Easy Vector (Promega) and propagated in JM109 bacterial cells.  Ten colonies 
were selected per promoter construct and expanded in liquid culture.  Plasmid DNA was 
purified using the Wizard Plus Miniprep DNA purification kit (Promega), before digestion 
with BglII and HindIII (New England Biolabs, Ipswich, MA) to liberate the CST6 promoter 
segment.  Restricted DNA samples were fractionated on 2% low temperature melting agarose 
gels and the cloned inserts were excised from the gel.  DNA fragments were ligated into the 
pGL4.17[luc2/Neo] vector  double digested with BglII and HindIII, cloned, and purified as 
described.  Reporter constructs were confirmed by restriction mapping and DNA sequencing 
with an Applied Biosystems automated sequencer at the UNC Genome Analysis Facility 
(Chapel Hill, NC). 
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In Vitro CST6 Promoter Construct Methylation  
 To analyze the effects of methylation on promoter activity, CST6 reporter constructs 
(CST6-1500, CST6-1000, and CST6-500) were methylated using SssI methylase (M. SssI, 
New England Biolabs), which methylates all cytosine residues within CpG dinucleotides.  
Approximately 2 μg of each DNA construct was incubated with 4 U of SssI in the presence 
of 1600 μM S-adenosylmethionine at 37°C overnight.  Methylated and unmethylated 
constructs were linearized with BSU36I (New England Biolabs) prior to transfection of breast 
cancer cells.   
 
J.  Luciferase Reporter Assay  
 
Transient Transfection of MCF-7 Breast Cancer Cells 
 MCF-7 breast cancer cells were seeded at approximately 2x105 per well into 6-well plates 
and grown to 80%-90% confluence.  CST6-1000 and CST6-500 promoter constructs (2.5 μg) 
were transfected by TransIT-LT1 Transfection Reagent (Mirus Bio, Madison, WI) according 
to the manufacturer’s protocol.  Cells were harvested 48 hours after transfection and 
luciferase activity was measured using the Steady-Glo Luciferase Assay System according to 
the manufacturer’s protocol.      
 
Stable Transfection of Human Breast Cancer Cell Lines  
 Human breast cancer cell lines were obtained from the Tissue Culture Core Facility of the 
UNC Lineberger Comprehensive Cancer Center at the University of North Carolina at 
Chapel Hill:  BT-20 (ATCC#HTB-19), MCF-7 (HTB-22), and MDA-MB-453 (HTB-131). 
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Normal breast epithelial cell line, MCF12A (CRL-10782) was obtained from the ATCC.  All 
cells were propagated according to recommendations from the ATCC (see above).  Human 
breast cells (approximately 8x105) were seeded in 100 mm plates and grown to 80%-90% 
confluence.  CST6-1000 and CST6-500 promoter constructs (2 μg) were transfected using 
Effectene Transfection Reagent (Qiagen) according to the manufacturer’s protocol.  Parallel 
cultures were transfected with control pGL4.17[luc2/Neo] vector, as described.  Stably 
transfected cells were selected using 400 μg/ml G418 (Invitrogen Corporation) in BT-20 
cells and MCF12A cells, 800 μg/ml G418 in MCF-7 cells, and 1200 μg/ml G418 in MDA-
MB-453 cells.  Luciferase activities corresponding to each reporter construct (CST6-1000 
and CST6-500) were determined for each transfected cell line three times over a 5 to 7-week 
time point (approximately once every two weeks) using the Steady-Glo Luciferase Assay 
System (Promega) according to the manufacturer’s protocol.  Luciferase activities for each 
reporter construct were calculated after subtraction of background, and determined using the 
promoterless pGL4.17[luc2/Neo] vector.   
 
K.  Genomic DNA Isolation  
 
Human Breast Cancer Cell Lines  
Genomic DNA from 2x106 cultured cells was isolated using the Puregene DNA 
Purification Kit (Gentra Systems, Minneapolis, PA) according to the manufacturer’s 
protocol.  Briefly, cells were lysed and incubated with proteinase K overnight at 55°C.  
Following incubation, RNase A solution was added and samples were incubated at 37°C for 
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1 hour.  Subsequently, DNA was precipitated, hydrated by incubating at 65°C for 1 hour, and 
stored at -20°C before use.   
 
Human Primary Breast Tumors, Lymph Nodes, and Normal Breast Tissue  
 Paraffin-embedded tissue specimens were scraped or microdissected from slides using a 
clean razor blade, deparaffinized, and genomic DNA was isolated using a QIAamp DNA 
Micro kit (Qiagen, Inc., Valencia, VA) according to manufacturer’s instructions.  Briefly, 
tissue samples were incubated overnight at 56°C with proteinase K.  Subsequently, carrier 
RNA (1 μg/μl) was added and DNA samples were applied to columns, washed, and eluted 
with 35 μl of distilled water.   
 
L.  Bisulfite Modification of Genomic DNA, Cloning, and Sequencing   
  
Human Breast Cancer Cell Lines  
 Bisulfite modification of genomic DNA was performed by a procedure adapted from 
Grunau et al. (122), generously provided by Dr. Randy Jirtle (Duke University, Durham, 
NC).  Genomic DNA (3 µg) was digested with 1 U of Xho I (New England Biolabs) 
overnight in 12 µl total volume and heat inactivated at 65°C for 20 minutes; 5 µl of digest 
was subjected to bisulfite modification.  Briefly, approximately 1.5 µg of DNA in 45 µl of 
distilled water was denatured by adding 5 µl 3 M NaOH and incubating for 20 minutes at 
42°C, followed by addition of 450 µl of sodium bisulfite solution (saturated sodium bisulfite, 
10 mM hydroquinone, pH 5.0) and incubation at 55°C for 4 hours.  Bisulfite modified DNA 
(500 µl) was purified using the Wizard DNA Clean-Up kit (Promega), reconstituted with 50 
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µl of Tris-Cl (pH 8.0) and desulfonated by addition of 5.5 µl 3 M NaOH and incubation at 
37°C for 20 minutes.  The solution was precipitated by adding 40 µl 7.5 M ammonium 
acetate and 300 µl 100% ethanol at -20°C for at least 30 minutes.  The DNA pellet was 
washed with 70% ethanol, dried briefly, and resuspended in 20 µl 1 mM Tris-Cl (pH 8.0).  
Bisulfite converted DNA was amplified using primers directed to specific segments within 
the promoter regions and exon 1 of selected genes (Table 2).  PCR amplification was 
accomplished using a step-cycle program consisting of 40 cycles of 94°C for denaturing (1 
minute), 55°C for annealing (1.5 minutes), and 72°C for extension (2 minutes).  PCR 
products were fractionated on 2% agarose gels containing 40 mM Tris-acetate/1.0 mM 
EDTA (pH 8.0) and visualized by ethidium bromide staining.  A portion of the PCR products 
(1 to 5 µl) was cloned into pGEM-T Easy Vector (Promega, Madison, WI).  Three to 12 
colonies were selected per gene segment and expanded in liquid culture.  Plasmid DNA was 
purified using the Wizard Plus Miniprep DNA purification kit (Promega, Madison, WI), 
prior to digestion with NcoI and NdeI (New England Biolabs, Beverly, MA) to confirm the 
presence and size of the cloned insert.  Validated clones were sequenced using the universal 
M13R3 primer with an Applied Biosystems automated sequencer at the UNC Genome 
Analysis Facility (Chapel Hill, NC).  The bisulfite conversion efficiency was calculated for 
each sequenced clone based upon the ratio of converted Cs (non-CpG) to total number of Cs 
(non-CpG) in a given gene segment.  Only clones determined to have a conversion efficiency 
of >95% were included in the present study.  The results of methylation analyses were 
expressed as total methylation index (TMI).  This measure of methylation can be applied to 
single CpG dinucleotides, select groups of CpG dinucleotides, or to continuous groups of 
CpG dinucleotides in a given gene segment.  TMI was calculated for each cell line and clone
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by dividing the number of methylated CpGs observed by the total CpGs analyzed and 
expressed as percent methylation.  For instance, in an analysis of a gene segment containing 
55 CpG dinucleotides and three clones sequenced, TMI would be calculated based upon 165 
possible CpG methylation events (3 x 55).  
 
Human Primary Breast Tumors, Lymph Nodes, and Normal Breast Tissue  
 Genomic DNA was modified with sodium bisulfite using the EZ DNA Methylation-Gold 
Kit (ZYMO Research Co., Orange, CA) according to the manufacturer’s protocol.  Briefly, 
approximately 1.5 μg denatured genomic DNA was treated with conversion reagent, 
incubated at 98°C for 10 minutes, and 53°C for 30 minutes, followed by a step-cycle 
program consisting of 8 cycles of 53°C for 6 minutes and 37°C for 30 minutes.  
Subsequently, samples were applied to columns, washed, desulfonated, washed and then 
eluted with 20 μl of elution buffer.  In general, 2 μl of modified DNA was used in subsequent 
PCR reactions as described above.  A portion of each PCR product (1 to 5 µl) was cloned 
into pGEM-T Easy Vector (Promega), expanded in liquid culture, and plasmid DNA was 
purified as described above.  The results of methylation analyses were expressed as total 
methylation index (TMI) as described above.  Tumors with a CST6 promoter TMI >11% 
were considered hypermethylated.  
 
CST6 Reporter Gene Constructs   
 Bisulfite modification of genomic DNA was performed by a procedure adapted from 
Grunau et al. (122).  Genomic DNA (3 µg) was digested with 1 U of EcoRI (New England 
Biolabs, Beverly, MA) overnight in 12 µl total volume and heat inactivated at 65°C for 20 
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min; 5 µl of digest was subjected to bisulfite modification as described above.  Bisulfite 
converted DNA was PCR amplified using primers directed to stably transfected CST6 
promoter constructs.  The primers were designed to encompass a region of the CST6 
promoter and luciferase reporter gene within the pGL4.17[luc2/Neo] vector  (5’-
TTGTATTGGTATTTGTTGTTGG-3’ and 5’-CTTCATAACTTTATACAACTAC-3’).  A 
portion of the PCR product was cloned, purified, and sequenced according to procedures 
described above.   
 
M.  Immunohistochemical Analysis of Human Primary Breast Tumors, Lymph Node 
Metastases, and Normal Breast Tissue 
 
Formalin-fixed, paraffin-embedded human breast tissues and lymph nodes were sectioned 
(5 μm thick) and mounted on glass microscope slides.  Immunohistochemical staining was 
performed according to standard methods.  Briefly, tissue sections were incubated on a slide 
warmer at 60°C for 15 minutes, deparaffinized in xylene, incubated with 3% H2O2 in 
methanol to block endogenous peroxidase activity, and rehydrated through a series of ethanol 
washes.  Antigen retrieval was accomplished by steaming in 1x citrate buffer (Dako Inc., 
Carpinteria, CA) for 30 minutes.  After incubation with serum-free protein block (Dako Inc.) 
for 10 minutes, tissues were incubated for 2 hours at room temperature with polyclonal rabbit 
anti-cystatin M antibodies diluted 1:1000 (116) generously supplied by Dr. Daniel Keppler 
(Louisiana State University Health Sciences Center, Shreveport, LA).  Subsequently, tissues 
were washed and layered with a two-step secondary set-up including a anti-rabbit 
biotintylated link and streptavidin-conjugated HRP solution (Dako Inc.) for 10 minutes each, 
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incubated with HRP substrate containing 3,3’diaminobenzidine (Dako Inc.) for a total of 5 
minutes, followed by counterstaining with hematoxylin.  Control immunostaining reactions 
were performed at room temperature with mouse monoclonal anti-cytokeratin 18 (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA) antibodies diluted 1:1000.  Negative control staining 
followed the same procedure except sections were incubated with either rabbit preimmune 
serum or 1x wash buffer instead of anti-cystatin M antibody.  Normal breast tissue was used 
as a positive control for the anti-cystatin M antibody.   
 
 
N.  Statistical Analysis 
 
 Values included in the text represent the mean ± S.E.M. for CpG content (observed CpG 
dinucleotides/total dinucleotides x 100).  The values for the mean and S.E.M. were calculated 
using the statistical function of KaleidaGraph Version 3.5 (Synergy Software, Essex 
Junction, VT).  Statistical significance was determined using an unpaired t-test 
(KaleidaGraph). 
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  III.  RESULTS 
 
A.  DNA Methylation-Dependent Epigenetic Regulation of Gene Expression in MCF-7 
Breast Cancer Cells 
 
Identification of Putative Epigenetically-regulated Genes in MCF-7 Breast Cancer Cells 
Through Microarray Analysis of Gene Expression  
 Microarray analysis of gene expression was performed using RNA samples from control 
MCF-7 cells harvested at the week 3 and week 8 time points of the cell culture period.  The 
gene expression profiles of these control cultures were found to be remarkably consistent 
when the levels of expression of individual transcripts were compared between the two time 
points.  Analysis of the week 3 versus week 8 control expression data produced a positive 
correlation coefficient close to 1 (r = 0.96, r2 = 0.92).  Based upon this result, the expression 
data for the two control time points were averaged and utilized for normalization of the 
expression data obtained with RNA samples from treated cells.  Treatment of MCF-7 cells 
with 250 nM 5-aza for 3 weeks resulted in an approximate >2-fold increased expression of 
79 genes (Figure 7A).  Likewise, treatment of MCF-7 cells with 250 nM 5-aza + 50 nM TSA 
for 3 weeks produced an approximate >2-fold increased expression of 107 genes (Figure 7C).  
To reduce the numbers of genes for analysis, and to enrich for genes that are putatively 
epigenetically regulated, we analyzed the microarray data to identify genes that were 
modified by treatment (increased expression levels) but then returned to control expression
Figure 7.  Identification of putative epigenetically-regulated genes in MCF-7 breast 
cancer cells after exposure to demethylating treatment.  M versus A plot of microarray 
data.  The values on the Y-axis reflect log2-scale fold-change (log ratios) for treatment 
samples relative to control values.  The values on the x-axis reflect the average signal 
intensity for individual control probe sets (transcripts).  For panels A and B, genes with >2-
fold (log ratio >1) increased expression in MCF-7 cells after 3 weeks of 5-aza treatment are 
shown in red, and genes that returned to control values after a 5 week recovery period 
(following withdrawal of 5-aza) are shown in blue (Panel A, week 3; Panel B, week 8).  This 
analysis identified 37 genes with increased expression in response to 5-aza treatment in week 
3 that returned to control levels by week 8.  For panels C and D, genes showing >2-fold 
increased expression in MCF-7 cells after 3 weeks of 5-aza + TSA treatment are shown in 
red, and genes that returned to control values after a 5 week recovery period (following 
withdrawal of 5-aza + TSA) are shown in blue (Panel C, week 3; Panel D, week 8).  This 
analysis identified 70 genes with increased expression in response to 5-aza + TSA treatment 
in week 3 that returned to control levels by week 8.   
 
 48
 A C
DB
Fold Change (log
2
)
Le
ve
l o
f 
E
xp
re
ss
io
n
Fold Change (log
2
)
Le
ve
l o
f 
E
xp
re
ss
io
n
Fold Change (log
2
)
Fold Change (log
2
)
Le
ve
l o
f 
E
xp
re
ss
io
n
Le
ve
l o
f 
E
xp
re
ss
io
n
5-
az
a-
2’
-d
eo
xy
cy
tid
in
e 
(3
 w
ee
ks
 o
f t
re
at
m
en
t)
5-
az
a-
2’
-d
eo
xy
cy
tid
in
e 
(a
ft
er
 5
 w
ee
ks
 o
f 
re
co
ve
ry
)
5-
az
a-
2’
-d
eo
xy
cy
tid
in
e 
+ 
T
SA
 
(3
 w
ee
ks
 o
f t
re
at
m
en
t)
5-
az
a-
2’
-d
eo
xy
cy
tid
in
e 
+ 
T
SA
 
(a
ft
er
 5
 w
ee
ks
 o
f r
ec
ov
er
y)
AA CC
DDBB
Le
ve
l o
f 
E
xp
re
ss
io
n
Le
ve
l o
f 
E
xp
re
ss
io
n
Le
ve
l o
f 
E
xp
re
ss
io
n
Le
ve
l o
f 
E
xp
re
ss
io
n
5-
az
a-
2’
-d
eo
xy
cy
tid
in
e 
(3
 w
ee
ks
 o
f t
re
at
m
en
t)
5-
az
a-
2’
-d
eo
xy
cy
tid
in
e 
(a
ft
er
 5
 w
ee
ks
 o
f 
re
co
ve
ry
)
5-
az
a-
2’
-d
eo
xy
cy
tid
in
e 
+ 
T
SA
 
(3
 w
ee
ks
 o
f t
re
at
m
en
t)
5-
az
a-
2’
-d
eo
xy
cy
tid
in
e 
+ 
T
SA
 
(a
ft
er
 5
 w
ee
ks
 o
f r
ec
ov
er
y)
49
levels following the withdrawal of treatment.  This analysis identified 37 genes in 5-aza-
treated MCF-7 cells and 70 genes in 5-aza + TSA treated MCF-7 cells that increased >2-fold 
at 3 weeks and returned to control level after 8 weeks (Figure 7B and 7D).  Comparison of 
these gene lists identified 20 genes in common between the 5-aza and 5-aza + TSA treatment 
groups (Table 3).  Most of these genes (16/20, 80%) have not been shown previously to be 
subject to methylation-dependent silencing in cancer cells.  However, there is evidence for 
epigenetic regulation of C8orf4, CYP1B1, PSG6, and SAT (72,123,124).  Suzuki and 
colleagues identified C8orf4 and PSG6 among genes that are up-regulated in human RKO 
colorectal carcinoma cells in response to 5-aza + TSA treatment (72).  CYP1B1 has been 
shown to be methylated in primary breast cancers (124), and SAT is subject to silencing 
through X-chromosome inactivation (123).  Genes that responded to demethylating treatment 
with either 5-aza (n=17) or 5-aza + TSA (n=50), but not both, are given in Table 4.  Most of 
these putative epigenetically-regulated genes were apparently induced with both 
demethylating treatments, but failed to indicate a greater than 2-fold difference in expression 
for one of the treatments.  For example, CYP1A1 was estimated to increase 2-fold in response 
to 5-aza treatment, but only 1.9-fold in response to 5-aza + TSA.  Likewise, SYNGR3 was 
estimated to increase 2.3-fold in response to 5-aza + TSA, but only 1.9-fold in response to 5-
aza (Table 4). 
   
Validation of Treatment-related Changes in Gene Expression by RT-PCR 
 RT-PCR was employed to validate the changes in gene expression identified by 
microarray analysis that occur in MCF-7 cells with 5-aza or 5-aza + TSA treatment.  RT-
PCR analysis of RNA samples prepared from control MCF-7 cells at 1, 2, 3, 6, 7, and 8
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Table 4.  Putative Epigenetically-regulated Genes Identified in MCF-7 Cells After Demethylating 
Treatment with Either 5-aza or 5-aza + TSAa
  GenBank  Relative 
Gene  Accession Expression 
Designation  Gene Name Number Levelb
 
Genes Responding to 5-aza Treatment (n=17)c
Genes with Typical CpG Featuresd
CENTB2  Centaurin, beta 2 NM_012287.3 2.2 
CYP1A1  Cytochrome P450, family 1, subfamily A, polypeptide 1 NM_000499.2  2.0 
ID1 Inhibitor of DNA binding 1 NM_002165.2 2.0 
MAP3K8  Mitogen-activated protein kinase kinase kinase 8 NM_005204.2 2.4 
 
Genes with Intermediate CpG Featuresd
COL4A6  Collagen type IV alpha 6 NM_001847 2.2 
GDF-15  Growth differentiation factor 15 NM_004864.1  2.5 
LCP2  Lymphocyte cytosolic protein 2 NM_005565.3  3.0 
LXN  Latexin protein NM_020169.2  2.0 
NOX1  NADPH oxidase 1 NM_007052.3  2.8 
SLICK  Potassium channel, subfamily T, member 2 NM_198503.2  2.5 
WISP2  WNT1 inducible signaling pathway protein 2 NM_003881.2  2.2 
ZFHX1B  Zinc finger homeobox 1b NM_014795.2 2.1 
 
Genes with Atypical CpG Featuresd
CTAGE-1  CTAGE-1 protein NM_022663.1  2.2 
GH2  Growth hormone 2 NM_022558 2.5 
GNRH1  Gonadotropin-releasing hormone 1 NM_000825.2  3.0 
RARRES3  Retinoic acid receptor responder NM_004585.2 2.2 
 
Genes Responding to 5-aza + TSA Treatment (n=50)c  
Genes with Typical CpG Featuresd
ABCG2  ATP-binding cassette, subfamily G, member 2 NM_004827.2 3.6 
AQP3  Aquaporin 3 NM_004925.3  2.7 
BUB1  Budding uninhibited by benzimidazoles 1 NM_004336 2.4 
FLJ90013  Cytomegalovirus partial fusion receptor NM_153365.1  2.1 
GREM1  Gremlin 1, cysteine knot superfamily NM_013372.4  2.1 
HAPLN1  Homo sapiens hyaluronan and proteogylcan link protein 1 NM_001884.2  2.2 
HLA-B  Major histocompatibility complex, class 1, B NM_000885.3 2.2 
HLA-C  Major histocompatibility complex, class 1, C NM_002117  2.4 
IFITM1  Interferon-inducible protein 9-27 NM_003641 2.0 
IGFBP3  Insulin-like growth factor binding protein 3 NM_000598.4 3.1 
INHA  Inhibin alpha NM_002191.2 2.6 
ITGA4  Integrin, alpha 4 (antigen CD49D) NM_000885.4 2.1 
KRTHB6  Keratin, hair, basic, 6 (monilethrix) NM_002284.2 2.5 
L1CAM  L1 cell adhesion molecule NM_000425.2 2.6 
LOXL2  Lysyl oxidase-like 2 NM_002318.1 2.5 
PLSCR1  Phospholipid scramblase 1 NM_021105.1 2.5 
PSMB9  Proteosome (prosome, macropain), subunit beta, type 9 NM_002800.3 2.3 
RAFTLIN  Raft-linking protein NM_015150.1  3.1 
RGS16  Regulator of G-protein signaling 16 NM_002928.2 2.3 
RIG-I  DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide NM_014314.2 2.1 
STAT1  Signal transducer and activator of transcription 1 NM_007315.2  2.0 
SYNGR3  Synaptogyrin 3 NM_004209.4  2.3 
TAP1  Transporter 1, ATP-binding cassette, subfamily B NM_00593.5  2.8 
TUBB  Tubulin, beta polypeptide NM_178014.2  2.2 
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TXNRD1  Thioredoxin reductase 1 NM_003330.2  2.4 
UBE2L6  Ubiquitin-conjugating enzyme E2L 6 NM_004223.3 2.3 
 
Genes with Intermediate CpG Featuresd
BST2  Bone marrow stromal cell antigen 2 NM_004335.2  2.7 
C3  Complement component 3 NM_000064.1  2.3 
CGB  Chorionic gonadotropin, beta polypeptide NM_000737.2  3.8 
DIO2  Deiodinase, iodothyronine, type II NM_013989.2  4.2 
FLJ20035  Hypothetical protein FLJ20035 NM_017631.3  3.0 
GAGE4  G antigen 4 NM_001474 2.2 
IFIT1  Interferon-induced protein with tetratricopeptide repeats 1 NM_001548.1 3.4 
LY6D  Lymphocyte antigen 6 complex, locus D NM_003695.2  2.2 
PDE6C  Phosphodiesterase 6C NM_006204.2  2.0 
PLAC8  Placenta-specific 8 NM_016619  2.6 
S100P  S100 calcium binding protein P NM_05980.2  2.2 
SCGB1A1  Secretoglobin, family 1A, member 1 (uteroglobin) NM_003357.3  2.6 
SP110  SP110 nuclear body protein NM_004509.1 2.2 
 
Genes with Atypical CpG Featuresd
CGA  Glycoprotein hormone, alpha polypeptide NM_000735.2  8.1 
CYP11A1  Cytochrome P450, family 11, subfamily A, polypeptide 1 NM_000781.1  4.0 
FLG  Filaggrin NM_002016.1  2.4 
GJA1  Gap junction protein, alpha 1 NM_00165.2  2.6 
ITGB6  Integrin, beta 6 NM_000888.3  2.5 
KYNU  Kynureninase (L-kynurenine hydrolase) NM_003937.1 2.1 
OAS1  2’,5’-Oligoadenylate synthetase 1 NM_016816 2.3 
S100A8  S100 calcium binding protein A8 (calgranulin A) NM_002964.3 2.9 
S100A9  S100 calcium binding protein A9 (calgranulin B) NM_002965.2 5.8 
S100A12  S100 calcium binding protein A12 (calgranulin C) NM_005621.1 2.1 
aGenes listed in this table were found to display increased expression in MCF-7 cells in response to treatment 
with either 5-aza and 5-aza + TSA, but not both.  Genes that displayed increased expression in response to 
both treatments are listed in Table 3. 
bRelative expression levels are expressed as average fold control levels of expression at the end of 3 weeks of 
demethylating treatment (5-aza or 5-aza + TSA). 
cGenes responding to 5-aza treatment included FLJ12055 (Genbank accession AK022117), and genes 
responding to 5-aza + TSA included DKFZp761G18121 (Genbank accession BC018100).  These genes were 
omitted from this analysis as no promoter sequence information was available. 
dGenes with typical CpG features contain typical CpG islands (defined as a region of >200 bp with >50% C+G 
and >0.6 CpG observed/CpG expected) (65).  Genes with intermediate CpG features contain weak CpG islands 
(defined as a region of >50 bp but <200 bp with >50% C+G and >0.6 CpG observed/CpG expected).  Genes 
with atypical CpG features do not contain CpG islands (typical or weak). 
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weeks of cell culture revealed no significant variations in gene expression level for C8orf4 or 
ZC3HDC1 across all time points (data not shown).  C8orf4 was not expressed at any time 
point and ZC3HDC1 was expressed at low (but detectable) levels at all time points.  β-actin 
RNA was also expressed evenly across all time points in control MCF-7 cells (data not 
shown).  These results indicate that MCF-7 cells propagated in control growth medium 
produce consistent patterns of gene expression over time in cell culture.  Subsequent analyses 
focused on the differential expression of putative epigenetically-regulated genes (n=20) in 
response to 5-aza and 5-aza + TSA treatment.  In total, 15/20 (75%) of these genes were 
shown by RT-PCR to be increased in response to 5-aza + TSA (including BF, C8orf4, 
CEACAM5, CEACAM6, CST6, CYP1B1, FLJ10134, G1P2, G1P3, IFI27, ISGF3G, 
KRTHB1, LCN2, SCNN1A, and ZC3HDC1), and 18/20 (90%) of these genes were shown by 
RT-PCR to be increased in response to 5-aza treatment alone (those listed above and 
IGFBP5, LGALS3BP, and SAT).  The remaining two genes were not examined (CRIP1 and 
PSG6).  Figure 8 shows representative RT-PCR reactions for seven genes (C8orf4, 
CEACAM5, CEACAM6, IFI27, ISGF3G, SCNN1A, and ZC3HDC1).  C8orf4, IFI27, and 
ZC3HDC1 were expressed at low or undetectable levels in control MCF-7 cells, but 
demonstrated significantly increased expression 3 weeks following treatment with either 5-
aza or 5-aza + TSA (Figure 8B-D).  Likewise, BF, CST6, CYP1B1, FLJ10134, G1P2, G1P3, 
KRTHB1, IGFBP5, LCN2, LGALS3BP, and SAT were expressed at very low levels in control 
MCF-7 cells followed by an increase in expression with 5-aza and/or 5-aza + TSA treatment 
(data not shown). CEACAM5, CEACAM6, ISGF3G, and SCNN1A were expressed at 
moderate levels in control MCF-7 cells, and each of these genes showed significantly 
increased levels of expression 3 weeks after treatment (Figure 8A, E-G).   
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Figure 8.  Expression of putative epigenetically-regulated genes in response to 
demethylating treatment in MCF-7 breast cancer cells.  Representative agarose gels of 
RT-PCR products are shown.  In each panel, lane 1 corresponds to a no cDNA template 
control, lane 2 corresponds to cDNA from untreated (control) MCF-7 cells, and lanes 3-4 
correspond to MCF-7 cells after 3 weeks of treatment with 5-aza or 5-aza + TSA, 
respectively.  Panel A, CEACAM6; Panel B, C8orf4; Panel C, IFI27; Panel D, ZC3HDC1; 
Panel E, CEACAM5; Panel F, SCNN1A; Panel G, ISGF3G. 
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Promoter Sequence Features of Putative Epigenetically-regulated Genes 
 An analysis of the promoters and 5’-upstream sequences (3000 bp) for each of the 20 
genes identified in MCF-7 cells that responded to both 5-aza and 5-aza + TSA treatment was 
performed to identify common sequence features that may be associated with methylation-
dependent epigenetic regulation, with emphasis on CpG dinucleotide frequency and 
distribution.  This analysis revealed a tremendous variation in promoter CpG content and 
organization among these putative epigenetically-regulated genes (Table 3).  Based upon a 
comparative analysis of the CpG features of their promoter and proximal sequences (exon 1), 
we grouped the putative epigenetically-regulated genes identified in this study into three 
distinct classes, including: (i) genes with typical CpG features (typical CpG islands within 
the promoter or exon 1), (ii) genes with intermediate CpG features (weak CpG islands within 
the promoter or exon 1), and (iii) genes with atypical CpG features (no CpG islands).   
 Using the commonly accepted criteria for a typical CpG island (65), 9/20 (45%) genes 
were found to contain a CpG island in either their promoter and/or exon 1 (Table 3).  This 
subset of genes exhibits the typical features expected for an epigenetically-regulated gene.  
Among these genes, 4/9 (44%) contain distinct (typical) CpG islands in both the promoter 
region and exon 1 (Table 3).  The CpG islands found in the promoter and/or exon 1 
sequences of CST6, CYP1B1, KRTHB1, SAT, and ZC3HDC1 withstood a more rigorous CpG 
island analysis (>200 bp with >60% G+C and >0.7 CpG observed/CpG expected), which 
approximates a new standard suggested by Takai and Jones (63).  In 7/9 (78%), genes with 
typical CpG features, distinct weak CpG islands were detected in the promoter and/or exon 1 
(Table 3).  As expected, all of the CpG island-containing genes demonstrated significant 
promoter CpG content, with the highest concentration of CpG dinucleotides in the first 500 
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bp upstream of the transcription start site in most cases (Table 3).  However, CpG islands 
were detected in several genes with relatively low CpG content (including G1P3 and 
KRTHB1).  In some cases, the CpG content of exon 1 exceeds that of the proximal promoter 
(like in the case of ZC3HDC1), reflecting the presence of a typical CpG island (Table 3).  
Five genes contain >10% CpG content in the first 500 bp upstream of the transcription start 
site, some with much more extensive regions of CpG density (Table 3).  Other genes contain 
more focused regions of CpG density that are confined to the portion of the promoter 
sequence that is proximal to the transcriptional start site.  These include CST6 (17.6% CpG in 
proximal 250 bp), G1P2 (10.4% CpG in proximal 250 bp), SAT (18.4% CpG in proximal 250 
bp), and FLJ10134 (20.8% CpG in proximal 250 bp).  While 8/9 (89%) genes with typical 
CpG islands contained Alu repeats (1-6 repeats; average = 3 repeats per promoter), the CpG-
rich regions (CpG islands) did not correspond to Alu repetitive elements.   
 Weak CpG islands were detected in the promoter and/or exon 1 sequences of 8/20 (40%) 
genes that lacked typical CpG islands (Table 3).  We have described this subset of genes as 
displaying intermediate CpG features based upon the observation that they lack typical CpG 
islands, but contain smaller regions of CpG density (weak CpG islands).  These weak CpG 
islands occur most often in gene promoter sequences (6/8, 75%), rarely in exon 1 alone (2/8, 
25%), or in both the promoter and exon 1 (1/8, 13%) (Table 3).  Genes with weak CpG 
islands display lower promoter and 5’-upstream sequence CpG content than genes containing 
typical CpG islands (3.0 + 0.3% versus 5.0 + 1.0%, N.S.), but this difference was most 
pronounced when the first 500 bp upstream from the transcription start site was examined 
(2.5 + 0.3% versus 9.1 + 1.8%, P=0.0066).  Alu repeats were detected in 5/8 (63%) genes 
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with intermediate CpG features, but with fewer repeats than genes with typical CpG features 
(1-4 repeats; average = 2 per promoter).   
 Three genes (IFI27, LGALS3BP, and SCNN1A) contain no CpG islands (typical or weak) 
in their promoter or exon 1 sequences (Table 3).  These genes are CpG-deficient, with no 
regions of CpG density and no clustering of CpG dinucleotides.  Based upon these CpG 
characteristics, we have described this subset of genes as exhibiting atypical CpG features.  
Similar to genes with intermediate CpG features, genes with atypical CpG features display 
significantly lower promoter and 5’-upstream sequence CpG content when compared to 
genes with typical CpG features.  The average CpG content of the atypical features genes 
was 2.9% when 3000 bp of sequence was examined and 2.7% when the first 500 bp proximal 
to the transcriptional start site was evaluated (Table 3).  Single Alu repeats were detected in 
the promoters of each of these genes. 
 A similar analysis of promoter and 5’-upstream CpG sequence features was performed 
for genes that respond to 5-aza (n=17) or 5-aza + TSA treatment (n=50), but not both.  
FLJ12055 and DKFZp761G1812 were omitted from this analysis due to a lack of known 
promoter sequence.  Genes with CpG sequence characteristics corresponding to each of the 
proposed classes of putative epigenetically-regulated genes were identified in these groups of 
genes.  Among those responding to 5-aza alone (n=16), 4/16 (25%) genes exhibit typical 
CpG features, 8/16 (50%) exhibit intermediate CpG features, and 4/16 (25%) display atypical 
CpG features (Table 4).  Likewise, among genes responding to 5-aza + TSA (n=49), 26/49 
(53%) exhibit typical CpG features, 13/49 (27%) exhibit intermediate CpG features, and 
10/49 (20%) display atypical CpG features (Table 4).      
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Bisulfite Sequencing Demonstrates that Putative Epigenetically-regulated Genes are 
Subject to Methylation-dependent Regulation 
 Methylation analysis by bisulfite sequencing (122) was performed on the promoter 
regions of prototype genes from each proposed class of putative epigenetically-regulated 
gene: CST6 (typical CpG features), C8orf4 (intermediate CpG features), and IFI27 (atypical 
CpG features).  This analysis produced evidence for the direct regulation of genes in each 
proposed class by CpG methylation in MCF-7 breast cancer cells, and began to identify CpG 
methylation events that are critical for gene silencing.   
 Methylation Analysis of the CST6 Promoter in MCF-7 Breast Cancer Cells.  To directly 
address whether CST6 is methylated in MCF-7 cells, we analyzed 33 CpG dinucleotides from 
a segment of the promoter region (+10 to -636) that contains a typical CpG island (Figure 9).  
CST6 is not expressed in untreated MCF-7 cells, but expression is significantly increased 
with 5-aza and 5-aza + TSA treatment (Figure 9).  Furthermore, the treatment-related 
increase in gene expression is reversible, and treatment withdrawal results in significant 
reduction of CST6 mRNA levels (Figure 9).  In untreated MCF-7 cells, 8/33 (24%) CpGs 
were 100% methylated, 25/33 (76%) CpGs were intermediately methylated, and 0/33 (0%) 
CpGs were unmethylated, producing a TMI for the promoter of 73%.  Treatment of MCF-7 
cells with 5-aza or 5-aza + TSA resulted in demethylation of 30/33 (91%) and 20/33 (61%) 
CpGs respectively, resulting in TMI values of 17% and 46%, and CST6 was expressed at 
detectable levels (Figure 9).  Treatment of MCF-7 cells with 5-aza resulted in a relatively 
higher level of expression for CST6, which appears to correlate with the degree of promoter 
demethylation in this region (Figure 9).  Withdrawal of 5-aza or 5-aza + TSA treatment
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Figure 9.  Correlative analysis of promoter methylation and gene expression for CST6 
in MCF-7 cells.  The distribution of CpG dinucleotides proximal to the transcription start 
site in the promoter (0 to -1400 nucleotides) and exon 1 (0 to +294 nucleotides) of CST6 are 
depicted schematically (vertical lines indicate the relative position of individual CpG 
dinucleotides).  Methylation analysis was performed on a region of the promoter spanning 
from +10 to -636 (indicated by a solid horizontal line), which contains 33 CpG dinucleotides 
and is part of a large CpG island.  A summary of results for the methylation analysis is 
shown for control MCF-7 cells and cells treated with 5-aza and 5-aza + TSA for the week 3 
and week 8 time points.  Each circle represents 3-5 replicates of bisulfite sequencing.  Black 
circles correspond to fully (100%) methylated CpGs, gray circles correspond to CpGs with 
intermediate methylation, and open circles correspond to unmethylated CpGs.  TMI values 
for the promoter region (33 CpGs) are given for control MCF-7 cells and cells treated with 5-
aza and 5-aza + TSA for the week 3 and week 8 time points.  Representative RT-PCR 
reactions are shown demonstrating the level of CST6 expression in control and treated MCF-
7 cells at each time point.  The correspondence between CST6 promoter methylation status 
and gene expression for all treatments is shown in the inset table. 
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resulted in silencing of CST6 gene expression concurrent with remethylation of the majority 
of CpG dinucleotides producing TMI values of 40% and 75%, respectively (Figure 9).   
 Methylation Analysis of the C8orf4 Promoter in MCF-7 Breast Cancer Cells.  The 
promoter of C8orf4 is CpG-deficient, but does contain a weak CpG island in exon 1. C8orf4 
is not expressed at detectable levels in MCF-7 cells.  We analyzed an 812 bp segment (-278 
to -1090) of the C8orf4 promoter containing 12 CpG dinucleotides (Figure 10).  In untreated 
MCF-7 cells, 4/12 (33%) of these CpGs were 100% methylated, 7/12 (58%) CpGs were 
methylated at an intermediate level, and 1/12 (8%) CpGs were unmethylated, with the 
greatest concentration of methylated CpGs in a 103 bp region (-926 to -1029) containing 5 
CpG dinucleotides (100% methylated; n=5), and producing a TMI value of 71% (Figure 10).  
Treatment of MCF-7 cells with 5-aza or 5-aza + TSA resulted in demethylation of 10/12 
(83%) and 8/12 (67%) CpG dinucleotides resulting in TMI values of 20% and 47% 
respectively, and coordinate expression of C8orf4 (Figure 10).  Treatment of MCF-7 cells 
with 5-aza resulted in a relatively higher level of expression for C8orf4, which appeared to 
correlate with the degree of promoter demethylation in this region (Figure 10).  However, 
treatment withdrawal resulted in silencing or significantly lower expression of C8orf4 and 
coordinate remethylation of the majority of these CpGs (Figure 10).  We also examined the 
methylation status of C8orf4 exon 1 (between +23 and +453) which contains 14 CpGs, 
forming a weak CpG island.  In control MCF-7 cells, 7/14 (50%) CpGs are 100% methylated 
and 7/14 (50%) CpGs were methylated at an intermediate level, producing a TMI for the 
exon 1 region of 73%.  Following treatment with 5-aza or 5-aza + TSA, 11/14 (79%) CpGs 
become demethylated resulting in TMI values of 31% and 29% respectively, and concurrent 
reexpression of the gene.  Withdrawal of the treatment resulted in silencing of gene
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Figure 10.  Correlative analysis of promoter methylation and gene expression for 
C8orf4 in MCF-7 cells.  The distribution of CpG dinucleotides proximal to the transcription 
start site in the promoter (0 to -1400 nucleotides) and exon 1 (0 to +529 nucleotides) of 
C8orf4 are depicted schematically (vertical lines indicate the relative position of individual 
CpG dinucleotides).  C8orf4 contains no typical CpG islands in the promoter, but does 
contain a weak CpG island in exon 1 (see results).  Methylation analysis was performed on a 
region of the promoter spanning from -278 to -1090 (indicated by a solid horizontal line), 
which contains 12 CpG dinucleotides.  A summary of results for the methylation analysis is 
shown for control MCF-7 cells and cells treated with 5-aza and 5-aza + TSA for the week 3 
and week 8 time points.  Each circle represents 5 replicates of bisulfite sequencing.  Black 
circles correspond to fully (100%) methylated CpGs, gray circles correspond to CpGs with 
intermediate methylation, and open circles correspond to unmethylated CpGs.  TMI values 
for the promoter region (12 CpGs) are given for control MCF-7 cells and cells treated with 5-
aza and 5-aza + TSA for the week 3 and week 8 time points.  The methylation status of 
C8orf4 exon 1 (between +23 and +453) which contains 14 CpGs was also analyzed (see 
results).  Representative RT-PCR reactions are shown demonstrating the level of C8orf4 
expression in control and treated MCF-7 cells at each time point.  The correspondence 
between C8orf4 promoter methylation status and gene expression for all treatments is shown 
in the inset table. 
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expression, but without significant remethylation of this weak CpG island (data not shown).  
These results suggest that CpG methylation events occurring within the promoter region 
rather than exon 1 may be most important for the silencing of C8orf4 in MCF-7 cells.             
Methylation Analysis of the IFI27 Promoter in MCF-7 Breast Cancer Cells.  We 
examined the methylation status of 15 CpGs within a 1271 bp segment (-16 to -1287) of the 
IFI27 promoter, which lacks typical or weak CpG islands.  Untreated MCF-7 cells do not 
express IFI27 and 12/15 (80%) CpG dinucleotides within the promoter region are 100% 
methylated and 3/15 (20%) are methylated at an intermediate level, producing a TMI value 
of 93% (Figure 11).  Treatment of MCF-7 cells with 5-aza or 5-aza + TSA resulted in 
expression of IFI27 and demethylation of the majority of CpG dinucleotides:  12/15 (80%) 
CpGs were demethylated following 5-aza treatment and 9/15 (60%) CpGs were 
demethylated after 5-aza + TSA treatment, resulting in TMIs of 35% and 44% respectively 
(Figure 11).  Withdrawal of 5-aza treatment leads to remethylation of the majority of CpG 
dinucleotides (13/15, 87%) with a TMI value of 83%.  Likewise, withdrawal of 5-aza + TSA 
treatment resulted in remethylation of 12/15 (80%) CpGs exhibiting a TMI value of 78% 
with concurrent loss of gene expression (Figure 11). 
 
B.  DNA Methylation-Dependent Silencing of CST6 in Human Breast Cancer Cell Lines 
 
CST6 is Differentially Expressed Among Breast Cancer Cell Lines 
CST6 gene expression was examined by semiquanitative RT-PCR in MDA-MB-231, 
MDA-MB-415, MDA-MB-435S, MDA-MB-436, MDA-MB-453, MDA-MB-468, BT-549, 
BT-20, Hs578T, MCF-7, SK-BR-3, and ZR-75-1 breast cancer cell lines and two normal
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Figure 11.  Correlative analysis of promoter methylation and gene expression for IFI27 
in MCF-7 cells.  The distribution of CpG dinucleotides proximal to the transcription start 
site in the promoter (0 to -1635 nucleotides) and exon 1 (0 to +65 nucleotides) of IFI27 are 
depicted schematically (vertical lines indicate the relative position of individual CpG 
dinucleotides).  IFI27 contains no CpG islands (typical or weak) or other regions of CpG 
density.  Methylation analysis was performed on a region of the promoter spanning from -16 
to -1287 (indicated by a solid horizontal line), which contains 15 CpG dinucleotides.  A 
summary of results for the methylation analysis is shown for control MCF-7 cells and cells 
treated with 5-aza and 5-aza + TSA for the week 3 and week 8 time points.  Each circle 
represents 4-5 replicates of bisulfite sequencing.  Black circles correspond to fully (100%) 
methylated CpGs, gray circles correspond to CpGs with intermediate methylation, and open 
circles correspond to unmethylated CpGs.  TMI values for the promoter region (15 CpGs) are 
given for control MCF-7 cells and cells treated with 5-aza and 5-aza + TSA for the week 3 
and week 8 time points.  Representative RT-PCR reactions are shown demonstrating the 
level of IFI27 expression in control and treated MCF-7 cells at each time point.  The 
correspondence between IFI27 promoter methylation status and gene expression for all 
treatments is shown in the inset table. 
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mammary epithelial cell lines, MCF10-2A and MCF12A.  Five of the 12 breast cancer cell 
lines (42%) express detectable levels of CST6 mRNA:  MDA-MB-468 and SK-BR-3 cells 
express low levels of CST6, MDA-MB-231 and MDA-MB-415 cells express moderate levels 
of CST6, and BT-20 cells strongly express CST6.  However, no CST6 mRNA was found in 
the remaining 7 cell lines (58%) (Figure 12).  Both MCF10-2A and MCF12A cells transcribe 
CST6 at low levels, and β-actin mRNA was expressed evenly across all cell lines examined 
(Figure 12).  These results are consistent with the recently published studies on MCF-7, SK-
BR-3, and MDA-MB-231 cells (8).  This analysis identified subsets of breast cancer cell 
lines that differentially express CST6 mRNA, providing the cellular reagents for examination 
of methylation-dependent epigenetic regulation of CST6 in breast cancer cells.     
      
5-aza Treatment Induces CST6 Expression in Breast Cancer Cell Lines 
CST6-negative cell lines Hs578T, MCF-7, MDA-MB-435S, MDA-MB-436, MDA-MB-
453, and ZR-75-1 were treated with 5-aza, to determine if gene silencing was the likely result 
of DNA methylation.  Four of 6 (67%) of these cell lines expressed significantly increased 
levels of CST6 mRNA in response to 5-aza treatment (Figure 12B).  The significant 
induction of CST6 mRNA in response to 5-aza treatment in MCF-7 cells observed in this 
study is consistent with similar published studies (8).  In contrast, 5-aza exposure of MDA-
MB-453 and MDA-MB-436 cells resulted in a modest, but detectable increase in CST6 
mRNA (Figure 12B).  The 5-aza-induced increase in CST6 expression was completely 
reversible.  Following a period of recovery after treatment withdrawal, CST6 mRNA 
diminished to control levels (corresponding to untreated cells) in all cell lines examined 
(Figure 12B).  The 5-aza treatment-related increases in CST6 expression, combined with the
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Figure 12.  CST6 expression in human breast cancer cell lines and normal mammary 
epithelial cells.  Representative agarose gels of RT-PCR products are shown.  (A) 
Differential expression of CST6 among breast cancer cell lines and two normal mammary 
epithelial cell lines (MCF10-2A and MCF12A).  The CST6 RT-PCR product is 163 bp in 
size.  β-actin was utilized as a sample control.  (B) Lane 1 corresponds to cDNA from 
indicated untreated breast cancer cell lines; lanes 2 and 3 correspond to cells after 5-aza 
treatment or treatment withdrawal, respectively.  β-actin RNA was evenly expressed in all 
samples (data not shown).   
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loss of CST6 expression following treatment withdrawal, suggests that CST6 may be subject 
to methylation-dependent silencing in these breast cancer cell lines.   
Expression of CST6 was analyzed using real-time PCR in CST6-negative cell lines 
Hs578T, MCF-7, MDA-MB-436, MDA-MB-453, and ZR-75-1 to quantitate the 5-aza 
treatment-related increases in gene expression.  Consistent with the RT-PCR results, 
untreated cell lines express extremely low levels of CST6 mRNA, and exposure to 5-aza 
resulted in significant increases in CST6 mRNA (Figure 13).  Exposure of Hs578T cells to 5-
aza led to a 49-fold increase in CST6 expression (P=0.0036 compared to control) and 
withdrawal of 5-aza resulted in a significant reduction (P=0.0021 compared to 5-aza treated) 
of gene expression to a level that approaches that of control (untreated) cells (Figure 13).  
Likewise, 5-aza treatment of MCF-7 and MDA-MB-436 cells produced 80-fold (P=0.0058) 
and 90-fold (P=0.0042) increases in CST6 expression, respectively, and withdrawal of the 5-
aza treatment lead to significant reductions in CST6 expression in both cell lines (P=0.0062 
and P=0.0043, respectively) (Figure 13).  Of note, the induction of CST6 mRNA in MDA-
MB-436 cells in response to 5-aza treatment was consistently demonstrable with all methods, 
but the magnitude of increased gene expression detected by real-time RT-PCR was greater 
than that detected using RT-PCR, possibly due to the increased sensitivity of the real-time 
method.  Exposure of MDA-MB-453 and ZR-75-1 cells to 5-aza produced modest increases 
in CST6 mRNA (3-fold and 8-fold, respectively) that were statistically significant (P=0.0017 
and P=0.0479), and withdrawal of treatment resulted in significant decreases in CST6 
expression to levels that were comparable to untreated cells (P=0.0070 and P=0.0393, 
respectively) (Figure 13).  These data show that 5-aza treatment of CST6-negative cell lines
 73
Figure 13.  Quantitative real-time PCR analysis of CST6 in breast cancer cell lines.  β-
actin was used to normalize gene expression levels for each cell line and differences in CST6 
expression were determined using the comparative Ct method.  CST6 gene expression for cell 
lines treated with 5-aza (green bars) and after treatment withdrawal (purple bars) are 
expressed as relative fold-change compared to control values (set at 1.0).  Error bars reflect 
S.E.M.  Values for gene expression that do not show error bars reflect data where the S.E.M 
could not be depicted graphically.  *, Denotes statistical significance at P<0.05 compared to 
control values.  **, Denotes statistical significance at P<0.04 compared to 5-aza treatment 
values.    
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results in statistically significant increases in CST6 mRNA, and suggests strongly that CST6 
is subject to methylation-dependent silencing in a variety of breast cancer cell lines.    
 
Methylation-dependent Silencing of CST6 in Select Breast Cancer Cell Lines 
 To facilitate a correlative analysis of CST6 gene expression and CST6 CpG island 
methylation status, we analyzed 55 CpG dinucleotides from a segment of the proximal 
promoter region and exon 1 (+242 to -228) in normal breast epithelial cells (MCF12A), two 
breast cancer cell lines (BT-20 and SK-BR-3) that express CST6, and five breast cancer cell 
lines (Hs578T, MCF-7, MDA-MB-435S, MDA-MB-436, and MDA-MB-453) that lack 
expression of CST6.  Multiple clones (n=3-5) corresponding to the CST6 promoter and exon 
1 from each cell line were analyzed by sodium bisulfite sequencing and individual CpGs 
were scored for methylation status.  In MCF12A cells, 35/55 (64%) CpGs were not 
methylated, 18/55 (33%) CpGs were methylated at an intermediate level, and 2/55 (3%) 
CpGs were 100% methylated, producing a TMI for the promoter/exon 1 of 16% (Figure 14).  
BT-20 cells exhibit sparse methylation of CST6:  53/55 (96%) CpGs were unmethylated in 
all clones analyzed, resulting in a TMI of 1%.  The CST6 gene in SK-BR-3 cells was 
significantly more methylated than MCF12A or BT-20 cells (especially within exon 1): 
39/55 (71%) CpGs show some level of methylation, producing a TMI of 45% (Figure 14).  
Overall, the CST6-positive cell lines (MCF12A, BT-20, and SK-BR-3) exhibit low levels of 
methylation within the proximal promoter/exon1 of CST6 (mean TMI = 21 ± 13%) (Table 5).  
In contrast, breast cancer cell lines that do not express CST6 exhibit hypermethylation of the 
CST6 promoter/exon 1 region, with TMI values ranging from 72% to 98% (Figure 14).  
MDA-MB-435S and MDA-MB-453 cells were 100% methylated at 52/55 (95%) and 51/55
 76
Figure 14.  Methylation analysis of the CST6 proximal promoter and exon 1 in breast 
cancer cell lines and normal mammary epithelial cells that differentially express CST6.  
A summary of the methylation analysis of the CST6 promoter (23 CpGs) and exon 1 (32 
CpGs) is shown.  The black arrow indicates the start of transcription between CpGs 23 and 
24.  Black circles correspond to fully (100%) methylated CpGs, gray circles correspond to 
CpGs with intermediate methylation, and open circles correspond to unmethylated CpGs.  
TMI values for the entire promoter/exon 1 region (55 CpGs) are given for each breast cancer 
cell line.  MCF12A, SK-BR-3, and BT-20 cells express CST6, while the remaining cell lines 
lack CST6 expression.    
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(93%) CpGs, respectively (Figure 14).  In MCF-7 cells, 42/55 (76%) CpGs were 100% 
methylated, 12/55 (22%) CpGs were methylated at an intermediate level, and 1/55 (2%) 
CpGs was unmethylated (Figure 14).  Hs578T and MDA-MB-436 cells were 100% 
methylated at 19/55 (35%) and 13/55 (24%) CpGs, respectively, with the remaining CpGs 
methylated at an intermediate level.  The average TMI for the CST6-negative cell lines was 
87 ± 5% (n=5), reflecting CST6 promoter/exon 1 hypermethylation among these cells (Table 
5).  When the methylation status of CST6 promoter/exon 1 was compared between groups of 
cell lines that differentially express CST6, a significant association (P=0.0227) between 
CST6 promoter/exon 1 region methylation (CpGs 1-55) and CST6 gene expression was found 
(Table 5).  However, hypermethylation of the proximal promoter of CST6 (CpGs 1-23 and 1-
31, P<0.001) was more strongly associated with loss of CST6 expression status than 
methylation involving exon 1 (CpGs 24-55, N.S.) (Table 5).  These observations suggest that 
hypermethylation of the CST6 CpG island contributes to the silencing of CST6 expression in 
breast cancer cell lines, and that hypermethylation of the proximal promoter is most 
important for down-regulation of CST6 gene expression.        
 In order to identify CpG dinucleotides that are critical in CST6 silencing, 5 CST6-
negative cell lines (Hs578T, MCF-7, MDA-MB-435S, MDA-MB-436, and MDA-MB-453) 
were treated with 5-aza, and 46 CpG dinucleotides from the proximal promoter region and 
exon 1 (+118 to -228, CpGs 10-55) were evaluated by sodium bisulfite sequencing (Figure 
15).  The CST6 promoter/exon 1 became significantly demethylated in response to 5-aza 
treatment in each cell line examined (P<0.0001), resulting in lower values for TMI (33 ± 
10%, range 1-64%) (Figure 15A).  Following withdrawal of 5-aza treatment, remethylation 
of the CST6 promoter/exon 1 occurred in MDA-MB-436, Hs578T, and MCF-7 cells (Figure
 80
Figure 15.    Methylation analysis of the CST6 proximal promoter and exon 1 in CST6-
negative breast cancer cell lines that have been exposed to demethylating treatment.  A 
summary of the methylation analysis of the CST6 promoter (14 CpGs) and exon 1 (32 CpGs) 
is shown.  Black circles correspond to fully (100%) methylated CpGs, gray circles 
correspond to CpGs with intermediate methylation, and open circles correspond to 
unmethylated CpGs.  TMI values for the promoter/exon 1 region (46 CpGs) are given for 
each breast cancer cell line.  (A) CpG methylation analysis of the CST6 promoter/exon 1 
region after treatment with 5-aza.  (B) CpG methylation analysis of the CST6 promoter/exon 
1 region after withdrawal of 5-aza treatment.    
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15B).  The extent of methylation after 5-aza withdrawal was indistinguishable from that of 
controls for MDA-MB-436 and Hs578T cells, reflecting a complete remethylation of the 
promoter/exon 1 (P<0.0001) (Figure 14 and 15B).  Likewise, significant remethylation of 
CST6 occurred in MCF-7 cells after treatment withdrawal, with methylation levels 
approaching that of control (TMI of 64% versus 89%) (Figure 14 and 15B).  In contrast, 
there was no apparent change in CST6 methylation in MDA-MB-435S cells after treatment 
withdrawal based upon calculated TMIs (42% versus 40%), but there was a significant 
qualitative change in the methylation pattern (Figure 15B).  MDA-MB-435S cells exhibit a 
loss of CST6 expression when the demethylating treatment was withdrawn, suggesting that 
some or all of the 12 CpGs that were differentially remethylated (CpGs 13, 15, 19, 27, 31, 
33, 39, 42, 46, 47, 50, 54, Figure 15) may be critical for CST6 silencing.  CST6 expression 
after 5-aza withdrawal was diminished in MDA-MB-453 cells in the absence of a dramatic 
increase in CST6 methylation, although loss of expression was accompanied by a 
redistribution of methylation across the CST6 promoter and exon 1 (Figure 15).  There is a 
significant association between CST6 methylation status and expression among CST6-
negative cell lines treated with 5-aza for both the promoter/exon 1 region (CpGs 10-55, 
control versus 5-aza, P=0.0033), as well as exon 1 alone (CpGs 24-55, control versus 5-aza, 
P=0.0127) (Table 5).   
A comparative analysis of CpG dinucleotides in the promoter and exon 1 regions of 
CST6-positive and -negative cell lines was performed to identify methylation events 
involving individual CpGs or regions of CpG density that are important for the silencing of 
CST6.  Average TMI values for individual CpG dinucleotides were calculated for CST6-
positive (BT-20, MCF12A, and SK-BR-3) and CST6-negative cell lines (Hs578T, MCF-7, 
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MDA-MB-435S, MDA-MB-436, and MDA-MB-453) (Figure 16).  The CST6-positive cell 
lines exhibit a low level of methylation (TMI < 33%) for the 15 CpG dinucleotides contained 
in segment 1 (corresponding to -50 to -200).  Of note, 6 CpGs (CpGs 2, 4, 5, 7, 12, and 13) 
were not methylated in these cell lines, suggesting a possible role for these CpGs and/or the 
sequences containing these CpGs in the positive regulation of CST6 expression (Figure 16B).  
In contrast, a high level of methylation for CpGs in segment 1 (TMI > 73%) was found in 
CST6-negative cell lines, including CpG 14, which was fully (100%) methylated in all cell 
lines (Figure 16B).  The extent of methylation of individual CpG dinucleotides correlated 
with CST6 gene expression for 14/15 CpGs in segment 1 (P=0.0197 to P<0.0001).  Segment 
2 spans the transcriptional start site of CST6 (+50 to -50), and consists of CpG dinucleotides 
16-31 (Figure 16C).  CST6-positive cell lines have a relatively low level of methylation at 
individual CpG dinucleotides (TMI range:  0% to 44%), whereas CST6-negative cell lines 
contain high levels of methylation in this region of the CST6 promoter/exon 1 region (TMI 
range:  66% to 93%) (Figure 16C).  The extent of methylation of individual CpG 
dinucleotides was significantly associated with CST6 gene expression for all CpGs in 
segment 2 (P=0.0343 to P=0.0046).  Segments 3 and 4 encompass CpG dinucleotides 32-55 
of CST6 exon 1 (+242 to +50). CpG dinucleotides in this region were moderately methylated 
in CST6-positive cell lines with TMI values ranging from 11% to 67% (Figure 16D).  Among 
CST6-negative cell lines, the calculated TMI values ranged from 80% to 100%, reflecting 
exon 1 hypermethylation in both segments.  With few exceptions there was no significant 
correlation between CST6 gene expression and methylation status of individual CpG 
dinucleotides in segments 3 and 4. 
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Figure 16.  Methylation analysis for individual CpG dinucleotides in CST6-positive and 
CST6-negative breast cancer cell lines.  (A) Distribution of CpG dinucleotides proximal to 
the transcriptional start site in the promoter (0 to -1400 nucleotides) and exon 1 (0 to +294 
nucleotides) of CST6 are depicted schematically.  Vertical lines represent the relative 
position of individual CpG dinucleotides and the segmented horizontal lines (designated 1-4) 
indicate the location of individual CpG dinucleotides depicted in (B) (segment 1), (C) 
(segment 2), and (D) (segment 4).  The results for CpGs in segment 3 are not shown.  
Representative CpG dinucleotides are indicated by lollipops corresponding to various 
segments of the promoter or exon 1 (+242 to -228).  TMI values represent averages of the 
three CST6-positive and five CST6-negative breast cell lines:  black circles correspond to 
100% methylated CpGs, partially-filled circles correspond to >40% methylated CpGs, gray 
circles correspond to <40% methylated CpGs, and white circles correspond to unmethylated 
CpGs.   †, Denotes statistical significance at P<0.001; **, denotes statistical significance at 
P<0.01; and *, denotes statistical significance at P<0.03, when comparing individual CpG 
methylation to CST6 gene expression status.  (B) CpGs 1-15 from segment 1 (-50 to -200) 
within the promoter region.  (C) CpGs 16-31 from segment 2 (+50 to -50) spanning the 
transcriptional start site.  (D) CpGs 43-55 from segment 4 (+242 to +138) within exon 1.       
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C.  Methylation-dependent Silencing of CST6 in Primary Human Breast Tumors and 
Metastatic Lesions 
 
Immunohistochemical Analysis of Cystatin M in Primary Breast Tumors and Lymph Node 
Metastases   
The expression of cystatin M was examined at the protein level using paraffin-embedded 
tissues and immunohistochemical (IHC) staining.  Table 6 shows primary breast tumor 
designations along with tumor type, pTNM, pathological stage, and cystatin M protein 
expression status.  A breast tissue microarray (TMA) containing 60 tissue cores was 
immunostained for cystatin M and cytokeratin 18 (CK18).  Seventeen tissue cores from the 
TMA could not be scored due to an absence of CK18 immunostaining.  The remaining 43/60 
(72%) cores (including 31 primary tumors) showed strong staining for CK18.  Therefore, 
these 43 tissue samples from the TMA were analyzed for cystatin M expression.  
Immunodetection of cystatin M in select normal human breast tissues (total n=5) and primary 
breast tumors (total n=45) are shown in Figure 17 and summarized in Table 6.  Epithelial and 
myoepithelial cells of 5/5 (100%) normal breast tissues showed strong immunostaining for 
cystatin M (Figure 17A, NB1).  Likewise, 20/45 (44%) primary tumors (Figure 17, P3, P4, 
P22, and P30) were positive for cystatin M expression.  In contrast, 25/45 (56%) primary 
breast tumors were found to be negative for cystatin M (Figure 17, P1, P35 and P44), 
including 21/38 (55%) IDC, 1/2 (50%) ductal carcinoma in situ (DCIS), 1/1 (100%) solid 
papillary carcinoma, 1/3 (33%) infiltrating lobular carcinoma, and 1/1 (100%) signet ring cell 
carcinoma. 
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Table 6.  Characteristics of Human Primary Breast Tumors and Normal Breast Tissues   
 
Tissue Tumor Cystatin M 
Designation1 Type2 pTNM Stage Expression  
 
P1 IDC T2N1Mx IIB No 
P2 IDC T1cN3aMx IIIC Yes 
P3 IDC T2N1Mx IIB Yes 
P4 IDC T2N1Mx IIB Yes 
P5 IDC T1cN2aMx IIIA No 
P6 IDC T1NxMx UNK No 
P7 IDC TxNxMx3 IIA Yes 
P8 IDC T2N1Mx IIB No 
P9 IDC T1bN0Mx I No 
P10 IDC T1cN1Mx IIA No 
P11 IDC T1N1Mx IIA No 
P12 IDC T2N1Mx IIB No 
P13 IDC T4N3M1 IV Yes 
P14 IDC T1N0Mx I Yes 
P15 solid papillary carcinoma T3N1aM0 IIIA No 
P16 IDC T4bN2aM0 IIIB No 
P17 IDC T3N0M0 IIB No 
P18 IDC T3N1aM0 IIIA No 
P19 IDC T3N3aN0 IIIC No 
P20 infiltrating lobular carcinoma T2N1aM0 IIB Yes 
P21 IDC T3N1aM0 IIIA Yes 
P22 IDC T2N1aM0 IIB Yes 
P23 infiltrating lobular carcinoma T3N3aM0 IIIC Yes 
P24 infiltrating lobular carcinoma  T3N3aM0 IIIC  No 
P25 IDC T2N1aM0 IIB No 
P26 IDC T2N0M0 IIA No 
P27 DCIS TisN0M0 0 No 
P28 IDC T2N2aM0 IIIA Yes 
P29 IDC T2N3bM0 IIIC Yes 
P30 DCIS TisN0M0 0 Yes 
P31 IDC T2N2M0 IIIA Yes 
P32 IDC T2N0M0 IIA No 
P33 IDC T2N0M0 IIA Yes 
P34 signet ring cell carcinoma T3N0M0 IIB No 
P35 IDC T3N2aM0 IIIA No 
P36 IDC T3N2aM0 IIIA No 
P37 IDC T2N0M0 IIA Yes 
P38 IDC T2N0M0 IIA Yes 
P39 IDC T2N2aM0 IIIA Yes 
P40 IDC T2N0M0 IIB Yes 
P41 IDC T3N1aM0 IIIA No 
P42 IDC T2N1aM0 IIB Yes 
P43 IDC T2N0M0 IIA No 
P44 IDC T3N2aM0 IIIA No 
P45 IDC T3N1aM0 IIIA No 
 
NB1 Normal NA NA Yes 
NB2 Normal NA NA Yes 
NB3 Normal NA NA Yes 
NB4 Normal NA NA Yes 
NB5 Normal NA NA Yes 
1Primary breast tumors are indicated as Px and normal breast tissues are designated NBx. 
2IDC refers to invasive ductal carcinoma and DCIS refers in ductal carcinoma in situ. 
3TxNxMx refers to a pTNM that is unknown. 
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Figure 17.  Immunohistochemical analysis of cystatin M expression in human primary 
breast tumors.  (A) Panels show H&E and cystatin M immunostaining in the same tumors.  
Normal breast (NB1) and primary tumors P3 and P4 show positive staining for cystatin M.  
Tumor P1 shows reduced cystatin M staining compared to NB1.  (B) Panels show 
cytokeratin 18 (CK18) and cystatin M immunostaining in the same tumors.   All tumors show 
strong staining for CK18.  Tumors P22 and P30 exhibit positive cystatin M immunostaining.  
Tumors P35 and P44 show reduced cystatin M staining.  (Original objective lens 
magnification 10x).   
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To examine cystatin M protein expression in metastatic lesions, 20 lymph nodes were 
obtained for immunostaining (12 of the lymph nodes were derived from 5 primary breast 
tumors).  Table 7 contains information related to the lymph nodes analyzed, including tumor 
designations, along with tumor type, pTNM, pathological stage from matched primary 
tumors, and cystatin M protein expression status.  Figure 18 shows representative cystatin M 
IHC staining in these metastatic lesions.  The majority (17/20, 85%) of metastatic lesions in 
lymph nodes were negative for cystatin M expression (Figure 18, P2N1, P4N1, LNM2, 
LNM5, LNM8, and LNM11).  In contrast, 3/20 (15%) metastatic lesions were positive for 
cystatin M expression (Figure 18, P1N1). Overall, these numbers reflect the presence of 
cystatin M-negative lymph node metastases in 13/16 (81%) patients.  These observations are 
consistent with the suggestion that loss of cystatin M expression is a common feature of 
metastatic breast tumors.  However, the presence of cystatin M-positive breast tumor in some 
lymph node specimens suggests that loss of cystatin M expression is not absolutely required 
for tumor invasion and metastasis.   
To examine the possibility that loss of cystatin M reflects a tumor progression-related 
event, 5 primary breast tumors and matched lymph node metastases were immunostained.  
Figure 19 shows representative examples of these primary tumor/lymph node pairs.  One of 
five (20%) matched pairs were negative for cystatin M expression in both the primary breast 
tumor and lymph node metastasis, indicating an early loss of cystatin M protein during breast 
tumorigenesis, with persistence in the metastatic lesion (Figure 19, P5 and P5N1).  
Additionally, 1/5 (20%) matched pairs showed positive cystatin M staining in both the 
primary breast and lymph node tissues, suggesting that tumor metastasis in this patient was 
mediated through a cystatin M-independent pathway (Figure 19, P3 and P3N1).  The
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Table 7.  Characteristics of Human Lymph Node Metastases   
 
Tissue Tumor  Cystatin M 
Designation1 Type pTNM2 Stage2  Expression 
 
P1N1 lymph node metastasis T2N1Mx IIB Yes  
P2N1-N33 lymph node metastasis T1cN3aMx IIIC No   
P3N1 lymph node metastasis T2N1Mx IIB Yes  
P4N1 lymph node metastasis T2N1Mx IIB No  
P5N1 lymph node metastasis T1cN2aMx IIA No  
LNM1-44 lymph node metastasis TxNxMx UNK No  
LNM5 lymph node metastasis TxNxMx UNK No  
LNM6 lymph node metastasis T3N3aM0 IIIC Yes  
LNM7 lymph node metastasis T3N3aM0 IIIC  No  
LNM8 lymph node metastasis T3N3aM0 IIIC  No  
LNM9 lymph node metastasis  T3N3M0 IIIC  No  
LNM10 lymph node metastasis  T3N2aM0 IIIA No  
LNM11 lymph node metastasis  T1cN1aM0 IIA No 
LMN12 lymph node metastasis  T2N3aM0 IIIC No  
LMN13 lymph node metastasis  T1bN3aM0 IIIC No  
 
1Metastaic lesions corresponding to a matched primary breast tumor are indicated as  
PxNx and lesions that have no matched primary are designated LNMx. 
2pTNM and pathological stage designations for lymph node metastases are derived  
from primary breast tumor designations.  TxMxNx refers to a pTNM that is unknown. 
3P2N1-N3 designates 3 independent lymph nodes corresponding to one primary tumor. 
4LNM1-4 designates 4 independent lymph nodes corresponding to one primary tumor. 
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Figure 18.  Immunohistochemical analysis of cystatin M expression in lymph node 
metastases.  (A) Panels show H&E and cystatin M immunostaining in the same lymph 
nodes.  Lymph node P1N1 shows positive staining for cystatin M.  Lymph nodes P2N1, 
P4N1, LNM2, and LNM5 show reduced cystatin M immunostaining.  (B) Panels show 
cytokeratin 18 (CK18) and cystatin M immunostaining in the same lymph nodes.   All 
metastatic lesions show strong staining for CK18 and exhibit reduced cystatin M 
immunostaining.  (Original objective lens magnification 10x). 
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Figure 19.  Immunohistochemical analysis of cystatin M expression in matched primary 
breast tumors and lymph node metastases.  Representative examples of matched pairs of 
primary breast tumors (top panel) and lymph node metastasis (bottom panel) are shown.  
Primary breast tumor P1 shows reduced cystatin M immunostaining compared to its matched 
lymph node P1N1.  Primary breast tumor P3 and lymph node metastasis P3N1 both show 
positive staining for cystatin M.  Primary breast tumor P4 shows positive staining for cystatin 
M compared to its matched lymph node metastasis P4N1.  Primary breast tumor P5 and 
lymph node metastasis P5N1 are negative for cystatin M expression.  (Original objective lens 
magnification 10x). 
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remaining 3 patients had cystatin M-positive primary tumors, but 2/3 (67%) of the matched 
lymph node metastases lacked cystatin M expression (Figure 19, P4 and P4N1).  This 
observation is consistent with a progression related loss of cystatin M expression during the 
evolution of the metastatic clone.  The remaining primary tumor/lymph node pair lacks 
cystatin M expression in the primary tumor, while the lymph node metastasis exhibits 
stronger staining for the cystatin M protein (Figure 19, P1 and P1N1).  This result is unclear, 
but may reflect heterogeneity of cystatin M expression in this tumor.  Thus, a cystatin M-
positive tumor cell population may have given rise to this metastatic lesion through a cystatin 
M-independent pathway.  
 
Methylation-Dependent Silencing of CST6 in Primary Breast Tumors and Lymph Node 
Metastases  
 To explore the possibility that loss of cystatin M expression is related to epigenetic 
silencing of CST6, we analyzed primary breast tumors and lymph node metastases for CST6 
promoter methylation.  A segment of the proximal promoter and exon 1 (-118 to +242, 
Figure 20A) containing 46 CpG dinucleotides was analyzed in normal breast tissue, 11 
primary breast tumors (5 express cystatin M and 6 lack cystatin M), and 12 lymph node 
metastases (2 express cystatin M and 10 lack cystatin M).  Multiple clones (n=5-12) 
corresponding to the CST6 promoter and exon 1 from each primary tumor or lymph node 
metastasis were analyzed by sodium bisulfite sequencing and individual CpGs were scored 
for methylation status.  Representative examples are shown in Figure 20B.  In normal breast 
tissue, 33/46 (72%) CpGs were consistently unmethylated, 13/46 (28%) CpGs were 
methylated at an intermediate level, and 0/46 (0%) were 100% methylated, producing a TMI
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Figure 20.  Methylation analysis of the CST6 proximal promoter and exon 1 in 
representative primary breast tumors and lymph node metastases.  (A) The distribution 
of CpG dinucleotides proximal to the transcription start site in the promoter (0 to -1400 
nucleotides) and exon 1 (0 to +294 nucleotides) of CST6 are depicted schematically (vertical 
lines indicate the relative position of individual CpG dinucleotides). Methylation analysis 
was performed on a region of the promoter spanning from -118 to +242 (indicated by a solid 
horizontal line), which contains 46 CpG dinucleotides and encompasses a large CpG island. 
(B) All clones analyzed for methylation of the CST6 promoter and exon 1 (46 CpGs) are 
shown for representative primary breast tumor and lymph node metastases examples.  Black 
circles correspond to methylated CpGs and open circles correspond to unmethylated CpGs.  
TMI values for the entire promoter/exon 1 region (46 CpGs) are given for each primary 
breast tumor and lymph node metastasis.  NB1, P4, and P3 express cystatin M, while LNM1 
and LNM5 lack cystatin M protein expression. 
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of 2% (Figure 20B, NB1).  The majority (3/5, 60%) of primary tumors that stain positive for 
cystatin M lack appreciable levels of methylation, with TMI values of 0 to 5% (Figure 20B, 
P4 and P3).   Primary breast tumors P2 and P9, exhibit methylation and express cystatin M.  
In P2, 23/46 (50%) CpGs were unmethylated, 22/46 (48%) CpGs were methylated at an 
intermediate level, and 1/46 (2%) was 100% methylated, producing a TMI of 38%.  In P9, 
the majority (33/46, 72%) of CpGs were unmethylated, although 13/46 (28%) were 100% 
methylated resulting in a TMI of 28%.  The continued expression of cystatin M in P2 and P9, 
despite CST6 promoter hypermethylation, suggests that there may be mechanisms to 
transcriptionally bypass promoter methylation.  Most, (5/6, 83%) primary breast tumors that 
are negative for cystatin M expression exhibit very low levels of CST6 methylation (TMI = 0 
to 3%).  This finding suggests that there may be other epigenetic or mutational mechanisms 
responsible for the silencing of cystatin M in these primary breast tumors.  In contrast, one 
tumor (P1) was negative for cystatin M protein expression and 45/46 (98%) CpGs were 
methylated at an intermediate level, resulting in a TMI of 28%.  Overall, a subset of primary 
tumors (3/11, 27%) exhibits CST6 promoter hypermethylation, and in one case this 
methylation was associated with loss of cystatin M expression.   
The majority (7/10, 70%) of metastatic lesions that are negative for cystatin M expression 
exhibit hypermethylation of the CST6 promoter/exon 1 region, with TMI values ranging from 
11% to 46% (average TMI 17 + 4%).  The TMIs for cystatin M-negative lymph node 
metastases were found to be statistically increased relative to that determined for normal 
breast (P<0.0001).  Figure 20B shows representative methylation analyses.  LNM1 and 
LNM5 were methylated at 17/46 (37%) and 38/46 (83%) CpGs, respectively, resulting in 
TMIs of 37% and 46% (Figure 20B, LNM1 and LNM5).  P4N1 and LNM2 were 100% or 
 100
intermediately methylated at 35/46 (76%) and 38/46 (83%) CpGs respectively, with the 
remaining CpGs unmethylated, reflecting TMIs of 22% and 24%.  Cystatin M negative nodes 
P2N1, LNM3, and LNM4 were intermediately methylated at 12/46 (26%), 34/46 (74%), and 
18/46 (39%) CpGs, resulting in TMI values of 11%, 13%, and 13% respectively.  There were 
3 cystatin M-negative lymph nodes that displayed TMI values ranging from 1% to 3%.  Two 
lymph node metastases were positive for cystatin M and exhibit low levels of methylation.  
In lymph node P1N1, 23/46 (50%) CpGs were methylated at an intermediate level and 23/46 
(50%) CpGs were unmethylated.  In lymph node P3N1, 8/46 (17%) CpGs were methylated at 
an intermediate level, and 38/46 (83%) CpGs were unmethylated.  In total, 8/12 (67%) 
metastatic lesions from 5/7 (71%) patients displayed CST6 promoter hypermethylation.    
 
CST6 Gene Methylation Correlates with Loss of Cystatin M Expression in a Subset of 
Primary Breast Tumors and Lymph Node Metastases   
 Cystatin M expression is associated with methylation status in the majority (12/23, 52%) 
of tumor tissues (Figure 21).  In most cases (4/7, 57%) cystatin M-positive tumors show a 
lack of CST6 promoter methylation (Figure 21, P3, P3N1, and P4).  In contrast, 3/7 (43%) 
cystatin M-positive tumors exhibit CST6 hypermethylation.  This result suggests the 
existence of other epigenetic or genetic mechanisms that can bypass promoter 
hypermethylation.  Eight of 16 (50%) cystatin M-negative tumors exhibit CST6 promoter 
hypermethylation with TMI values ranging from 11% to 46% (Figure 21, P4N1, LNM1, and 
LNM5).  These include one primary breast tumor and 7 lymph node metastases that lack 
expression of cystatin M.  The remaining 8/16 (50%) cystatin M-negative tumors show very 
low levels of CST6 promoter methylation (TMI values ranging from 0% to 3%), including 5
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Figure 21.  Correlation analysis of cystatin M expression and CST6 methylation status 
in primary breast tumors and lymph node metastases.  Panels show cystatin M 
immunostaining (on left) and a summary of the methylation analysis of the CST6 
promoter/exon 1 (46 CpGs) is show on the right.  Black circles correspond to fully (100%) 
methylated CpGs, gray circles correspond to CpGs with intermediate methylation, and open 
circles correspond to unmethylated CpGs.  TMI values for the entire promoter/exon 1 region 
(46 CpGs) are given for each tissue sample.  P4 and P3 primary breast tumors, and lymph 
node metastasis P3N1 express cystatin M.  Metastatic lesions P4N1, LNM1, and LNM5 
show reduced expression of cystatin M.  (Original objective lens magnification 10x).     
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primary tumors and 3 metastatic lesions.  Overall, the extent of CST6 methylation 
corresponds with the expression of cystatin M expression in the majority (52%) of breast 
neoplasms, suggesting that methylation-dependent silencing of CST6 may represent an 
important mechanism for loss of cystatin M in a subset of breast neoplasms. 
  
F.  CST6 CpG Methylation Requires an Upstream DNA Sequence Element that Directs 
Promoter CpG Island Methylation  
 
Cloning the Promoter Region of CST6 and Analysis of Luciferase Activity  
 To address the question of whether cis-acting elements direct DNA methylation of 
specific promoter target sequences, two truncations (designated CST6-500 and CST6-1000) 
of the CST6 promoter region (encompassing the CpG island) were cloned into the 
pGL4.17[luc2/Neo] reporter vector.  Luciferase reporter constructs were transiently 
transfected into MCF-7 cells to assess promoter activity and to ensure that construction of the 
reporter gene cassette did not compromise that ability of the truncated CST6 promoter to 
drive luciferase activity.  Both CST6 reporter gene constructs produced good luciferase 
activity after transient transfection:  CST6-500, 604 units, and CST6-1000, 2572 units.  CST6 
reporter gene constructs were treated with SssI methylase in order to test if the CST6-500 and 
CST6-1000 promoter constructs are sensitive to methylation (Figure 22).  Both luciferase 
reporter constructs were transiently transfected into MCF-7 cells to assess promoter activity 
after SssI methylase treatment.  Methylated CST6 reporter gene constructs produced minimal 
luciferase activity after transient transfection relative to the luciferase activity of the 
unmethylated constructs, suggesting that both promoter constructs are sensitive to silencing
 104
Figure 22.  Analysis of luciferase activity of CST6 promoter reporter constructs treated 
with SssI methylase.  The bars depict levels of luciferase activity from the SssI methylase 
treated CST6-500 (green diagonal bar) and CST6-1000 (pink diagonal bar) promoter reporter 
constructs, and untreated CST6-500 (green bar) and CST6-1000 (pink bars) constructs 
following transient transfection into MCF-7 breast cancer cells.  Levels of luciferase activity 
from the methylated reporter constructs relative to untreated reporter constructs are shown, 
where untreated reporter constructs are set as 100%.   
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by methylation (Figure 22).  Subsequently, these reporter constructs were stably transfected 
into BT-20 breast cancer cells (which express CST6 and lack promoter methylation), and 
MCF-7 and MDA-MB-453 cells (that lack CST6 expression and exhibit promoter 
hypermethylation).  After stable transfection and cell propagation, firefly luciferase activity 
expressed from the CST6-500 promoter construct was assayed in cell lysates prepared 2, 4, 
and 5 weeks after transfection into BT-20 and MCF-7 cells, and 5 weeks after transfection 
into MDA-MB-453 cells.  Likewise, firefly luciferase activity expressed from the CST6-1000 
promoter construct was determined 3, 4, and 5 weeks after transfection into BT-20 and MCF-
7 cells, and 5, 6, and 7 weeks after transfection into MDA-MB-453 cells for firefly luciferase 
activity.  Temporal analysis of luciferase activities enables examination of progressive 
methylation-dependent changes in reporter construct expression.  Both CST6-500 and CST6-
1000 reporter constructs were analyzed for DNA methylation by bisulfite sequencing after 
the last luciferase determination (5-7 weeks following initial transfection).   
 In BT-20 cells, the CST6-500 construct demonstrated a low level of luciferase activity 
(Figure 23A).  In contrast, MCF-7 and MDA-MB-453 cells, expressed significantly higher 
levels of luciferase activity from the CST6-500 construct compared to BT-20 cells (P<0.01) 
(Figure 23A).  When normalized to BT-20 cells, MCF-7 and MDA-MB-453 cells express 4-
fold more luciferase activity from the CST6-500 construct than BT-20 cells  (Figure 23B).  
This difference may reflect greater general transcriptional activity in MCF-7 and MDA-MB-
453 cells, compared to BT-20.  These results show that the CST6-500 construct, which 
contains the majority of the CST6 promoter CpG island, can drive transcription of the 
luciferase gene. This observation suggests that the CST6-500 construct represents a 
minimal/essential promoter for CST6.  The level of luciferase activity resulting from CST6-
 107
Figure 23.  Analysis of luciferase activity of CST6 promoter reporter constructs.  The 
bars depict levels of luciferase activity from the CST6-500 and CST6-1000 promoter reporter 
constructs following stable transfection into BT-20 (yellow bars), MCF-7 (blue bars), and 
MDA-MB-453 (pink bars) breast cancer cell lines.  Luciferase activities represent the mean 
of 3-9 independent determinants.  Error bars reflect S.E.M.  (A) Levels of luciferase activity 
per 100,000 cells (arbitrary units) from the CST6-500 reporter construct.  (B) Levels of 
luciferase activity from the CST6-500 reporter construct normalized to BT-20, where BT-20 
is set as 100.  (C) Levels of luciferase activity per 100,000 cells (arbitrary units) from the 
CST6-1000 reporter construct.  (D) Levels of luciferase activity from the CST6-1000 reporter 
construct normalized to BT-20, where BT-20 is set as 100. 
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500 remained consistent over time in each of the three cell lines.  The continued expression 
of CST-500 in the hypermethylator cell lines (MCF-7 and MDA-MB-453) over a period of 
five weeks suggests that the minimal/essential promoter does not become methylated in these 
cells.       
 The CST6-1000 construct produced increased levels of luciferase activity in each of the 
three breast cancer cell lines (Figure 23C) compared to the CST-500 construct.  This overall 
increase in promoter activity from the CST6-1000 construct (measured as increased 
luciferase activity) may reflect the presence of positive regulatory elements in the sequence 
region upstream of the CpG island.  MDA-MB-453 cells produced the highest levels of 
luciferase activity from the CST6-1000 construct, but there was no significant difference in 
luciferase activities among the cell lines examined (Figure 23C and D).  The CST6-1000 
construct exhibited a consistent level of luciferase activity over time in each of the three cell 
lines.  The continued expression of CST6-1000 in hypermethylator cell lines over a period of 
five to seven weeks, suggests that the CST6 promoter region contained in this reporter 
construct does not become methylated in these cell lines.   
 
CST6 Promoter Construct Methylation Analysis in Differentially Expressing Breast 
Cancer Cell Lines 
 Cystatin M contains a large CpG island (424 bp) including 54 CpG dinucleotides that 
spans the proximal promoter and exon 1, encompassing the start site for transcription.  We 
examined the methylation status of 34 CpGs that are contained within the CST6-500 and 
CST6-1000 constructs by bisulfite sequencing using primers designed to amplify a region of 
the firefly luciferase gene and the proximal region of the constructs.  BT-20 cells transfected 
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with the CST6-500 construct demonstrated luciferase activity and lacked methylation five 
weeks after transfection, exhibiting a TMI value of 4% (Figure 24).  Likewise, methylation 
analysis of the CST6-500 construct from MCF-7 and MDA-MB-453 cells five weeks after 
transfection exhibited a lack of methylation, producing TMI values of 5% and 0% 
respectively (Figure 24).  These results suggest that truncation of the CST6 promoter 
disassociates an upstream cis regulatory element that directs DNA methylation of the CpG 
island region of the CST6-500 construct.  This finding also establishes that the CST6 
promoter CpG island is not sufficient to recruit the DNA methylation machinery and direct 
its own methylation.        
 BT-20 cells transfected with the CST6-1000 construct produced strong expression of 
luciferase activity and lacked methylation five weeks after transfection, exhibiting a TMI 
value of 7% (Figure 25).  Likewise, methylation analysis of the CST6-1000 construct 
transfected into MCF-7 and MDA-MB-453 cells after five weeks exhibited a lack of 
methylation, demonstrating TMI values of 1% and 0% respectively (Figure 25).  Thus, there 
is perfect correspondence between expression of luciferase activity and lack of promoter 
CpG island methylation using this construct and these cell lines.  These observations suggest 
that the CST6-1000 promoter truncation dissociated a critical regulatory (directive) sequence 
(cis element) from the CpG island target sequence within the CST6 promoter.  This result 
suggests that the putative instructional cis element must be located >1200 bp upstream of the 
transcription start site, and >1000 bp upstream of the target CpG island.   
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Figure 24.  Methylation analysis of the CST6-500 promoter reporter construct.  The 
distribution of the CpG dinucleotides in the CST6-500 promoter reporter construct inserted 
proximal to the firefly luciferase gene (pink box) is depicted schematically (vertical lines 
indicate the relative position of individual CpG dinucleotides).  Methylation analysis was 
performed on a region containing 34 CpG dinucleotides from the CST6-500 promoter 
reporter construct following transfection into BT-20, MCF-7, and MDA-MB-453 breast 
cancer cell lines.  All clones analyzed for methylation of the CST6-500 promoter reporter 
construct are shown.  Black circles correspond to methylated CpGs and open circles 
correspond to unmethylated CpGs.  TMI values for the entire region (34 CpGs) are given for 
each breast cancer cell lines. 
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Figure 25.  Methylation analysis of the CST6-1000 promoter reporter construct.  The 
distribution of the CpG dinucleotides in the CST6-1000 promoter reporter construct inserted 
proximal to the firefly luciferase gene (pink box) is depicted schematically (vertical lines 
indicate the relative position of individual CpG dinucleotides).  Methylation analysis was 
performed on a region containing 34 CpG dinucleotides from the CST6-1000 promoter 
reporter construct following transfection into BT-20, MCF-7, and MDA-MB-453 breast 
cancer cell lines.  All clones analyzed for methylation of the CST6-1000 promoter reporter 
construct are shown.  Black circles correspond to methylated CpGs and open circles 
correspond to unmethylated CpGs.  TMI values for the entire region (34 CpGs) are given for 
each breast cancer cell lines. 
 114
 Fi
re
fly
 L
uc
ife
ra
se
C
ST
6-
10
00
M
D
A
-M
B-
45
3
M
C
F-
7
BT
-2
0
TM
I
7% 1% 0%
Fi
re
fly
 L
uc
ife
ra
se
C
ST
6-
10
00
M
D
A
-M
B-
45
3
M
C
F-
7
BT
-2
0
M
D
A
-M
B-
45
3
M
C
F-
7
BT
-2
0
TM
I
7% 1% 0%
115
IV.  DISCUSSION 
 
A.  Identification of Putative Epigenetically-regulated Genes in MCF-7 Breast Cancer 
Cells 
 
 Recent evidence suggests that epigenetic mechanisms play a major role in breast 
carcinogenesis, contributing to genetic instability in breast cancer, as well as to the silencing 
of specific genes (24,125).  A number of different genes have been shown to be inactivated in 
breast cancer through methylation-dependent gene silencing, including cell cycle control 
genes (p16INK4a), steroid receptor genes (ERα, PR, RARα2), tumor suppressor genes 
(BRCA1), genes associated with cancer metastasis (E-cadherin, TIMP-3), and others (24,40-
43).  In an attempt to more comprehensively catalogue methylation-sensitive genes in breast 
cancer, several recent studies have employed treatment of cells in culture with demethylating 
drugs and microarray analysis of gene expression (72-74).  We have utilized a similar 
strategy to identify epigenetically-regulated genes in human breast cancer cells.  In our study, 
MCF-7 cells were treated with a low concentration of 5-aza (250 nM) or 5-aza + TSA (50 
nM) for 3 weeks, followed by a 5 week recovery period after treatment withdrawal (Figure 
7).  The concentration of 5-aza and TSA, utilized in this study was 4-fold to 6-fold lower 
than traditional methods (126-129), eliminating the typically encountered cytotoxic effects 
(72,130) and allowing prolonged exposure of MCF-7 cells to the demethylating drugs.  
Treatment of MCF-7 cells resulted in increased and decreased expression of numerous genes 
(Figure 7), many of which may not be directly regulated by DNA methylation.  Therefore, to 
enrich for genes that are putatively epigenetically regulated, we identified subsets of genes 
that demonstrated a significant increase in expression level in response to treatment (5-aza or 
5-aza + TSA), but then returned to steady-state levels of expression following a recovery 
period (Figure 26).  Increased gene expression in response to treatment presumably reflects a 
demethylation event, resulting in an induction or enhancement of gene expression (Figure 
26).  Likewise, the return of gene expression to control levels following treatment withdrawal 
presumably reflects remethylation of the promoter sequence, resulting in gene silencing or 
down-regulation of expression (Figure 26).  This analysis identified a group of 20 putative 
epigenetically-regulated genes for further study, some of which have been suggested to be 
epigenetically regulated by other investigators (72,123,124).  These observations combine to 
suggest that our strategy for selection of putative epigenetically-regulated genes was sound.  
In addition to genes that exhibited increased expression, we identified genes that showed 
decreased expression upon demethylating treatment.  These genes may be important as well, 
but we chose to focus on the genes that demonstrated an increase in gene expression level in 
response to treatment, possibly reflecting a demethylation event.   
 
B.  Classification of Epigenetically-regulated Genes Based Upon Promoter CpG 
Features 
 
 It is well known that methylation affecting the promoter and downstream proximal 
sequences can result in gene silencing, but that methylation elsewhere in a gene will not 
hinder transcription (68).  Therefore, we expected that many of the putative epigenetically-
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Figure 26.  Alteration of gene expression and CpG methylation status during 
demethylation treatment.  Representation of a gene promoter CpG island located proximal 
to the transcription start site (indicated by the bent arrow) is depicted schematically (vertical 
lines indicate the relative position of individual CpG dinucleotides).  The gene is silenced by 
promoter CpG methylation (represented by pink lollipops) resulting in a lack of expression.  
After demethylating treatment the gene promoter becomes unmethylated resulting in gene 
expression.  Treatment withdrawal results in CpG remethylation and consequently loss of 
gene expression.      
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regulated genes identified in MCF-7 cells would contain CpG islands within their promoter 
sequences.  However, we found that only 45% of putative epigenetically-regulated genes 
contain typical CpG islands (65) in their promoter and/or exon 1, consistent with other 
studies reporting that genes lacking CpG islands are frequently induced in response to 
demethylating drugs (72-77,131).  Some (or all) of these genes lacking CpG islands may 
respond to demethylating drugs as a result of indirect regulation by DNA methylation.  That 
is, these genes may be regulated directly by the protein products (transcription factors, etc.) 
of genes containing CpG islands.  Alternatively, novel CpG targets of DNA methylation may 
function to confer methylation-sensitivity to genes lacking CpG islands.  In the present study, 
40% of putative epigenetically-regulated genes contained weak CpG islands, whereas three 
genes were identified that lack features expected for epigenetically-regulated genes (typical 
or weak CpG islands).  It is intriguing to suggest that novel CpG target sequences may confer 
methylation-sensitivity to these genes.  Direct evidence for methylation-dependent regulation 
of genes lacking CpG islands has emerged from a few investigations (79,132,133).  Based 
upon our observations, we propose that putative epigenetically-regulated genes can be 
classified based upon their promoter sequence characteristics related to CpG frequency and 
distribution: (i) genes with typical CpG features (CpG islands within the promoter or exon 1), 
(ii) genes with intermediate CpG features (weak CpG islands within the promoter or exon 1), 
and (iii) genes with atypical CpG features (no CpG islands).  
  
Genes with Typical CpG Features 
 Putative epigenetically-regulated genes with typical CpG features contain conventionally-
defined CpG islands (65), and in some cases weak CpG islands as well.  CST6 represents the 
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prototype of a gene with typical CpG features, with a large CpG island that spans the 
promoter and exon 1, encompassing the start site for transcription.  CST6 is a member of a 
family of proteins that represent physiological inhibitors of lysosomal cysteine proteases that 
are expressed in normal and premalignant breast epithelium, but not in metastatic breast 
cancer cell lines (103).  Ectopic expression of CST6 suppresses the neoplastic phenotype of 
MDA-MD-435S breast cancer cells, reducing their cell proliferation, migration, and invasion 
in vitro (113), and delaying tumor growth and reducing metastatic tumor burden in vivo 
(116).  CST6 expression is significantly diminished in primary human breast cancers (116), 
which is unrelated to gene deletion (103) but may be due to transcriptional silencing through 
methylation of its CpG island (134).  Our methylation analysis of the CST6 promoter shows 
that this gene is subject to DNA methylation in MCF-7 cells, and that there is an inverse 
correlation between CST6 expression and methylation of its promoter CpG island (Figure 9).  
These results strongly suggest that CST6, a putative breast cancer tumor suppressor gene 
(116), is sensitive to DNA methylation and that methylation-dependent epigenetic silencing 
may represent an important mechanism for loss of this gene during breast carcinogenesis 
and/or tumor progression. 
 
Genes with Intermediate CpG Features 
 Putative epigenetically-regulated genes with intermediate CpG features contain small 
regions of CpG density (weak CpG islands), but lack typical CpG islands.  C8orf4 is an 
example of a gene with intermediate CpG features.  While the specific function of C8orf4 is 
not known, its loss of expression in primary tumors, metastases, and cancer cell lines (135), 
along with its expression/involvement in the TGFβ-suppressive pathway, suggest that this 
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gene is a growth suppressive gene associated with negative regulation of cell proliferation.  
Thus, decreased C8orf4 expression could contribute to the loss of TGFβ responsiveness in 
breast cancer (136).  The relative paucity of CpG dinucleotides within the promoter/exon 1 of 
C8orf4 argues against its direct regulation by DNA methylation.  Nonetheless, C8orf4 is 
responsive to demethylating drugs in RKO colorectal carcinoma cells (72), as well as MCF-7 
breast cancer cells (this study), suggesting the possibility that this gene contains novel CpG 
targets for methylation.  The two strongest possibilities for novel methylation targets include 
the weak CpG island contained in exon 1, and individual CpG dinucleotides contained in the 
gene promoter.  The weak CpG island is substantially methylated when C8orf4 is silent, and 
becomes demethylated in response to treatment, coordinate with reexpression of the gene.  
However, treatment withdrawal results in gene silencing with only partial remethylation of 
these CpG dinucleotides, suggesting that methylation events in the promoter rather than exon 
1 may be responsible for regulation of C8orf4 in MCF-7 breast cancer cells.  In fact, the 
greatest concentration of methylated CpGs in the C8orf4 promoter was localized to a 103 bp 
region containing 5 CpG dinucleotides.  Treatment of MCF-7 cells resulted in demethylation 
of this region and coordinate expression of C8orf4, while treatment withdrawal resulted in 
silencing of C8orf4 expression and remethylation of these CpGs (Figure 10).  These results 
suggest that C8orf4 is subject to methylation-dependent epigenetic silencing in MCF-7 breast 
cancer cells through discrete promoter methylation events, possibly resulting in loss of TGFβ 
responsiveness. 
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Genes with Atypical CpG Features  
 The third class of genes identified in this study lack all features expected for 
epigenetically-regulated genes (including CpG islands).  IFI27 is a prototype for genes with 
atypical CpG features and an example of an interferon α-inducible gene (137), which have 
been implicated in primary breast tumors (138) and breast cancer cell lines (139) suggesting 
their importance in breast carcinogenesis.  Untreated MCF-7 cells lack expression of IFI27 
and most (93%) CpG dinucleotides within the promoter region are methylated.  Treatment of 
MCF-7 cells results in demethylation of the majority of CpG dinucleotides and concurrent 
expression of the gene, while treatment withdrawal leads to remethylation and loss of gene 
expression (Figure 10).  These results suggest that IFI27 is subject to epigenetic regulation in 
MCF-7 breast cancer cells, related to methylation of individual CpG dinucleotides contained 
in its promoter.  
 
C.  An Expanded Model for Methylation-dependent Epigenetic Regulation of Gene 
Expression 
 
 DNA methylation has three major effects on gene promoter sequences: (i) direct 
interference with the binding of transcription factors, (ii) attraction of methylated-DNA 
binding proteins, and (iii) alteration in chromatin packaging (26,140).  Each of these effects 
results in diminished promoter activity as a consequence of impaired interactions between the 
transcription machinery and the promoter DNA sequence.  To this point in time, it has been 
thought that a promoter CpG island was necessary to effectively catalyze methylation-
dependent gene silencing through one of these mechanisms.  However, recent evidence 
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suggests that genes lacking CpG islands can be directly regulated through methylation-
dependent mechanisms (79,132,133).  Therefore, based upon our results and studies from the 
literature, we propose expansion of the current model for DNA methylation-dependent 
epigenetic regulation of gene expression to include genes lacking typical CpG islands (Figure 
27).  The expanded model we propose recognizes (a) that all promoter CpG dinucleotides 
represent legitimate targets for methylation, (b) that sites for methylation may represent 
regional targets (CpG islands), local CpG density (weak CpG islands), or isolated CpGs, (c) 
that discrete methylation events occurring within CpG target sequences can contribute to 
gene silencing, and (d) that CpG methylation can contribute to gene silencing (or diminished 
expression) through several different mechanisms.  This expanded model highlights the 
importance of the CpG characteristics of individual gene promoters and the targets for 
methylation that they contain, the nature of specific methylation events, and how these 
factors combine to regulate gene expression and/or silencing. 
   
Mechanisms of DNA Methylation-dependent Silencing  
 Promoter CpG islands represent a recognized target for methylation leading to gene 
silencing.  In most cases, methylation of a CpG island is considered to be a regional 
methylation event, where methylation of specific CpG dinucleotides is less important than 
the overall methylation of the CpG-dense region.  CpG island methylation can result in gene 
silencing through several different mechanisms, including recruitment of methylated DNA 
binding proteins and/or direct interference with transcription factor complex binding to the 
promoter region.  A number of methylated DNA binding proteins have been identified (141-
143), several of which have particular affinity for CpG-rich heterochromatin (144).  The
 124
Figure 27.  Expanded model for methylation-dependent epigenetic regulation of gene 
expression.  The distribution of CpG dinucleotides proximal to the transcription start site 
(indicated by the bent arrow) is depicted schematically (vertical lines indicate the relative 
position of individual CpG dinucleotides) for theoretical genes with variable promoter CpG 
density.  CpG sequence features (CpG islands, weak CpG islands) are indicated.  Green 
lollipops correspond to methylated CpG dinucleotides.  Genes with typical CpG features (A) 
are subject to both regional and discrete methylation events.  Regional methylation can affect 
transcription through recruitment of methylated DNA binding proteins (pink ball).  Likewise, 
focal methylation within a larger CpG island may attract methylated DNA binding proteins 
(orange ball) that might inhibit transcription by blocking the procession of the transcription 
machinery to the transcriptional start site.  Alternatively, focal or regional methylation of a 
CpG island at a transcription factor binding sequence may directly interfere with binding by 
the transcription machinery (represented as associated green, blue, and purple balls).  Similar 
or identical consequences could result from methylation events involving promoters of genes 
with intermediate CpG features (B) or atypical CpG features (C). This proposed model 
highlights the importance of the CpG characteristics of individual gene promoters and the 
targets for methylation that they contain, the nature of specific methylation events, and how 
these factors combine to regulate gene expression and/or silencing. 
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binding of these proteins to methylated target sequences results in inhibition of transcription 
(145), possibly through the specific function of transcription repression domains (146).  In 
addition, several transcription factors have been shown to be sensitive to methylation of their 
recognition sequence (147).  However, some investigators have suggested that transcriptional 
silencing requires association of proteins to methylated sequences (148,149).  Nonetheless, 
there is strong evidence that methylation can directly interfere with the binding of some 
transcription factors to their recognition site (80,150).  While several mechanisms for 
inhibition of transcription involving methylation of CpG islands have been established or 
proposed, DNA methylation-dependent mechanisms of regulation of genes lacking well-
defined CpG islands are more elusive.  One possibility is that genes lacking CpG islands are 
not truly epigenetically regulated, but that their expression is governed by indirect 
methylation-dependent mechanisms, secondary to the epigenetic regulation of CpG island-
containing regulatory genes (encoding transcription factors or other regulatory proteins).  
While in some cases this may be true, in other cases there is direct evidence for methylation-
dependent regulation of genes lacking CpG islands (62).  We propose that mechanisms for 
methylation-dependent gene silencing similar to those suggested for genes with typical CpG 
features may also apply to genes with intermediate or atypical CpG features.  Hence, 
methylation of weak CpG islands or discrete methylation events affecting specific CpG 
dinucleotides may (i) recruit methylated DNA binding proteins resulting in a blockade of 
transcription factor access to crucial recognition sequences, or (ii) directly inhibit 
transcription factor binding to the promoter region.  Methylated DNA binding proteins that 
require very few methylated CpG sites or only a single methylated CpG dinucleotide for 
binding have been described (151).  Likewise, methylation of specific CpG dinucleotides 
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within or proximal to transcription factor binding sequences can lead to loss of proper 
transcription factor interaction with its target sequence, negatively impacting on gene 
transcription (80,150).  There are several examples in the literature of methylation-dependent 
silencing of genes with intermediate or atypical CpG features.  Well-characterized examples 
of methylation-sensitive genes with intermediate CpG features include E-cadherin (25,78), 
RAR-β2 (79), and APC (80).  Our survey of the literature identified only one example of a 
well characterized gene with atypical CpG features, LAMB3, which is silenced through 
promoter methylation in cancers of the prostate, breast, lung, and bladder (81-84).  Whereas 
there are only a few examples of methylation-sensitive genes lacking CpG islands in the 
current literature, numerous genes with intermediate or atypical CpG features are likely to 
have been identified in microarray studies aimed at cataloguing cancer-related epigenetically-
regulated genes (72-74).  The results from the current study suggest that genes lacking CpG 
islands from these previous studies should be rigorously evaluated to characterize their 
methylation status in breast cancer, and to examine the possible mechanisms through which 
methylation of weak CpG islands or discrete methylation targets (individual CpG 
dinucleotides) produce gene silencing.   
 
D.  CST6 is Silenced by DNA Methylation in Breast Cancer Cells 
 
CST6:  A Candidate Breast Tumor Suppressor Gene 
 CST6 (which encodes cystatin M) was originally identified as a gene whose expression is 
lost in metastatic breast cancer, suggesting a possible role for this gene in suppression of the 
invasive/metastatic phenotype (103).  Consistent with this suggestion, normal human breast 
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epithelial cells express high levels of cystatin M, while invasive ductal carcinoma cells do 
not express or express very low levels of this protein (116).  Cystatin M is a member of a 
family of proteins that function as inhibitors of lysosomal cysteine proteases, which include 
the cathepsin proteases (134,152).  Increased levels of cathepsin protease activity have been 
noted in breast cancer (153), and predict poor prognosis among these patients (154).  Thus, 
breast cancer invasiveness may be a direct consequence of inappropriate cathepsin protease 
activity in the absence of their inhibitory molecules, which include cystatin M (155).  While 
CST6 expression is known to be lost in many primary breast tumors and cancer cell lines, the 
mechanism that accounts for loss of CST6 expression has only recently been investigated.  
Given a role for CST6 in tumor suppression and/or metastasis suppression, possible 
mechanisms for loss of expression include genetic alterations (mutation or deletion) and 
epigenetic silencing.  Southern blotting in breast cancer cell lines failed to identify gross 
structural rearrangements of the CST6 gene or deletion of the gene locus (103), leading to the 
more recent suggestion that CST6 expression may be lost due to gene silencing, either in 
response to a transcriptional repressor protein or as a consequence of promoter 
hypermethylation (134).   
  
CST6 is Silenced by Methylation in Multiple Cancers 
 The CST6 gene contains a large CpG island that encompasses the proximal promoter and 
exon 1, consisting of 54 CpG dinucleotides distributed over a 424 bp region (CpGPlot, 
http://www.ebi.ac.uk/emboss/cpgplot/).  We identified CST6 as a target for methylation-
dependent gene silencing in MCF-7 breast cancer cells by a microarray-based gene 
expression study, and showed that loss of CST6 expression in these cells is related to 
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hypermethylation of its CpG island (156).  More recently, Ai et al. showed that 12/20 (60%) 
primary breast tumors exhibit CST6 promoter hypermethylation, and microdissection of 
individual cells from select tumors revealed that methylation occurs in both DCIS and IDC 
cells (8).  Additionally, Kim et al. (112) reported CST6 to be frequently methylated in glioma 
cell lines and primary brain tumors.  We have established a direct association between CST6 
promoter hypermethylation and gene silencing in a panel of human breast cancer cell lines 
that differentially express CST6.  The majority of CST6-negative cell lines examined were 
originally isolated from invasive/metastatic breast neoplasms (157-159), whereas the CST6-
positive BT-20 cells (which express very high levels of CST6) were derived from a primary 
breast carcinoma (160).  These results suggest strongly that (i) CpG island hypermethylation 
contributes to CST6 silencing in breast cancer cell lines, and (ii) the loss of CST6 expression 
is associated with the invasive/metastatic phenotype of the breast cancer cell line. 
 
Epigenetic Mechanisms of CST6 Gene Silencing by DNA Methylation    
 Epigenetic silencing of gene expression is a consequence of DNA hypermethylation 
and/or chromatin remodeling related to direct interference with the binding of transcription 
factors to their recognition sequences (80,150), indirect mechanisms associated with 
recruitment and binding of methylated DNA binding proteins (141-144), and/or modification 
of histone proteins and alteration of chromatin structure (140).  In the current study, we 
generated evidence for CpG island hypermethylation in the epigenetic silencing of CST6 in 
human breast cancer cell lines.  However, the precise mechanism and the temporal order of 
events related to CST6 gene silencing have not been determined.  Nonetheless, we were able 
to gain significant insight into the process through comparison of the natural methylation 
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pattern of CST6-positive and -negative cell lines.  CST6-negative cell lines are characterized 
by extensive CpG island methylation, suggesting the possibility that regional methylation 
across the CST6 proximal promoter and exon 1 may be required for gene silencing.  
However, a subset of CST6-positive cell lines contain a significant level of methylation in 
exon 1, indicating that methylation in this portion of the CpG island does not negatively 
impact on CST6 transcription.  In contrast, methylation of CpG dinucleotides in the proximal 
promoter is strongly associated with loss of CST6 expression, suggesting that regional 
methylation or specific methylation events affecting this portion of the promoter contribute to 
gene silencing.  There is evidence that discrete methylation events within a larger 
methylation target (CpG island) can negatively affect gene expression.  The AP-2α tumor 
suppressor gene is an example of a gene that is silenced in response to CpG methylation of a 
discrete region that is contained within a larger CpG island (71).  Discrete methylation events 
may negatively impact on promoter function by direct interference with transcription factor 
binding or through indirect interference related to binding by methylated DNA binding 
proteins.  Among the 55 CpGs that comprise the CST6 CpG island, seven CpGs in the 
proximal promoter were found to be unmethylated in all cell lines that express the gene, and 
these CpGs were frequently methylated in CST6-negative cell lines.  Specific methylation 
events affecting these CpG dinucleotides may be required for CST6 gene silencing, but it is 
not clear if these specific methylation events occur in isolation or if they always take place in 
conjunction with more extensive regional methylation.  Methylation of these CpGs may 
directly impact on the binding of specific transcription factors to their recognition sequence.  
Analysis of the CST6 promoter using ProSpector (http://prospector.nci.nih.gov) identified 16 
CpGs within the proximal promoter that directly impinge upon transcription factor binding 
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sites and are associated with loss of CST6 expression when methylated, including sequences 
for AP-2, AP-4, Egr-1, MEIS1, NF-κB, Sp1, and YY1.  Methylated CpGs in the binding sites 
for AP-2 and Sp1 transcription factors have been shown to directly down-regulate gene 
expression (161,162).  Of note, CpG dinucleotide 13, which impinges on three transcription 
factor binding sites, is never methylated in CST6-positive cell lines.  The transcription factor 
requirements for expression of the CST6 promoter have not been determined.  Nonetheless, 
CpG methylation of the proximal promoter of CST6 is likely to inhibit or impair gene 
transcription by either direct or indirect interference with the transcription machinery.   
  
Methylation Events Leading to CST6 Silencing in Breast Cancer 
 The differential CpG island methylation profile among CST6-postive and -negative breast 
cancer cell lines indicates that certain methylation events and/or specific promoter regions 
are strongly associated with gene silencing.  Nevertheless, CST6-negative cell lines tend to 
be heavily methylated across the entire promoter/exon 1 CpG island.  We posit that there is a 
succession of methylation events that progressively leads to CST6 gene silencing in 
metastatic breast cancer cell lines:  (i) individual CpG dinucleotides within the promoter 
region are preferentially methylated resulting in transient silencing of CST6, (ii) methylation 
spreads throughout the promoter/exon 1 CpG island, (iii) chromatin remodeling occurs 
resulting in stable silencing of CST6.  Alternatively, chromatin remodeling might occur prior 
to the completion of regional methylation affecting the entire CpG island.  Additional studies 
will be required to establish the temporal order of events and the nature of chromatin 
alterations that accompany CST6 silencing in breast cancer cell lines.  Likewise, additional 
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studies will be required to determine if methylation-dependent gene silencing accounts for 
loss of CST6 expression in primary breast tumors and their metastatic lesions. 
 
E.  Methylation-dependent Silencing of CST6 in Human Breast Cancer 
 
Role of Tumor Suppressor CST6 in Human Breast Cancer 
Cystatin M was originally described as exhibiting diminished expression in metastatic 
breast cancer, suggesting a role in suppression of the invasive/metastatic phenotype (103).  It 
has been shown that CST6 is epigenetically regulated by DNA methylation-dependent 
silencing in breast cancer cell lines (8,113-115) and primary invasive ductal carcinomas 
(8,115).  In a recent study, Schagdarsurengin et al. showed that 24/40 (60%) breast 
carcinomas exhibited CST6 promoter hypermethylation, and that estrogen-receptor positive 
tumors were more frequently methylated than estrogen-receptor negative tumors (115).  
While CST6 is suggested to be epigenetically regulated through DNA methylation-dependent 
mechanisms in breast cancer cell lines and primary breast tumors that lack cystatin M protein 
expression, tumor metastases have not been examined for cystatin M expression or 
methylation status.  Given a putative role for CST6 in suppression of tumor invasion and 
metastasis, loss of cystatin M expression may be one mechanism that enables tumor cells to 
spread from the primary site and invade adjacent tissues (or distant sites) during breast cancer 
progression.  Furthermore, evidence from breast cancer cell lines suggests that CST6 
promoter hypermethylation leading to gene silencing may represent one major mechanism 
for loss of cystatin M in breast cancer.  CST6 is located in the chromosomal region 11q13, 
which is subject to amplification or loss of heterozygosity in several cancers (94,118,163).  
 133
Previously, we reported that the majority of CST6-negative breast cancer cell lines were 
originally established from metastatic lesions (pleural effusions) rather than primary breast 
tumors and that CST6-positive breast cancer cell line (BT-20) was derived from a primary 
breast carcinoma (114).  These observations argue that the loss of CST6 expression is 
strongly associated with the invasive/metastatic phenotype of the breast cancer cell line and 
that CST6 promoter hypermethylation may be frequently involved in gene silencing/loss.  In 
the current study, we present evidence that metastatic breast cancers exhibit lower levels of 
cystatin M protein expression and increased CST6 promoter hypermethylation compared to 
primary breast tumors.  
 
Proposed Mechanism for Epigenetic Silencing of CST6 in Human Breast Cancer 
The differential CpG island methylation of CST6 between primary breast tumors and 
lymph node metastases indicates that certain individual methylation events occur during or 
following stromal invasion and tumor spread.  We envision that there is a succession of 
methylation events that lead to CST6 gene silencing in metastatic breast cancer:  (i) 
individual CpG dinucleotides within the promoter region are preferentially methylated 
resulting in decreased expression of cystatin M in DCIS and/or primary breast carcinomas, 
(ii) methylation spreads throughout the CpG island during surrounding stromal invasion of 
tumor cells and metastasis to the regional lymph nodes resulting in a complete loss of 
cystatin M protein expression, and (iii) chromatin remodeling occurs resulting in the stable 
silencing of CST6.  However, breast tumors that exhibit silencing of cystatin M but lack 
DNA methylation could achieve this silencing through histone deacetylation or through a 
putative transcription repressor binding to the promoter regulatory regions of CST6.  
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Likewise, we have observed areas of tumor sections that show strong staining for cystatin M 
and areas that show weak staining.  This finding may indicate that cystatin M silencing can 
be heterogeneous within a single breast tumor and can reflect different levels of DNA 
methylation.   
 
F.  CST6 CpG Methylation Requires an Upstream DNA Sequence Element that Directs 
Promoter Methylation Events   
 
Regulation of DNA Methylation by Directive DNA Sequences 
   Genomic DNA exhibits a specific pattern of CpG methylation in normal cells, and a 
different pattern in cancer cells, both of which reflect nonrandom hypermethylation of 
specific regions of DNA resulting in silencing of specific genes.  The mechanisms that 
control this nonrandom distribution of CpG methylation are poorly understood.  We suggest 
that the instructional signals that govern (direct) DNA methylation at specific CpG targets 
will be contained within the DNA sequence (cis elements) of regulatory regions of 
methylation-sensitive genes.  Possible mechanisms that direct CpG methylation include, (i) 
CG-rich regions such as CpG islands within the promoter of a gene that can direct 
methylation to the CG-dense region, and (ii) that CpG methylation can be signaled by a cis-
acting DNA sequence element.  The promoter region of many genes contain CpG islands, 
and sequences have been identified that can protect CpG islands from DNA methylation 
(87,164).  Likewise, several lines of evidence support the notion that cis-acting sequence 
elements exist that regulate de novo methylation, including directive (methylation-
promoting) instructions (85,86).  It is conceivable that these directive and protective elements 
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coexist in the promoter regions of epigenetically-regulated genes, and that a balance between 
these forces dictates the methylation status of the promoter in specific cell types or under 
specific cellular conditions. 
 
Methylation Directing Cis-acting Elements in DNA Sequences  
 Recognizing that methylated genes are nonrandom in normal and cancer cell types, a 
number of studies have addressed the question of whether cis elements direct DNA 
methylation of specific target genes.  A cis element responsible for aberrant methylation of 
the APRT promoter was localized to a 838 bp region approximately 1.3 kbp upstream of the 
transcription start site (90,91).  Deletion analysis of the chloramphenicol acetyltransferase 
(CAT) gene localized two cis-acting elements to 775 bp and 1.3 kbp upstream of the 
transcription start site (165).  The effects of these elements appeared to be exerted in cis, and 
dependent on proximity, but not on orientation (165).  The ideal size of the cis elements was 
between 500-700 bp and small retrotransposon sequences within the larger cis-acting element 
sequences show greater efficiency in attracting methylating enzymes (165).   In addition, a 
number of sequence elements have been identified that predict methylation of promoter 
sequences with high discrimination potential (92).  However, it has not been determined if 
these sequences function to direct or promote methylation.  In a recent study, a computational 
epigenetics approach was utilized to discriminate between CpG islands that are methylation-
prone from those that remain unmethylated (166).  Bock et al. showed that the methylation 
state of CpG islands (methylated and unmethylated) were determined by a complex 
combination of the presence or absence of sequence motifs found within the DNA sequence, 
and proposed that the methylation pattern of an individual CpG island can be assigned a 
degree based on DNA sequence (166).  These findings support the idea that promoter regions 
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in genes containing a CpG methylation target contain specific DNA sequences involved in 
the regulation of DNA methylation.     
 
Disassociation of Methylation Directing Cis-acting Elements From the Upstream 
Promoter Sequence of CST6 
   We have utilized the breast tumor suppressor CST6 as an index gene for the identification 
of cis elements that direct promoter CpG island methylation.  The CST6 gene contains a large 
CpG island that encompasses sequences within the proximal promoter and exon 1.  This CpG 
island represents the target for methylation in our model system.  To examine the existence 
of instructional cis regulatory elements upstream of this promoter CpG island target 
sequence, two regions of the CST6 gene promoter (-1187 to +33 and -438 to +33), including 
the proximal promoter CpG island, were cloned into luciferase reporter constructs and 
transfected into cell lines known to methylate and silence the CST6 gene (114).  Using this 
model system, truncation of the CST6 promoter region disassociated a putative instructional 
cis element from the target CpG island, resulting in a lack of methylation of the downstream 
target sequence.  Thus, breast cancer cell lines that hypermethylate and silence the 
endogenous CST6 gene fail to hypermethylate the exogenous CST6-luciferase reporter 
construct.  Consistent with several previous reports on other methylation-sensitive genes 
(85,86,90,91,165), this observation suggests that the CST6 promoter CpG island does not 
direct its own methylation.  This result supports the suggestion that regulatory sequences are 
required to direct CpG island methylation by the DNA methylation machinery.  A few 
investigators have identified and characterized cis regulatory sequences that appear to direct 
CpG island methylation.  Hasse et al. localized a cis-acting regulatory element responsible 
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for the methylation of the CAT gene approximately 775 bp upstream of the transcriptional 
start site (165).  However, our studies of the CST6 promoter indicate that the putative cis 
regulatory element is >1200 bp upstream of the transcription start site, similar to the findings 
of other published studies (90,91).  While the results of the current study are intriguing, a 
more extensive CST6 promoter truncation analysis needs to be performed to precisely 
identify the location of the cis regulatory element that governs CpG island methylation of the 
CST6 promoter and to characterize its properties. 
  
 
G.  Conclusions and Impact 
  
 The studies contained in this dissertation are relevant to breast cancer research and DNA 
methylation-dependent gene regulation in many significant ways.  These studies (i) 
characterize a group of putative methylation-sensitive genes identified in MCF-7 breast 
carcinoma cells, (ii) validates that the methylation-sensitive gene, CST6 is subject to 
methylation-dependent regulation in multiple breast cancer cell lines, primary breast tumors, 
and lymph node metastases, and (iii) identifies critical promoter methylation targets.  Thus, 
the completion of these studies has established a role for methylation-dependent epigenetic 
mechanisms in the silencing of important genes in the molecular pathogenesis of breast 
cancer.  Furthermore, this dissertation has begun to establish several distinct classes of 
epigenetically-regulated genes, and that these classes can be distinguished based upon the 
CpG content and CpG organization of their promoters.  Thus, a new definition for an 
epigenetically-regulated gene that recognizes the importance of all CpG targets has been 
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proposed.  In addition, this dissertation identifies the existence of cis regulatory sequences 
located in the 5’ upstream promoter region of CST6 that function to direct CpG methylation.  
Consequently, these results advance our understanding of mechanisms governing DNA 
methylation in breast carcinogenesis. 
 
 139
V.  REFERENCES 
1. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., and Thun, M. J. (2007) Cancer 
statistics, 2007. CA Cancer J Clin 57, 43-66 
 
2. Reis, L. A. G., Harkins, D., Krapcho, M., Mariotto, A., Miller, B. A., Feuer, E. J., 
Clegg, L., Eisner, M. P., Horner, M. J., Howlader, N., Hayat, M., Hankey, B. F., and 
Edwards, B. K. (2007) SEER Cancer Statistics Review, 1975-2003, National Cancer 
Institute, Bethesda, MD 
 
3. Coleman, W. B., and Tsongalis, G. J. (2002) Cancer Epidemiology: Incidence and 
Etiology of Human Neoplasms in The Molecular Basis of Human Cancer (Coleman, 
W. B., and Tsongalis, G. J., eds) pp. 3-22, Humana Press, Totowa 
 
4. Charpentier, A., and Aldaz, C. M. (2002) The Molecular Basis of Breast 
Carcinogenesis in The Molecular Basis of Human Cancer (Coleman, W. B., and 
Tsongalis, G. J., eds), pp. 347-363, Humana Press, Totowa, N.J. 
 
5. Ponten, J., Holmberg, L., Trichopoulos, D., Kallioniemi, O., Kvale, G., Wallgren, A., 
and Taylor-Papadimitriou, J. (1990) Biology and the natural history of breast cancer. 
Int. J. Cancer 5, 5-21 
 
6. Symmans, W. F. (2005) Histopathology of Breast Cancer: Correlation with Molecular 
Markers in Molecular Oncology of Breast Cancer (Ross, J. S., and Hortobagyi, G. N., 
eds) pp. 106-116, Jones and Bartlett, Sudbury, M.A. 
 
7. Simpson, P. T., Reis-Filho, J. S., Gale, T., and Lakhani, S. R. (2005) Molecular 
evolution of breast cancer. J Pathol 205, 248-254 
 
8. Ai, L., Kim, W. J., Kim, T. Y., Fields, C. R., Massoll, N. A., Robertson, K. D., and 
Brown, K. D. (2006) Epigenetic silencing of the tumor suppressor cystatin M occurs 
during breast cancer progression. Cancer Res 66, 7899-7909 
 
9. Muller, V., Kasimir-Bauer, S., and Pantel, K. (2005) Sentinel Lymph Node 
Dissection and Micrometastasis Detection in Bone Marrow and Lymph Nodes in 
Molecular Oncology of Breast Cancer (Ross, J. S., and Hortobagyi, G. N., eds) pp. 
117-127, Jones and Bartlett, Boston 
 
10. Hortobagyi, G. N. (2005) Introduction and Background in Molecular Oncology of 
Breast Cancer (Ross, J. S., and Hortobagyi, G. N., eds) pp. 1-11, Jones and Bartlett 
Publishers, Sudbury, M.A. 
 
11. Reed, W., Hannisdal, E., Boehler, P. J., Gundersen, S., Host, H., and Marthin, J. 
(2000) The prognostic value of p53 and c-erb B-2 immunostaining is overrated for 
patients with lymph node negative breast carcinoma: A multivariate analysis of 
 140
prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer 88, 804-
813 
 
12. Mirza, A. N., Mirza, N. Q., Vlastos, G., and Singletary, S. E. (2002) Prognostic 
factors in node-negative breast cancer: A review of studies with sample size more 
than 200 and follow-up more than 5 years. Ann Surg 235, 10-26 
 
13. Lau, R., Grimson, R., Sansome, C., Tornos, C., and Moll, U. M. (2001) Low levels of 
cell cycle inhibitor p27kip1 combined with high levels of Ki-67 predict shortened 
disease-free survival in T1 and T2 invasive breast carcinomas. Int J Oncol 18, 17-23 
 
14. Sutcliffe, S., Pharoah, P. D., Easton, D. F., and Ponder, B. A. (2000) Ovarian and 
breast cancer risks to women in families with two or more cases of ovarian cancer. 
Int. J. Cancer 87, 110-117 
 
15. Gayther, S. A., Pharoah, P. D., and Ponder, B. A. (1998) The genetics of inherited 
breast cancer. J. Mammary Gland Biol. 3, 365-376 
 
16. Sotiriou, C., Desmedt, C., Durbecq, V., Dal Lago, L., Lacroix, M., Cardoso, F., and 
Piccart, M. (2005) Genomic and Molecular Classification of Breast Cancer in 
Molecular Oncology of Breast Cancer (Ross, J. S., and Hortobagyi, G. N., eds) pp. 
81-95, Jones and Bartlett, Sudbury, M.A. 
 
17. Lakhani, S. R., Gusterson, B. A., Jacquemier, J., Sloane, J. P., Anderson, T. J., van de 
Vijver, M. J., Venter, D., Freeman, A., Antoniou, A., McGuffog, L., Smyth, E., Steel, 
C. M., Haites, N., Scott, R. J., Goldagar, D., Neuhausen, S., Daly, P. A., Ormiston, 
W., McManus, R., Scherneck, S., Ponder, B. A., Futreal, P. A., Peto, J., Stoppa-
Lyonnet, D., Bignon, Y. J., and Stratton, M. R. (2000) The pathology of familial 
breast cancer: Histological features of cancers in families not attributable to mutations 
in BRCA1 and BRCA2. Clin. Cancer Res. 6, 782-789 
 
18. Srivastava, S., Zou, Z. Q., Pirollo, K., Blattner, W., and Chang, E. H. (1990) Germ-
line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni 
syndrome. Nature 348, 747-749 
 
19. Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Jr., Nelson, C. E., Kim, D. H., 
Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., and Friend, S.H. (1990) 
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other 
neoplasms. Science 250, 1233-1238 
 
20. Kelsey, J. L., and Berkowitz, G. S. (1988) Breast cancer epidemiology. Cancer Res. 
48, 5617-5623 
 
21. Hsieh, C. C., Trichopoulos, D., Katsouyanni, K., and Yuasa, S. (1990) Age at 
menarche, age at menopause, height and obesity as risk factors for breast cancer:  
 141
Associations and interactions in an international case-control study. Int. J. Cancer 46, 
796-800 
 
22. Kelsey, J. L., Gammon, M. D., and John, E. M. (1993) Reproductive factors and 
breast cancer. Epidemiol Rev 15, 36-47 
 
23. Lipworth, L. (1995) Epidemiology of breast cancer. Eur J Cancer Prev 4, 7-30 
 
24. Yang, X., Yan, L., and Davidson, N. E. (2001) DNA methylation in breast cancer. 
Endocr Relat Cancer 8, 115-127 
 
25. Widschwendter, M., and Jones, P. A. (2002) DNA methylation and breast 
carcinogenesis. Oncogene 21, 5462-5482 
 
26. Herman, J. G., and Baylin, S. B. (2003) Gene silencing in cancer in association with 
promoter hypermethylation. N Engl J Med 349, 2042-2054 
 
27. Baylin, S. (2001) DNA methylation and epigenetic mechanisms of carcinogenesis. 
Dev Biol (Basel) 106, 85-87 
 
28. Baylin, S. B., Herman, J. G., Graff, J. R., Vertino, P. M., and Issa, J. P. (1998) 
Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 
72, 141-196 
 
29. Feinberg, A. P., and Vogelstein, B. (1983) Hypomethylation distinguishes genes of 
some human cancers from their normal counterparts. Nature 301, 89-92 
 
30. Feinberg, A. P., and Vogelstein, B. (1987) Alterations in DNA methylation in human 
colon neoplasia. Semin Surg Oncol 3, 149-151 
 
31. Goelz, S. E., Vogelstein, B., Hamilton, S. R., and Feinberg, A. P. (1985) 
Hypomethylation of DNA from benign and malignant human colon neoplasms. 
Science 228, 187-190 
 
32. Feinberg, A. P., and Vogelstein, B. (1983) Hypomethylation of ras oncogenes in 
primary human cancers. Biochem Biophys Res Commun 111, 47-54 
 
33. Narayan, A., Ji, W., Zhang, X. Y., Marrogi, A., Graff, J. R., Baylin, S. B., and 
Ehrlich, M. (1998) Hypomethylation of pericentromeric DNA in breast 
adenocarcinomas. Int J Cancer 77, 833-838 
 
34. Eden, A., Gaudet, F., Waghmare, A., and Jaenisch, R. (2003) Chromosomal 
instability and tumors promoted by DNA hypomethylation. Science 300, 455 
 
 142
35. Gaudet, F., Hodgson, J. G., Eden, A., Jackson-Grusby, L., Dausman, J., Gray, J. W., 
Leonhardt, H., and Jaenisch, R. (2003) Induction of tumors in mice by genomic 
hypomethylation. Science 300, 489-492 
 
36. Momparler, R. L. (2003) Cancer epigenetics. Oncogene 22, 6479-6483 
 
37. Jones, P. A., and Laird, P. W. (1999) Cancer epigenetics comes of age. Nat Genet 21, 
163-167 
 
38. Tsou, J. A., Hagen, J. A., Carpenter, C. L., and Laird-Offringa, I. A. (2002) DNA 
methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 21, 
5450-5461 
 
39. Hanahan, D., and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70 
 
40. Yan, P. S., Shi, H., Rahmatpanah, F., Hsiau, T. H., Hsiau, A. H., Leu, Y. W., Liu, J. 
C., and Huang, T. H. (2003) Differential distribution of DNA methylation within the 
RASSF1A CpG island in breast cancer. Cancer Res 63, 6178-6186 
 
41. Dammann, R., Yang, G., and Pfeifer, G. P. (2001) Hypermethylation of the CpG 
island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor 
gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. 
Cancer Res 61, 3105-3109 
 
42. Widschwendter, M., Berger, J., Muller, H. M., Zeimet, A. G., and Marth, C. (2001) 
Epigenetic downregulation of the retinoic acid receptor-beta2 gene in breast cancer. J 
Mammary Gland Biol Neoplasia 6, 193-201 
 
43. Widschwendter, M., Berger, J., Hermann, M., Muller, H. M., Amberger, A., 
Zeschnigk, M., Widschwendter, A., Abendstein, B., Zeimet, A. G., Daxenbichler, G., 
and Marth, C. (2000) Methylation and silencing of the retinoic acid receptor-beta2 
gene in breast cancer. J Natl Cancer Inst 92, 826-832 
 
44. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J. P., Davidson, N. E., 
Sidransky, D., and Baylin, S. B. (1995) Inactivation of the CDKN2/p16/MTS1 gene 
is frequently associated with aberrant DNA methylation in all common human 
cancers. Cancer Res 55, 4525-4530 
 
45. Woodcock, D. M., Linsenmeyer, M. E., Doherty, J. P., and Warren, W. D. (1999) 
DNA methylation in the promoter region of the p16 (CDKN2/MTS-1/INK4A) gene 
in human breast tumours. Br J Cancer 79, 251-256 
 
46. Lapidus, R. G., Nass, S. J., and Davidson, N. E. (1998) The loss of estrogen and 
progesterone receptor gene expression in human breast cancer. J Mammary Gland 
Biol Neoplasia 3, 85-94 
 
 143
47. Ottaviano, Y. L., Issa, J. P., Parl, F. F., Smith, H. S., Baylin, S. B., and Davidson, N. 
E. (1994) Methylation of the estrogen receptor gene CpG island marks loss of 
estrogen receptor expression in human breast cancer cells. Cancer Res 54, 2552-2555 
 
48. Lapidus, R. G., Ferguson, A. T., Ottaviano, Y. L., Parl, F. F., Smith, H. S., Weitzman, 
S. A., Baylin, S. B., Issa, J. P., and Davidson, N. E. (1996) Methylation of estrogen 
and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and 
progesterone receptor gene expression in breast tumors. Clin Cancer Res 2, 805-810 
 
49. Merajver, S. D., Pham, T. M., Caduff, R. F., Chen, M., Poy, E. L., Cooney, K. A., 
Weber, B. L., Collins, F. S., Johnston, C., and Frank, T. S. (1995) Somatic mutations 
in the BRCA1 gene in sporadic ovarian tumours. Nat Genet 9, 439-443 
 
50. Dobrovic, A., and Simpfendorfer, D. (1997) Methylation of the BRCA1 gene in 
sporadic breast cancer. Cancer Res 57, 3347-3350 
 
51. Magdinier, F., Ribieras, S., Lenoir, G. M., Frappart, L., and Dante, R. (1998) Down-
regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation 
patterns of the putative promoter region. Oncogene 17, 3169-3176 
 
52. Rice, J. C., Massey-Brown, K. S., and Futscher, B. W. (1998) Aberrant methylation 
of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in 
sporadic breast cancer cells. Oncogene 17, 1807-1812 
 
53. Bianco, T., Chenevix-Trench, G., Walsh, D. C., Cooper, J. E., and Dobrovic, A. 
(2000) Tumour-specific distribution of BRCA1 promoter region methylation supports 
a pathogenetic role in breast and ovarian cancer. Carcinogenesis 21, 147-151 
 
54. Catteau, A., Harris, W. H., Xu, C. F., and Solomon, E. (1999) Methylation of the 
BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with 
disease characteristics. Oncogene 18, 1957-1965 
 
55. Hedenfalk, I., Duggan, D., Chen, Y., Radmacher, M., Bittner, M., Simon, R., Meltzer, 
P., Gusterson, B., Esteller, M., Kallioniemi, O. P., Wilfond, B., Borg, A., and Trent, J. 
(2001) Gene-expression profiles in hereditary breast cancer. N Engl J Med 344, 539-
548 
 
56. Magdinier, F., Billard, L. M., Wittmann, G., Frappart, L., Benchaib, M., Lenoir, G. 
M., Guerin, J. F., and Dante, R. (2000) Regional methylation of the 5' end CpG island 
of BRCA1 is associated with reduced gene expression in human somatic cells. 
FASEB J 14, 1585-1594 
 
57. Miyamoto, K., Fukutomi, T., Asada, K., Wakazono, K., Tsuda, H., Asahara, T., 
Sugimura, T., and Ushijima, T. (2002) Promoter hypermethylation and post-
transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human 
breast cancers. Jpn J Clin Oncol 32, 79-84 
 144
 
58. Bringuier, P. P., Umbas, R., Schaafsma, H. E., Karthaus, H. F., Debruyne, F. M., and 
Schalken, J. A. (1993) Decreased E-cadherin immunoreactivity correlates with poor 
survival in patients with bladder tumors. Cancer Res 53, 3241-3245 
 
59. Nass, S. J., Herman, J. G., Gabrielson, E., Iversen, P. W., Parl, F. F., Davidson, N. E., 
and Graff, J. R. (2000) Aberrant methylation of the estrogen receptor and E-cadherin 
5' CpG islands increases with malignant progression in human breast cancer. Cancer 
Res 60, 4346-4348 
 
60. Uria, J. A., Ferrando, A. A., Velasco, G., Freije, J. M., and Lopez-Otin, C. (1994) 
Structure and expression in breast tumors of human TIMP-3, a new member of the 
metalloproteinase inhibitor family. Cancer Res 54, 2091-2094 
 
61. Bachman, K. E., Herman, J. G., Corn, P. G., Merlo, A., Costello, J. F., Cavenee, W. 
K., Baylin, S. B., and Graff, J. R. (1999) Methylation-associated silencing of the 
tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, 
and other human cancers. Cancer Res 59, 798-802 
 
62. Jones, P. A., and Takai, D. (2001) The role of DNA methylation in mammalian 
epigenetics. Science 293, 1068-1070 
 
63. Takai, D., and Jones, P. A. (2002) Comprehensive analysis of CpG islands in human 
chromosomes 21 and 22. Proc Natl Acad Sci U S A 99, 3740-3745 
 
64. Bird, A. P. (1986) CpG-rich islands and the function of DNA methylation. Nature 
321, 209-213 
 
65. Gardiner-Garden, M., and Frommer, M. (1987) CpG islands in vertebrate genomes. J 
Mol Biol 196, 261-282 
 
66. Razin, A., and Riggs, A. D. (1980) DNA methylation and gene function. Science 210, 
604-610 
 
67. Razin, A., and Szyf, M. (1984) DNA methylation patterns. Formation and function. 
Biochim Biophys Acta 782, 331-342 
 
68. Jones, P. A. (1999) The DNA methylation paradox. Trends Genet 15, 34-37 
 
69. Csankovszki, G., Nagy, A., and Jaenisch, R. (2001) Synergism of Xist RNA, DNA 
methylation, and histone hypoacetylation in maintaining X chromosome inactivation. 
J Cell Biol 153, 773-784 
 
70. Ferguson, A. T., Evron, E., Umbricht, C. B., Pandita, T. K., Chan, T. A., Hermeking, 
H., Marks, J. R., Lambers, A. R., Futreal, P. A., Stampfer, M. R., and Sukumar, S. 
 145
(2000) High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene 
silencing in breast cancer. Proc Natl Acad Sci U S A 97, 6049-6054 
 
71. Douglas, D. B., Akiyama, Y., Carraway, H., Belinsky, S. A., Esteller, M., Gabrielson, 
E., Weitzman, S., Williams, T., Herman, J. G., and Baylin, S. B. (2004) 
Hypermethylation of a small CpGuanine-rich region correlates with loss of activator 
protein-2alpha expression during progression of breast cancer. Cancer Res 64, 1611-
1620 
 
72. Suzuki, H., Gabrielson, E., Chen, W., Anbazhagan, R., van Engeland, M., 
Weijenberg, M. P., Herman, J. G., and Baylin, S. B. (2002) A genomic screen for 
genes upregulated by demethylation and histone deacetylase inhibition in human 
colorectal cancer. Nat Genet 31, 141-149 
 
73. Sato, N., Fukushima, N., Maitra, A., Matsubayashi, H., Yeo, C. J., Cameron, J. L., 
Hruban, R. H., and Goggins, M. (2003) Discovery of novel targets for aberrant 
methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 
63, 3735-3742 
 
74. Liang, G., Gonzales, F. A., Jones, P. A., Orntoft, T. F., and Thykjaer, T. (2002) 
Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to 
the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Res 62, 961-966 
 
75. Soengas, M. S., Capodieci, P., Polsky, D., Mora, J., Esteller, M., Opitz-Araya, X., 
McCombie, R., Herman, J. G., Gerald, W. L., Lazebnik, Y. A., Cordon-Cardo, C., 
and Lowe, S. W. (2001) Inactivation of the apoptosis effector Apaf-1 in malignant 
melanoma. Nature 409, 207-211 
 
76. Eggert, A., Grotzer, M. A., Zuzak, T. J., Wiewrodt, B. R., Ho, R., Ikegaki, N., and 
Brodeur, G. M. (2001) Resistance to tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of 
caspase-8 expression. Cancer Res 61, 1314-1319 
 
77. Ueki, T., Takeuchi, T., Nishimatsu, H., Kajiwara, T., Moriyama, N., Narita, Y., 
Kawabe, K., Ueki, K., and Kitamura, T. (2001) Silencing of the caspase-1 gene 
occurs in murine and human renal cancer cells and causes solid tumor growth in vivo. 
Int J Cancer 91, 673-679 
 
78. Graff, J. R., Gabrielson, E., Fujii, H., Baylin, S. B., and Herman, J. G. (2000) 
Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the 
dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. 
J Biol Chem 275, 2727-2732 
 
79. Arapshian, A., Kuppumbatti, Y. S., and Mira-y-Lopez, R. (2000) Methylation of 
conserved CpG sites neighboring the beta retinoic acid response element may mediate 
 146
retinoic acid receptor beta gene silencing in MCF-7 breast cancer cells. Oncogene 19, 
4066-4070 
 
80. Deng, G., Song, G. A., Pong, E., Sleisenger, M., and Kim, Y. S. (2004) Promoter 
methylation inhibits APC gene expression by causing changes in chromatin 
conformation and interfering with the binding of transcription factor CCAAT-binding 
factor. Cancer Res 64, 2692-2698 
 
81. Sathyanarayana, U. G., Maruyama, R., Padar, A., Suzuki, M., Bondaruk, J., 
Sagalowsky, A., Minna, J. D., Frenkel, E. P., Grossman, H. B., Czerniak, B., and 
Gazdar, A. F. (2004) Molecular detection of noninvasive and invasive bladder tumor 
tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding 
genes. Cancer Res 64, 1425-1430 
 
82. Sathyanarayana, U. G., Padar, A., Huang, C. X., Suzuki, M., Shigematsu, H., Bekele, 
B. N., and Gazdar, A. F. (2003) Aberrant promoter methylation and silencing of 
laminin-5-encoding genes in breast carcinoma. Clin Cancer Res 9, 6389-6394 
 
83. Sathyanarayana, U. G., Padar, A., Suzuki, M., Maruyama, R., Shigematsu, H., Hsieh, 
J. T., Frenkel, E. P., and Gazdar, A. F. (2003) Aberrant promoter methylation of 
laminin-5-encoding genes in prostate cancers and its relationship to 
clinicopathological features. Clin Cancer Res 9, 6395-6400 
 
84. Sathyanarayana, U. G., Toyooka, S., Padar, A., Takahashi, T., Brambilla, E., Minna, 
J. D., and Gazdar, A. F. (2003) Epigenetic inactivation of laminin-5-encoding genes 
in lung cancers. Clin Cancer Res 9, 2665-2672 
 
85. Turker, M. S. (1999) The establishment and maintenance of DNA methylation 
patterns in mouse somatic cells. Semin Cancer Biol 9, 329-337 
 
86. Turker, M. S., and Bestor, T. H. (1997) Formation of methylation patterns in the 
mammalian genome. Mutat Res 386, 119-130 
 
87. Butcher, D. T., Mancini-DiNardo, D. N., Archer, T. K., and Rodenhiser, D. I. (2004) 
DNA binding sites for putative methylation boundaries in the unmethylated region of 
the BRCA1 promoter. Int J Cancer 111, 669-678 
 
88. Turker, M. S., Mummaneni, P., and Bishop, P. L. (1991) Region- and cell type-
specific de novo DNA methylation in cultured mammalian cells. Somat Cell Mol 
Genet 17, 151-157 
 
89. Turker, M. S., Mummaneni, P., and Cooper, G. E. (1994) The mouse APRT gene as a 
model for studying epigenetic gene inactivation. Adv Exp Med Biol 370, 647-652 
 
 147
90. Mummaneni, P., Bishop, P. L., and Turker, M. S. (1993) A cis-acting element 
accounts for a conserved methylation pattern upstream of the mouse adenine 
phosphoribosyltransferase gene. J Biol Chem 268, 552-558 
 
91. Mummaneni, P., Walker, K. A., Bishop, P. L., and Turker, M. S. (1995) Epigenetic 
gene inactivation induced by a cis-acting methylation center. J Biol Chem 270, 788-
792 
 
92. Feltus, F. A., Lee, E. K., Costello, J. F., Plass, C., and Vertino, P. M. (2003) 
Predicting aberrant CpG island methylation. Proc Natl Acad Sci U S A 100, 12253-
12258 
 
93. Hayashi, H., Tokuda, A., and Udaka, K. (1960) Biochemical study of cellular 
antigen-antibody reaction in tissue culture. I. Activation and release of a protease. J. 
Exp. Med. 112, 237-247 
 
94. Keppler, D. (2006) Towards novel anti-cancer strategies based on cystatin function. 
Cancer Lett 235, 159-176 
 
95. Dubin, G. (2005) Proteinaceous cysteine protease inhibitors. Cell. Mol. Life Sci. 62, 
653-669 
 
96. Katunuma, N., Towatari, T., Kominami, E., Hashida, S., Takio, K., and Titani, K. 
(1981) Rat liver thiol porteinases: cathepsin B, cathepsin H, and catepsin L. Acta 
Biol. Med. Ger. 40, 1419-1425 
 
97. Takio, K., Towatari, T., Katunuma, N., Teller, D., and Titani, K. (1983) Homology of 
amino acid sequences of rat liver cathepsins B and H with that of papain. Proc. Natl 
Acad. Sci. USA 80, 3666-3670 
 
98. Levicar, N., Strojnik, T., Kos, J., Dewey, R., Pilkington, G., and Lah, T. (2002) 
Lysosomal enzymes, cathepsins in brain tumour invasion. J. of Neuro-Oncol. 58, 21-
32 
 
99. Kos, J., and Lah, T. (1998) Cysteine proteinases and their endogenous inhibitors: 
Target proteins for prognosis, diagnosis, and therapy in cancer (Review). Oncol Rep 
5, 1349-1361 
 
100. Kopitar-Jerala, N. (2006) The role of cystatins in cells of the immune system. FEBS 
Letters 580, 6295-6301 
 
101. Rawlings, N., Tolle, D., and Barrett, A. (2004) Evolutionary families of peptidase 
inhibitors. Biochem J. 378, 705-716 
 
102. Bode, W., Engh, R., Musil, D., Thiele, U., Huber, R., Karshikov, A., Brzin, J., Kos, 
J., and Turk, V. (1988) The 2.0 A X-ray crystal structure of chicken egg white 
 148
cystatin and its possible mode of interaction with cysteine proteinases. EMBO J. 7, 
2593-2599 
 
103. Sotiropoulou, G., Anisowicz, A., and Sager, R. (1997) Identification, cloning, and 
characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated 
in breast cancer. J Biol Chem 272, 903-910 
 
104. Ni, J., Abrahamson, M., Zhang, M., Fernandez, M. A., Grubb, A., Su, J., Yu, G. L., 
Li, Y., Parmelee, D., Xing, L., Coleman, T. A., Gentz, S., Thotakura, R., Nguyen, N., 
Hesselberg, M., and Gentz, R. (1997) Cystatin E is a novel human cysteine proteinase 
inhibitor with structural resemblance to family 2 cystatins. J Biol Chem 272, 10853-
10858 
 
105. Vigneswaran, N., Wu, J., Nagaraj, N., James, R., Zeeuwen, P., and Zacharias, W. 
(2006) Silencing of cystatin M in metastatic oral cancer cell line MDA-686Ln by 
siRNA increase cysteine proteinases and legumain activities, cell proliferation and in 
vitro invasion. Life Sciences 78, 898-907 
 
106. Lah, T., and Kos, J. (1998) Cysteine proteinases in cancer progression and their 
clinical relevance for prognosis. Biol Chem 379, 125-130 
 
107. Kos, J., Werle, B., Lah, T., and Brunner, N. (2000) Cysteine proteinases and their 
inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int J 
Biol Markers 15, 84-89 
 
108. Frosch, B., Berquin, I., Emmert-Buck, M., Moin, K., and Slone, B. (1999) Molecular 
regulation, membrane association and secretion of tumor cathepsin B. APMIS 107, 
28-37 
 
109. Zeeuwen, P. L. (2004) Epidermal differentiation: the role of proteases and their 
inhibitors. Eur J Cell Biol 83, 761-773 
 
110. Zeeuwen, P. L., van Vlijmen-Willems, I. M., Egami, H., and Schalkwijk, J. (2002) 
Cystatin M/E expression in inflammatory and neoplastic skin disorders. Br J 
Dermatol 147, 87-94 
 
111. Zhong, S., Fields, C. R., Su, N., Pan, Y. X., and Robertson, K. D. (2006) 
Pharmacologic inhibition of epigenetic modifications, coupled with gene expression 
profiling, reveals novel targets of aberrant DNA methylation and histone 
deacetylation in lung cancer. Oncogene, Epub 
 
112. Kim, T. Y., Zhong, S., Fields, C. R., Kim, J. H., and Robertson, K. D. (2006) 
Epigenomic profiling reveals novel and frequent targets of aberrant DNA 
methylation-mediated silencing in malignant glioma. Cancer Res 66, 7490-7501 
 
 149
113. Shridhar, R., Zhang, J., Song, J., Booth, B. A., Kevil, C. G., Sotiropoulou, G., Sloane, 
B. F., and Keppler, D. (2004) Cystatin M suppresses the malignant phenotype of 
human MDA-MB-435S cells. Oncogene 23, 2206-2215 
 
114. Rivenbark, A. G., Jones, W. D., and Coleman, W. B. (2006) DNA methylation-
dependent silencing of CST6 in human breast cancer cell lines. Lab Invest 86, 1233-
1242 
 
115. Schagdarsurengin, U., Pfeifer, G. P., and Dammann, R. (2006) Frequent epigenetic 
inactivation of cystatin M in breast carcinoma. Oncogene, Epub 
 
116. Zhang, J., Shridhar, R., Dai, Q., Song, J., Barlow, S. C., Yin, L., Sloane, B. F., Miller, 
F. R., Meschonat, C., Li, B. D., Abreo, F., and Keppler, D. (2004) Cystatin M: A 
novel candidate tumor suppressor gene for breast cancer. Cancer Res 64, 6957-6964 
 
117. Song, J., Jie, C., Polk, P., Shridhar, R., Clair, T., Zhang, J., Yin, L., and Keppler, D. 
(2006) The candidate tumor suppressor CST6 alters the gene expression profile of 
human breast carcinoma cells: Down-regulation of the potent mitogenic, motogenic, 
and angiogenic factor autotaxin. Biochem Biophy Res Comm 340, 175-182 
 
118. Srivatsan, E. S., Chakrabarti, R., Zainabadi, K., Pack, S. D., Benyamini, P., 
Mendonca, M. S., Yang, P. K., Kang, K., Motamedi, D., Sawicki, M. P., Zhuang, Z., 
Jesudasan, R. A., Bengtsson, U., Sun, C., Roe, B. A., Stanbridge, E. J., Wilczynski, S. 
P., and Redpath, J. L. (2002) Localization of deletion to a 300 Kb interval of 
chromosome 11q13 in cervical cancer. Oncogene 21, 5631-5642 
 
119. Chomczynski, P., and Sacchi, N. (1987) Single-step method of RNA isolation by acid 
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162, 156-159 
 
120. Bolstad, B. M., Irizarry, R. A., Astrand, M., and Speed, T. P. (2003) A comparison of 
normalization methods for high density oligonucleotide array data based on variance 
and bias. Bioinformatics 19, 185-193 
 
121. Zhang, L., Miles, M. F., and Aldape, K. D. (2003) A model of molecular interactions 
on short oligonucleotide microarrays. Nat Biotechnol 21, 818-821 
 
122. Grunau, C., Clark, S. J., and Rosenthal, A. (2001) Bisulfite genomic sequencing: 
systematic investigation of critical experimental parameters. Nucleic Acids Res 29, 
E65-65 
 
123. Mank-Seymour, A. R., Murray, T. R., Berkey, K. A., Xiao, L., Kern, S., and Casero, 
R. A., Jr. (1998) Two active copies of the X-linked gene spermidine/spermine N1-
acetyltransferase (SSAT) in a female lung cancer cell line are associated with an 
increase in sensitivity to an antitumor polyamine analogue. Clin Cancer Res 4, 2003-
2008 
 
 150
124. Widschwendter, M., Siegmund, K. D., Muller, H. M., Fiegl, H., Marth, C., Muller-
Holzner, E., Jones, P. A., and Laird, P. W. (2004) Association of breast cancer DNA 
methylation profiles with hormone receptor status and response to tamoxifen. Cancer 
Res 64, 3807-3813 
 
125. Salisbury, J. L. (2001) The contribution of epigenetic changes to abnormal 
centrosomes and genomic instability in breast cancer. J Mammary Gland Biol 
Neoplasia 6, 203-212 
 
126. Paz, M. F., Fraga, M. F., Avila, S., Guo, M., Pollan, M., Herman, J. G., and Esteller, 
M. (2003) A systematic profile of DNA methylation in human cancer cell lines. 
Cancer Res 63, 1114-1121 
 
127. Robert, M. F., Morin, S., Beaulieu, N., Gauthier, F., Chute, I. C., Barsalou, A., and 
MacLeod, A. R. (2003) DNMT1 is required to maintain CpG methylation and 
aberrant gene silencing in human cancer cells. Nat Genet 33, 61-65 
 
128. Weisenberger, D. J., Velicescu, M., Cheng, J. C., Gonzales, F. A., Liang, G., and 
Jones, P. A. (2004) Role of the DNA methyltransferase variant DNMT3b3 in DNA 
methylation. Mol Cancer Res 2, 62-72 
 
129. Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G., and Baylin, S. B. 
(1999) Synergy of demethylation and histone deacetylase inhibition in the re-
expression of genes silenced in cancer. Nat Genet 21, 103-107 
 
130. Bender, C. M., Pao, M. M., and Jones, P. A. (1998) Inhibition of DNA methylation 
by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. Cancer 
Res 58, 95-101 
 
131. Pompeia, C., Hodge, D. R., Plass, C., Wu, Y. Z., Marquez, V. E., Kelley, J. A., and 
Farrar, W. L. (2004) Microarray analysis of epigenetic silencing of gene expression in 
the KAS-6/1 multiple myeloma cell line. Cancer Res 64, 3465-3473 
 
132. Zhang, J., Yu, J., Gu, J., Gao, B. M., Zhao, Y. J., Wang, P., Zhang, H. Y., and De 
Zhu, J. (2004) A novel protein-DNA interaction involved with the CpG dinucleotide 
at -30 upstream is linked to the DNA methylation mediated transcription silencing of 
the MAGE-A1 gene. Cell Res 14, 283-294 
 
133. Shimamoto, T., Ohyashiki, J. H., and Ohyashiki, K. (2005) Methylation of p15 
(INK4b) and E-cadherin genes is independently correlated with poor prognosis in 
acute myeloid leukemia. Leuk Res 29, 653-659 
 
134. Keppler, D. (2005) Towards novel anti-cancer strategies based on cystatin function. 
Cancer Lett 235, 159-176  
 
 151
135. Friedman, J. B., Brunschwig, E. B., Platzer, P., Wilson, K., and Markowitz, S. D. 
(2004) C8orf4 is a transforming growth factor b induced transcript downregulated in 
metastatic colon cancer. Int J Cancer 111, 72-75 
 
136. Benson, J. R. (2004) Role of transforming growth factor beta in breast carcinogenesis. 
Lancet Oncol 5, 229-239 
 
137. Huang, C., Sloan, E. A., and Boerkoel, C. F. (2003) Chromatin remodeling and 
human disease. Curr Opin Genet Dev 13, 246-252 
 
138. Chung, C. H., Bernard, P. S., and Perou, C. M. (2002) Molecular portraits and the 
family tree of cancer. Nat Genet 32, 533-540 
 
139. Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., 
Jeffrey, S. S., Van de Rijn, M., Waltham, M., Pergamenschikov, A., Lee, J. C., 
Lashkari, D., Shalon, D., Myers, T. G., Weinstein, J. N., Botstein, D., and Brown, P. 
O. (2000) Systematic variation in gene expression patterns in human cancer cell lines. 
Nat Genet 24, 227-235 
 
140. Fazzari, M. J., and Greally, J. M. (2004) Epigenomics: Beyond CpG islands. Nat Rev 
Genet 5, 446-455 
 
141. Meehan, R. R., Lewis, J. D., McKay, S., Kleiner, E. L., and Bird, A. P. (1989) 
Identification of a mammalian protein that binds specifically to DNA containing 
methylated CpGs. Cell 58, 499-507 
 
142. Lewis, J. D., Meehan, R. R., Henzel, W. J., Maurer-Fogy, I., Jeppesen, P., Klein, F., 
and Bird, A. (1992) Purification, sequence, and cellular localization of a novel 
chromosomal protein that binds to methylated DNA. Cell 69, 905-914 
 
143. Hendrich, B., and Bird, A. (1998) Identification and characterization of a family of 
mammalian methyl-CpG binding proteins. Mol Cell Biol 18, 6538-6547 
 
144. Nan, X., Tate, P., Li, E., and Bird, A. (1996) DNA methylation specifies 
chromosomal localization of MeCP2. Mol Cell Biol 16, 414-421 
 
145. Boyes, J., and Bird, A. (1991) DNA methylation inhibits transcription indirectly via a 
methyl-CpG binding protein. Cell 64, 1123-1134 
 
146. Nan, X., Campoy, F. J., and Bird, A. (1997) MeCP2 is a transcriptional repressor with 
abundant binding sites in genomic chromatin. Cell 88, 471-481 
 
147. Lux, W., Klobeck, H. G., Daniel, P. B., Costa, M., Medcalf, R. L., and Schleuning, 
W. D. (2005) In vivo and in vitro analysis of the human tissue-type plasminogen 
activator gene promoter in neuroblastomal cell lines: evidence for a functional 
upstream kappaB element. J Thromb Haemost 3, 1009-1017 
 152
 
148. Bird, A. P., and Wolffe, A. P. (1999) Methylation-induced repression--belts, braces, 
and chromatin. Cell 99, 451-454 
 
149. Kass, S. U., Pruss, D., and Wolffe, A. P. (1997) How does DNA methylation repress 
transcription? Trends Genet 13, 444-449 
 
150. Prendergast, G. C., and Ziff, E. B. (1991) Methylation-sensitive sequence-specific 
DNA binding by the c-Myc basic region. Science 251, 186-189 
 
151. Nan, X., Meehan, R. R., and Bird, A. (1993) Dissection of the methyl-CpG binding 
domain from the chromosomal protein MeCP2. Nucleic Acids Res 21, 4886-4892 
 
152. Abrahamson, M. (1994) Cystatins. Methods Enzymol 244, 685-700 
 
153. Yano, M., Hirai, K., Naito, Z., Yokoyama, M., Ishiwata, T., Shiraki, Y., Inokuchi, M., 
and Asano, G. (2001) Expression of cathepsin B and cystatin C in human breast 
cancer. Surg Today 31, 385-389 
 
154. Foekens, J. A., Kos, J., Peters, H. A., Krasovec, M., Look, M. P., Cimerman, N., 
Meijer-van Gelder, M. E., Henzen-Logmans, S. C., van Putten, W. L., and Klijn, J. G. 
(1998) Prognostic significance of cathepsins B and L in primary human breast cancer. 
J Clin Oncol 16, 1013-1021 
 
155. Bervar, A., Zajc, I., Sever, N., Katunuma, N., Sloane, B. F., and Lah, T. T. (2003) 
Invasiveness of transformed human breast epithelial cell lines is related to cathepsin 
B and inhibited by cysteine proteinase inhibitors. Biol Chem 384, 447-455 
 
156. Rivenbark, A. G., Jones, W. D., Risher, J. D., and Coleman, W. B. (2006) DNA 
methylation-dependent epigenetic regulation of gene expression in MCF-7 breast 
cancer cells. Epigenetics 1, 32-44 
 
157. Cailleau, R., Olive, M., and Cruciger, Q. V. (1978) Long-term human breast 
carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 14, 
911-915 
 
158. Hackett, A. J., Smith, H. S., Springer, E. L., Owens, R. B., Nelson-Rees, W. A., 
Riggs, J. L., and Gardner, M. B. (1977) Two syngeneic cell lines from human breast 
tissue: The aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial 
(Hs578Bst) cell lines. J Natl Cancer Inst 58, 1795-1806 
 
159. Soule, H. D., Vazguez, J., Long, A., Albert, S., and Brennan, M. (1973) A human cell 
line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51, 
1409-1416 
 
 153
160. Lasfargues, E. Y., and Ozzello, L. (1958) Cultivation of human breast carcinomas. J 
Natl Cancer Inst 21, 1131-1147 
 
161. Harder, A., Rosche, M., Reuss, D. E., Holtkamp, N., Uhlmann, K., Friedrich, R., 
Mautner, V. F., and von Deimling, A. (2004) Methylation analysis of the 
neurofibromatosis type 1 (NF1) promoter in peripheral nerve sheath tumours. Eur J 
Cancer 40, 2820-2828 
 
162. Zhang, Q., Rubenstein, J. N., Jang, T. L., Pins, M., Javonovic, B., Yang, X., Kim, S. 
J., Park, I., and Lee, C. (2005) Insensitivity to transforming growth factor-beta results 
from promoter methylation of cognate receptors in human prostate cancer cells 
(LNCaP). Mol Endocrinol 19, 2390-2399 
 
163. Cromer, A., Carles, A., Millon, R., Ganguli, G., Chalmel, F., Lemaire, F., Young, J., 
Dembele, D., Thibault, C., Muller, D., Poch, O., Abecassis, J., and Wasylyk, B. 
(2004) Identification of genes associated with tumorigenesis and metastatic potential 
of hypopharyngeal cancer by microarray analysis. Oncogene 23, 2484-2498 
 
164. Szyf, M., Tanigawa, G., and McCarthy, P. L., Jr. (1990) A DNA signal from the Thy-
1 gene defines de novo methylation patterns in embryonic stem cells. Mol Cell Biol 
10, 4396-4400 
 
165. Hasse, A., and Schulz, W. A. (1994) Enhancement of reporter gene de novo 
methylation by DNA fragments from the alpha-fetoprotein control region. J Biol 
Chem 269, 1821-1826 
 
166. Bock, C., Paulsen, M., Tierling, S., Mikeska, T., Lengauer, T., and Walter, J. (2006) 
CpG island methylation in human lymphocytes is highly correlated with DNA 
sequence, repeats, and predicted DNA structure. PLoS Genet 2, e26 
 154
